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ABSTRACT OF THE DISSERTATION 
Human iPSC Tissue-Engineered Cartilage for  
Disease Modeling of Skeletal Dysplasia-Causing TRPV4 Mutations 
by 
Amanda Dicks 
Doctor of Philosophy in Biomedical Engineering 
Washington University in St. Louis, 2021 
Professor Farshid Guilak, Chair  
 Cartilage is essential to joint development and function. However, there is a variety of 
cartilage diseases, ranging from developmental (e.g., skeletal dysplasias) to degenerative (e.g., 
arthritis), in which treatments and therapeutics are lacking. For example, specific point mutations 
in the ion channel transient receptor potential vanilloid 4 (TRPV4) prevent proper joint 
development, leading to mild brachyolmia and severe, neonatally lethal metatropic dysplasia. 
Tissue-engineered cartilage offers an opportunity to elucidate the underlying mechanisms of 
these cartilage diseases for the development of treatments.  
Human induced pluripotent stem cells (hiPSCs) are an improved cell source option for 
cartilage tissue engineering given their minimal donor site morbidity, absence of ethical 
concerns, and extensive proliferation, differentiation, and gene editing capacities. Unfortunately, 
previously published hiPSC chondrogenesis protocols were time consuming, difficult to 
reproduce, and resulted in off-target differentiation. Here, we used two methods to enhance 
hiPSC chondrogenesis using our previously published stepwise chondrogenic differentiation 
protocol. Next, we used the improved protocol to perform in vitro disease modeling of 
 xvi 
 
brachyolmia and metatropic dysplasia resulting from mutations in mechanosensor TRPV4. 
  To enhance chondrogenesis, we used a CRISPR-Cas9-edited hiPSC cell line with a GFP 
reporter to determine surface markers co-expressed with early chondrogenic marker and cartilage 
matrix protein COL2A1. We found that chondroprogenitors that were positive for PDGFRβ, 
CD146, and CD166 and negative for CD45 had enhanced chondrogenic potential. In fact, sorted 
chondroprogenitors from the reporter line and an unedited line had significantly improved 
homogeneity compared to unsorted as determined by single-cell RNA sequencing. Furthermore, 
the derived chondrocytes synthesized more homogenous and robust matrix proteins and had 
higher chondrogenic gene expression.  
In a continued effort to improve the chondrogenesis protocol, we used bulk and single-
cell RNA sequencing to determine where the off-target differentiation occurred. We found that 
Wnt and melanocyte inducing transcription factor (MITF) signaling were driving the two 
primary off-target populations: neurogenic and melanogenic, respectively. Single-cell RNA 
sequencing, histology, and quantification of matrix production confirmed pan-Wnt and MITF 
inhibition during chondrogenesis improved homogeneity of the cells throughout differentiation 
and increased chondrogenic potential.  
 Using the findings from these studies, we created an hiPSC chondrogenesis protocol that 
follows the developmental mesodermal lineage and uses chemically defined medium. We also 
provide instructions for digesting the chondrogenic tissue to isolate hiPSC-derived chondrocytes 
at the single cell level. This protocol has applications for a variety of tissue engineering uses 
including regenerative therapies, gene editing, drug screening, and disease modeling.  
 In fact, we applied this protocol for disease modeling of TRPV4 mutations that result in 
skeletal dysplasias. Using CRISPR-Cas9 gene editing technology, we created two hiPSC lines 
 xvii 
 
harboring either the brachyolmia-causing V620I substitution or the metatropic dysplasia-causing 
T89I substitution. The hiPSCs were chondrogenically differentiated and then were treated with 
BMP4 to stimulate hypertrophic differentiation. We determined that TRPV4 mutations increased 
basal signaling but decreased sensitivity to chemical agonist GSK1016790A using 
electrophysiology techniques and confocal imaging. Furthermore, using bulk RNA sequencing, 
we found the mutations suppressed chondrocyte maturation and hypertrophy, likely preventing 
endochondral ossification and long bone formation leading to the disease phenotype.  
 We also used these cell lines to study the effects of the mutations on 
mechanotransduction. The hiPSC-derived chondrocytes were physiologically loaded in agarose 
constructs for 3 hours and then sequenced to elucidate the temporal response to loading. We 
found the mutant TRPV4 increased gene expression in response to loading compared to 
wildtype. Gene expression patterns indicated increased proliferation in mutant cells, which could 
prevent chondrocyte hypertrophic differentiation and endochondral ossification.  
 Overall, we have developed an improved chondrogenic hiPSC protocol. The resulting 
tissue-engineered cartilage has many uses including in vitro disease modeling of genetic, 
developmental conditions, as shown here. Our findings provide target genes for future drug 
development to treat brachyolmia and metatropic dysplasia. Furthermore, we have increased the 
understanding of TRPV4 function in chondrocytes, which can be applied to cartilage tissue 







Cartilage is an avascular, aneural soft tissue composed only of chondrocytes and the extracellular 
matrix they produce. Cartilage serves two functions in the joint: as a template for endochondral 
ossification and long bone development and as a lining of long bones to provide a nearly 
frictionless surface. The transient receptor potential vanilloid 4 (TRPV4) ion channel serves as a 
regulator of both chondrogenic development and cartilage homeostasis through 
mechanotransduction. Physiologic loading mediated through TRPV4 promotes cartilage matrix 
synthesis. Moreover, gain-of-function mutations in the TRPV4 gene cause mild to lethal skeletal 
dysplasias. While the underlying mechanisms of skeletal dysplasias is unclear, tissue-engineered 
cartilage offers the possibility to study these processes. Tissue-engineered cartilage, which can 
be derived from human induced pluripotent stem cells (hiPSCs) among other cell types, serves as 
an option to study cartilage development, homeostasis, function, and disease. In fact, in vitro 
disease modeling, drug screening, and genetic engineering with hiPSC-derived chondrocytes can 
aid in the development of regenerative therapeutics and treatments for cartilage diseases. In this 
thesis, we developed an hiPSC chondrogenic differentiation protocol and applied it to disease 
modeling of skeletal dysplasia-causing TRPV4 mutations.  
1.2 Cartilage Development and Homeostasis 
Following chondrogenesis, cartilage undergoes one of two fates: hypertrophy or homeostasis. In 
the first, chondrocytes differentiate into hypertrophic chondrocytes and undergo endochondral 
 2 
 
ossification, or the formation of long bones. The second fate is homeostasis, during which the 
soft tissue lines diarthrodial joints throughout one’s lifetime. Chondrocytes, the primary cell type 
of cartilage, are under strict regulation via transcription factors and biochemical and 
biomechanical cues that guide their differentiation, anabolic matrix synthesis, and catabolic 
matrix degradation occurring in both fates.  
1.2.1 Chondrocyte differentiation 
During embryogenesis, cartilage develops and forms the template for long bones (1, 2). 
Mesenchymal cells aggregate together before undergoing SOX9-driven chondrogenesis (2-4). 
Sry-related high-mobility-group box 9 (SOX9) and its downstream targets, SOX5 and SOX6, 
form a transcription factor axis responsible for driving chondrocyte differentiation and 
proliferation (3). Chondrocyte expression of SOX9 is regulated by fibroblast growth factor 
(FGF), insulin-like growth factor I (IGF-I), transient receptor potential vanilloid 4 (TRPV4), and 
transcription factors Sp1 and CREB (3). SOX9 is required to upregulate expression of 
chondrogenic matrix proteins, such as collagen type II alpha chain I (COL2A1) and cartilage 
oligomeric matrix protein (COMP) (3, 5). Resting and proliferating chondrocytes secrete the 
cartilage extracellular matrix (ECM) primarily composed of sulfated glycosaminoglycans 
(sGAGs) and type II collagen (COL2) (2, 6, 7). Some of the chondrocytes will then stop 
proliferating, begin to hypertrophy, and undergo endochondral ossification.  
Endochondral ossification is separate from membranous ossification, in which neural 
crest cells differentiate into osteoblasts and secrete cortical bone to form flat bones (e.g., skull, 
clavicle) (2). In contrast, endochondral ossification is responsible for formation of the long bones 
of the appendicular skeleton. Chondrocyte hypertrophy, which leads to endochondral 
ossification, is driven by transcription factors runt related transcription factor 2 (RUNX2) and 
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Indian hedgehog (IHH). Hypertrophic chondrocytes switch from COL2 to COL10 production, 
increase in size, and organize in columnar formations (2, 6, 7). Additionally, they begin secreting 
bone morphogenic proteins (BMPs), vascular endothelial growth factors (VEGFs), and 
parathyroid hormone-related peptide (PTHR) to recruit osteoblast progenitors (2, 6, 7). 
Hypertrophic chondrocytes the either undergo apoptosis or differentiate into osteoblasts (2, 6, 7). 
The newly differentiated osteoblasts express osteogenic factors (e.g., bone sialoprotein, 
osteopontin), begin to mineralize bone, and allow for vascular invasion (2, 6, 7). This process 
occurs in the center of the bone during embryogenesis and continues to occur in secondary 
ossification sites (i.e., growth plate), towards the ends of the bones, after birth and through 
adolescence (2, 6, 7).  
1.2.2 Cartilage homeostasis 
The remaining chondrocytes that did not undergo hypertrophy are the only cell type present in 
articular cartilage, the soft tissue lining the ends of the long bones (8, 9). In adults, chondrocytes 
compose 5% of cartilage’s volume and maintain cartilage homeostasis in response to genetic and 
environmental signals, such as growth factors or physiologic loading, through a balanced 
regulation of anabolic and catabolic ECM synthesis and degradation (10, 11). The resulting ECM 
is avascular, aneural, and primarily composed of proteoglycans (e.g., glycosaminoglycans) and 
type II collagen, alongside several other collagens and non-collagenous proteins (e.g., 
hyaluronate, fibronectin) (8, 9, 12). Glycosaminoglycans (GAGs), largely comprising the large 
aggregating proteoglycan aggrecan (ACAN), make up 4-7% of cartilage (8, 13, 14). Due to their 
negative charge, GAGs retain water, which composes 65-80% of the tissue weight, contributing 
to the compressive properties of cartilage (8, 13, 14). Type II collagen, approximately 10-20% of 
cartilage matrix, primarily contributes to the shear and tensile properties of the tissue (8, 13, 14).  
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Cartilage has a highly hydrated, cross-linked composition that also has a unique structure: 
zonal organization. In the superficial zone, which experiences immediate strain and interacts 
with the opposing bone’s cartilage, chondrocytes are flat, and the matrix proteins are aligned 
parallel with the surface, providing tensile strength. The deep zone provides compressive 
strength with rounded chondrocytes in a columnal alignment and matrix proteins in an alignment 
perpendicular to the surface. The chondrocytes and matrix proteins are randomly aligned and 
organized in the middle zone, providing a transition between the superficial and deep zones. The 
composition and structure of cartilage results in biphasic properties and viscoelastic behavior 
with a compressive Young’s modulus of 240-850 kPa, an aggregate modulus of 100-2000 kPa, 
and a Poisson’s ratio of 0.06-0.3 (1, 8, 9, 15-21). Due to these properties, articular cartilage can 
distribute stress while experiencing millions of cycles of compressive loading several times one’s 
body weight (1, 12, 16-18, 22, 23).  
Not only does cartilage withstand loading, but the mechanical forces from joint 
movements (e.g., walking, running, climbing stairs) are vital for tissue development and 
homeostasis (17, 24-26). Matrix synthesis, chondrogenic gene expression, and anti-inflammatory 
responses are stimulated by physiologic levels of compressive, shear, hydrostatic pressure, and 
osmotic forces (9, 16, 17, 20, 23-25, 27-30). Cartilage stress and strain during loading is filtered 
through the zonal organization to the pericellular matrix (PCM). The PCM, composed of 
collagen type VI (COL6), fibronectin 1, and proteoglycans perlecan and biglycan (31-33), 
integrates with the ECM and has approximately 35% of the ECM’s mechanical properties (34, 
35). The PCM surrounds the chondrocyte, forming the chondron, to serve as a biomechanical 
and biochemical filter (31-33). The chondrocyte senses load through mechanosensors such as 
integrins, primary cilium, and ion channels (e.g., TRPV4) and converts the signal into 
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downstream pathways (e.g., Indian hedgehog, Wnt, TGFβ, MAPK-ERK) resulting in 
transcriptomic changes (27, 32). 
1.3 Transient Receptor Potential Vanilloid 4 
Transient receptor potential vanilloid 4 (TRPV4) is a non-selective, calcium-permeable ion 
channel. The cell membrane protein is tetrameric with each component composed of six 
transmembrane alpha helices and a pore loop with an amino group on one end and a carboxyl 
group on the other (36). Recently, the crystalline cryo-EM structure has been identified, giving 
insights into gating mechanisms and therapeutics (37). It is well known that TRPV4 is an osmo-
sensor (38-41) found in multiple osmotically-regulating cell types including the brain, liver, and 
kidneys (36, 42, 43). Furthermore, TRPV4 function has been found to play a role in bone (44), 
vasculature (45), adipose (46), and nociception (47, 48). The channel is activated by, but not 
limited to, heat (49, 50), hypo-osmolarity or cell swelling (39, 41), shear stress (51, 52), 
mechanical loading (53), and chemical agonists such as 4α-phorbol 12,13-didecanoate, 
ruthenium red, and GSK1016790A (43, 54). Mutations in TRPV4 lead to a variety of genetic 
disorders (55, 56) including hyponatremia (57), chronic obstructive pulmonary disorder (58, 59), 
and neuropathies (e.g., distal spinal muscular atrophy congenital non-progressive (60-62), 
Charcot–Marie–Tooth disease type 2C (CMT2C) (63-68), scapuloperoneal spinal muscular 
atrophy (SPSMA) (63, 64, 68)). TRPV4 mutations also lead to skeletal disorders including 
arthropathies, such as familial digital arthropathy-brachydactyly (69), and skeletal dysplasias, 
such as brachyolmia (70), metatropic dysplasia (71-76), spondyloepiphyseal dysplasia 
Maroteaux type (77-80), and parastremmatic dwarfism (81). Given the number of skeletal-




In fact, TRPV4 plays a role in both chondrogenesis and cartilage homeostasis. TRPV4 
activation was found to upregulate transcription factor SOX9 in chondrogenic ATDC5 cells (82), 
while deletion of TRPV4 decreased chondrogenic potential of murine adipose-derived stem cells 
(83). Studies using compressive loading and chemical agonists to activate TRPV4 found that the 
resulting calcium signaling is coupled with transforming growth factor beta (TGFβ) signaling, an 
essential growth factor family in chondrogenesis and cartilage homeostasis (84, 85). 
Furthermore, TRPV4 activation also increased matrix production, elastic modulus, and anti-
inflammatory gene expression in primary porcine chondrocytes (53, 86-88). Studies in mouse 
models found a TRPV4 global knockout increased the incidence of osteoarthritis (OA) (89) in 
male mice, especially on a high fat diet (83). However, a cartilage-specific knockout protected 
against age-related OA but not post-traumatic OA (90). In summary, TRPV4 is a critical 
component and regulator of chondrogenic development and homeostasis.  
1.4 Cartilage Diseases 
Cartilage diseases include, but are not limited to: aggrecanopathies, arthritis, arthropathies, 
cartilaginous tumors, chondrocalcinosis, chondrodysplasia, collagenopathies, osteochondritis 
dissecans, relapsing polychondritis, and skeletal dysplasias (91). Not only do these diseases 
range in severity, but they also range in onset – from developmental to degenerative disease. The 
large variety of cartilage diseases require research into their mechanisms, symptoms, treatment, 
and regenerative therapies. Here, we describe the most common cartilage disorder family, 
arthritis, and a family of developmental disorders, skeletal dysplasia.  
1.4.1 Arthritis 
Arthritis is a family of diseases that causes pain, swelling, and loss of motion of the diarthrodial 
joints (92, 93). It has been reported as one of the top three leading causes of pain and disability 
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across the United States (94). Arthritis currently affects at least 54 million adults in the United 
States (95), and the number is expected to rise with the aging, obese population (12, 92). 
Furthermore, it was estimated that by 2040 the number of adults affected by arthritis will 
increase to 78.4% in the US with 11.4% of the total population suffering from activity-limiting 
arthritis (96). As of 2007, arthritis cost the US $128 billion (direct medical and indirect losses 
combined) (97), and with incidence continuing to rise, so will the cost (12, 92). Beyond the costs 
and disability caused by arthritis, it is associated with many comorbidities including heart 
disease, respiratory disease, diabetes, and obesity (92, 98). Moreover, 31% of patients with 
arthritis also reported having anxiety (99), and 27% (compared to 12% without arthritis) reported 
fair to poor health-related quality of life (100). 
Arthritis is typically diagnosed through repeated doctor’s appointments using 
radiographs, looking for erosion and boney spurs, and self-reported joint pain, inflammation, and 
stiffness (92, 101). In fact, inflammation is the primary driver of disease onset, as the avascular 
and aneural environment leaves cartilage more susceptible to inflammatory degeneration without 
the ability to regenerate (8, 92, 93, 102). The degeneration, erosion, and cracking of articular 
cartilage occurs as collagen and proteoglycans are degraded by aggrecanases and matrix 
metalloproteinases (MMPs) stimulated by inflammatory cytokines interluekin-1 beta, -6, and -8 
(IL-1, IL-6, IL-8) and tumor necrosis factor alpha (TNF) (9, 16, 17, 19, 20, 30, 92, 97, 103). 
Systemic, inflammatory flares occur in rheumatoid arthritis (RA), an autoimmune disease with a 
prevalence of 1% that affects women more often (93, 104). In osteoarthritis (OA), inflammation 
is caused by metabolic and biomechanical factors (17, 22, 32, 102, 103, 105, 106). Risk factors 
include age (107), female sex (108), genetics (108), obesity (22), and injury (92, 103, 109, 110). 
Despite the homeostatic benefits of physiologic loading (17, 24, 25, 28), injurious loading (i.e., 
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greater than 35% strain) increases chondrocyte catabolism leading to post-traumatic OA (PTOA) 
(17, 103). In fact, prevalence of PTOA is higher in the younger population and risk increases to 
approximately 50% after traumatic injury that results in misalignment of the joint (e.g., ligament 
or meniscal tears) (103, 109, 111).   
There is no cure for arthritis, and treatments are limited. Patients are encouraged to lose 
weight and exercise to reduce systemic inflammation. In mild cases, treatments include non-
steroidal anti-inflammatories, which treat disease-induced pain short term (17, 92, 97). Disease-
modifying antirheumatic drugs have been developed to treat RA; however, they are effective in 
only a fraction of individuals and have been associated with significant side effects (93). As the 
arthritis progresses, surgery and total joint arthroplasty becomes an option (92, 101), but the 
surgery has a dissatisfaction rate of up to 20% (112). Additionally, joint replacements have a 
limited lifespan, increasing the number of revisions and decreasing their effectiveness in younger 
populations (113, 114). Therefore, there is a critical need for treatment and therapeutics for 
arthritis. 
1.4.2 Skeletal dysplasias 
Skeletal dysplasias are a group of over 450 bone and cartilage diseases including achondroplasia, 
type 2 collagenopathies, osteogenesis imperfecta, brachyolmia, spondylometaphyseal dysplasia 
Kozlowski, and metatropic dysplasia (115-118). The diseases, which range in severity from 
moderate to neonatally lethal, are characterized by disproportionate stature and bones (116). 
With a birth incidence of 1 in 5000 (119), the dysplasias can be diagnosed prenatally with 
radiographic evidence of disproportion followed by skeletal surveying, histopathology, and 
molecular genetic testing (115-118). Early diagnosis, especially in severe or lethal incidences, is 
important for family counseling and immediate stabilization of the airway and respiratory status 
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upon birth to prevent death due to small chest size, pulmonary restriction, and cardiopulmonary 
compromise (75, 116). In non-lethal cases, the patient requires a multidisciplinary team to assess, 
diagnose, treat, and manage orthopedic, neurologic, auditory, visual, pulmonary, cardiac, renal, 
and psychological complications (116, 120). Skeletal dysplasia patients may require physical 
therapy and surgical intervention throughout their life (121-123). Additionally, a study showed 
that depression and anxiety, often associated with pain, is present in 34% and 31% of patients 
with skeletal dysplasia, respectively, representing the need for pain management and mental 
health counseling (124).  
 The heterogenous phenotypes of skeletal dysplasias is inherent to the cause of this family 
of diseases: genetic mutations. Skeletal dysplasia-causing mutations occur in ECM proteins, 
transcription factors, tumor suppressors, signal transducers, cellular transporters, and growth 
factor receptors (116, 120). A common location of these mutations is transient receptor vanilloid 
4 (TRPV4), a non-selective cation channel. These mutations cause a spectrum of skeletal 
dysplasias, including autosomal-dominant brachyolmia and metatropic dysplasia, among other 
diseases (55). Autosomal-dominant brachyolmia is caused by a gain-of-function mutation in the 
transmembrane 5 pore region of TRPV4 caused by an exon 12 858G>A transition encoding a 
V620I substitution (55, 70, 125). The moderate dysplasia exhibits a phenotype of moderately 
short stature, mildly short limbs, mild brachydactyly, scoliosis, flattened and irregular vertebra, 
mild irregularities in metaphyses, and delayed epiphyseal and carpal ossification (70, 125, 126). 
In contrast, metatropic dysplasia is caused by a mutation in the cytoplasmic NH2 end protein 
domain of TRPV4 caused by an exon 2 C366>T transition encoding a T89I substitution (55, 75, 
125). Some studies have shown the T89I mutation to be gain-of-function (126, 127), while other 
reports have claimed it does not cause a change in conductivity (55, 125). This severe dysplasia 
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can be neonatally lethal and exhibits a phenotype of short extremities, dumbbell-shaped long 
bones with widened metaphyses, elongated and narrow trunk, scoliosis, flat vertebral bodies, 
joint contractures, prominent forehead, squared-off jaw, and brachydactyly with delayed carpal 
ossification (75, 125). Histological analysis of brachyolmia and metatropic dysplasia have shown 
disorganized, hypertrophic chondrocytes and cartilage islands among bone, indicating 
dysregulation of endochondral ossification and skeletal development to be an underlying cause 
of the diseases (75, 116, 120). It was hypothesized that increased TRPV4 signaling prevented 
proper endochondral ossification through an upregulated expression of follistatin, a potent BMP 
antagonist, a potential underlying cause of these conditions (127-129). 
1.5 Tissue-Engineered Cartilage  
Tissue-engineered cartilage provides opportunities for regenerative therapies, particularly for 
degenerative diseases such as arthritis. Furthermore, it can serve as an in vitro disease model for 
drug screening and as a tool for the elucidation of underlying mechanisms of cartilage diseases. 
To engineer cartilage, one needs a chondrocyte source, a 3D scaffold or environment, and 
chondrogenic medium. As the chondrocytes are cultured, they will synthesize the cartilaginous 
ECM, thus producing tissue-engineered cartilage. An advantage of using cartilage in the tissue 
engineering field is that it does not have any other cell types, such as vasculature. However, the 
unique composition and organization of the chondrocytes and ECM, which produces its 
impressive mechanical properties, poses much more of a challenge.  
1.5.1 Cell sources  
Studies have used a range of cell types for the chondrocyte cell source including primary 
chondrocytes and chondrocytes derived from adult multipotent stem cells and pluripotent stem 
cells (14). Primary chondrocytes eliminate in vitro chondrogenic differentiation as they are 
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already able to synthesize a cartilaginous matrix in 3D (130). However, their limited expansion 
potential paired with dedifferentiation during monolayer passaging limits their applicability 
(130). Furthermore, they are difficult to obtain due to donor site morbidity and limited cadaveric 
and surgical waste sources (14). 
Therefore, most tissue engineering studies differentiate stem cells into chondrocytes. One 
of the most common sources are adult multipotent stem cells, such as mesenchymal stem cells 
(MSCs) and adipose-derived stem cells (ASCs). Chondrogenesis protocols for these cell types 
have been successfully optimized to produce robust cartilage-like tissue (131-135). While ASCs 
are isolated from adipose tissue, such as during liposuction (131), MSCs are typically isolated 
from adult bone marrow, an invasive process (1, 135). A drawback to this method, however, is it 
is well-recognized that adult stem cells are a heterogenous cell population with significant donor-
to-donor variability and limited proliferation and differentiation potential after long-term 
expansion in vitro (135-139).  
Pluripotent stem cells solve these problems with their high proliferation and 
differentiation capacities, which also provide the opportunity for gene editing (140, 141). 
Embryonic stem cells (ESCs) are derived from embryos prior to implantation, which may raise 
ethical concerns or be restricted in some places (142). However, adult somatic cells, such as 
fibroblasts, can be reprogrammed into a pluripotent state by defined transcriptional factors 
providing patient-specific cells with low to no donor morbidity (140-143). These reprogramed 
cells are known as induced pluripotent stem cells (iPSCs) and behave comparably to ESCs in 
terms of proliferation and differentiation (136, 140-143).  
1.5.2 hiPSC chondrogenesis  
Previously our lab developed a chondrogenic differentiation protocol for mouse iPSCs (144); 
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however, human cells have remained a larger challenge for the field. Using a variety of growth 
factor and morphogen combinations and chondrogenic medium solutions, several studies have 
reported protocols for differentiating human iPSCs (hiPSCs) into chondrocytes (1, 136, 145-
152). Unfortunately, the methods are time consuming, have modest expression of chondrogenic 
genes, have irregular chondrocyte morphology, do not follow developmental pathways, or are 
difficult to reproduce. For example, many methods rely on the use of fetal bovine serum (FBS) in 
their medium to increase cell viability; however, FBS has extensive lot-to-lot variability 
preventing consistency and reproducibility.  
Therefore, we aimed to develop a serum-free, chemically-defined chondrogenic 
differentiation protocol for hiPSCs. Using the newly elucidated temporal sequence of signaling 
cues required for stem cell differentiation across various lineages in vivo (146) and previous in 
vitro reports of stem cell chondrogenic differentiation (144, 153, 154), we developed a stepwise 
protocol for hiPSC differentiation following the paraxial mesodermal lineage (155). The protocol 
differentiates sclerotome cells into chondroprogenitors with bone morphogenic protein 4 
(BMP4), similar to mesenchymal condensation during development (155, 156). 
Chondroprogenitors are then treated with transforming growth factor beta 3 (TGFβ3) to stimulate 
chondrogenesis (144, 145, 148, 155, 157-159). Given the chondrogenic requirement for a 3D 
environment, this protocol uses a conventional 3D pellet culture system (9, 159). With this 
culture system, chondroprogenitors are centrifuged in a tube to form a spherical construct, or 
“pellet,” over multiple weeks growing in diameter as the cells differentiate and produce 
cartilaginous matrix. After 28 days in pellet culture, tissue-engineered cartilage matrix 
synthesized by hiPSC-derived chondrocytes has formed (155). Unfortunately, this protocol, 
among others has resulted in significant and unpredictable cellular and matrix heterogeneity 
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(155, 160, 161). 
1.6 In Vitro Disease Modeling and Therapeutic Development 
Tissue-engineered cartilage, particularly from hiPSCs, provides opportunities for in vitro disease 
modeling, genetic engineering, gene therapy, and drug development and validation (162-172). 
Genetic engineering tools such as clustered regularly interspaced short palindromic repeats 
(CRISPR) and the CRISPR-associated protein (Cas9) are valuable tools for disease modeling 
(173). For example, hiPSCs can be derived from adult patients with a genetic disorder, and the 
mutation can be corrected using CRISPR-Cas9 technology to create an isogenic control (140, 
141, 163, 173). If patient samples are not available, CRISPR-Cas9 can be used to create the 
mutation in a control line (140, 141, 163, 173). After the development of mutant and isogenic 
lines, scientists can study the effects of the mutation on chondrogenesis and cartilage 
homeostasis. Additionally, diseased environments can be simulated using hiPSC-derived 
chondrocyte culture, such as the introduction of inflammatory cytokines to mimic arthritis (162). 
This system has pharmaceutical potential, as patient-specific, genetically engineered, or diseased 
hiPSC-derived chondrocytes can be used for drug development, and the large volumes produced 
provide the opportunity for high throughput screening.  
Beyond disease modeling, hiPSC-derived chondrocytes are useful for elucidating the 
mechanisms driving or repressing chondrogenesis and regulating cartilage homeostasis (e.g., 
mechanical forces) (26). These findings will not only answer fundamental questions regarding 
chondrocyte biology, but they will provide insights into optimizing tissue engineering strategies 
for regenerative therapeutics. Moreover, our lab has developed stem cells modified for 
autonomous regenerative therapy (i.e., self-regulating “SMART” cells) harnessing synthetic 
biology to create cell-based therapies in murine iPSCs, which could be translated to human cells 
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in the future (84, 174-176). 
1.7 Summary 
Due to the importance of articular cartilage to skeletal development and joint loading, we 
developed an hiPSC chondrogenic differentiation protocol as a tool to study chondrogenesis and 
cartilage homeostasis. Unfortunately, there was cellular and matrix heterogeneity in the tissue-
engineered cartilage. To address this, we applied two strategies: cell sorting and inhibition of off-
target pathways. In the first method, CD146, CD166, and PDGFR were identified as pro-
chondrogenic surface markers in hiPSC-derived chondroprogenitor cells as described in Chapter 
2. In the second method, we used next-generation sequencing to identify wingless/integrated 
(Wnt) and melanocyte inducing transcription factor (MITF) signaling as the drivers of off-target 
differentiation. We found inhibition of these factors during chondrogenesis significantly 
improved the protocol and resulted in homogenous, robust tissue-engineered cartilage as 
described in Chapter 3 and 4. Next, we applied this protocol to a disease modeling application. 
We differentiated hiPSCs harboring skeletal dysplasia-causing TRPV4 mutations into 
chondrocytes to study the effects on TRPV4 function, chondrogenesis, and chondrocyte 
hypertrophy and on TRPV4 mechanotransduction, as described in Chapters 5 and 6, respectively. 
The findings from the disease modeling studies provide insights into therapeutic targets for mild 
brachyolmia and severe metatropic dysplasia. Furthermore, the hiPSC chondrogenesis protocol 
can be applied to other disease models, such as osteoarthritis risk mutations in type VI collagen, 




Figure 1.1 Representation of the thesis chapters and their integration. We developed a protocol 
to derive chondroprogenitors; however, they produced heterogenous hiPSC-derived cartilage. 
Therefore, we enhanced chondrogenesis through cell sorting or inhibition of off-target pathways. 
Then using the improved chondrogenesis protocol, we used hiPSC-derived cartilage for disease 
modeling of skeletal dysplasia-causing TRPV4 mutations. We found the mutations suppress 
chondrocyte hypertrophy but increase sensitivity to physiologic loading. 
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Prospective Isolation of Chondroprogenitors 
from Human iPSCs Based on  
Cell Surface Markers Identified using a 
CRISPR-Cas9-Generated Reporter 
Partially adapted from: Dicks A*, Wu CL*, Steward N, Adkar SS, Gersbach CA, Guilak F. 
Prospective isolation of chondroprogenitors from human iPSCs based on cell surface markers 
identified using a CRISPR-Cas9-generated reporter. Stem Cell Research and Therapy. 2020 Feb 
18;11(1):66. 
2.1 Abstract 
2.1.1 Background  
Articular cartilage shows little or no capacity for intrinsic repair, generating a critical need of 
regenerative therapies for joint injuries and diseases such as osteoarthritis. Human induced 
pluripotent stem cells (hiPSCs) offer a promising cell source for cartilage tissue engineering and 
in vitro human disease modeling; however, off-target differentiation remains a challenge during 
hiPSC chondrogenesis. Therefore, the objective of this study was to identify cell surface markers 
that define the true chondroprogenitor population and use these markers to purify iPSCs as a 
means of improving homogeneity and efficiency of hiPSC chondrogenic differentiation.  
2.1.2 Methods  
We used a CRISPR-Cas9-edited COL2A1-GFP knock-in reporter hiPSC line, coupled with a 
surface marker screen, to identify a novel chondroprogenitor population. Single-cell RNA 
sequencing was then used to analyze the distinct clusters within the population.  An unpaired t-
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test with Welch’s correction or an unpaired Kolmogorov-Smirnov test was performed with 
significance reported at a 95% confidence interval. 
2.1.3 Results  
Chondroprogenitors expressing CD146, CD166, and PDGFR, but not CD45, made up an 
average of 16.8% of the total population. Under chondrogenic culture conditions, these triple 
positive chondroprogenitor cells demonstrated decreased heterogeneity as measured by single-
cell RNA sequencing with fewer clusters (9 clusters in unsorted vs. 6 in sorted populations) 
closer together. Additionally, there was more robust and homogenous matrix production 
(unsorted: 1.5 ng/ng vs. sorted: 19.9 ng/ng sGAG/DNA; p < 0.001) with significantly higher 
chondrogenic gene expression (i.e., SOX9, COL2A1, ACAN; p < 0.05).  
2.1.4 Conclusions  
Overall, this study has identified a unique hiPSC-derived subpopulation of chondroprogenitors 
that are CD146+/CD166+/PDGFR+/CD45- and exhibit high chondrogenic potential, providing a 
purified cell source for cartilage tissue engineering or disease modeling studies. 
2.2 Introduction 
Articular cartilage is the load-bearing tissue that lines the ends of long bones in diarthrodial 
joints, serving to resist compression and provide a nearly frictionless surface during joint loading 
and movement (1, 2). The extracellular matrix of cartilage is comprised primarily of type II 
collagen and proteoglycans, which are synthesized by the main residing cell type, chondrocytes 
(3, 4). However, because it is aneural and avascular, cartilage shows little or no capacity for 
intrinsic repair (4). Traumatic injury and a chronic inflammatory state lead to irreversible 
degeneration of the tissue, driving diseases such as osteoarthritis (OA) (5, 6). Current treatments 
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only target disease symptoms, creating a great demand for tissue-engineered cartilage as a 
system for disease modeling, drug testing, and tissue replacement.  
Human induced pluripotent stem cells (hiPSCs) offer a promising source for cartilage 
tissue engineering and in vitro disease modeling (7) as they have virtually unlimited expansion 
capacity, can be genetically modified, and avoid many of the ethical considerations associated 
with embryonic stem cells (8, 9). Despite reports of several chondrogenic differentiation 
protocols for pluripotent stem cells (10-15), incomplete differentiation and cell heterogeneity 
remain major obstacles for iPSC chondrogenesis (16, 17). This challenge has been addressed in 
other stem and progenitor cell types by prospectively isolating cells that exhibit chondrogenic 
lineage commitment using surface marker expression. For example, previous studies have 
identified chondroprogenitors within adult articular cartilage that can be isolated using 
fibronectin adhesion assays since progenitors express integrins 5 and 1 (18, 19). Additionally, 
mesenchymal progenitor cells, which express CD105, CD166, and CD146, have been reported to 
have a high chondrogenic potential (19-21). Adult multipotent cells, such as bone marrow 
mesenchymal stem cells (MSCs) or adipose stem cells (ASCs), exhibit chondrogenic potential 
and have been used extensively for cartilage tissue engineering. They are often characterized by 
a range of cell surface marker expression, including CD105, CD73, CD90, CD271, CD146, Stro-
1, and SSEA-4 (22). In an effort to identify a more developmentally-relevant progenitor 
population, self-renewing human skeletal stem cells characterized by CD164+, CD73-, and 
CD146- showed chondrogenic differentiation when implanted in a mouse renal capsule (23). In 
another study, limb bud cells expressing CD73 and BMPR1 while having low to no expression 
of CD166, CD146, and CD44 were proposed to be the earliest cartilage committed cells 
(prechondrocytes) in human embryonic development (24). However, surface markers 
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characteristics of hiPSC-derived chondroprogenitors or chondrocytes remain to be identified.  
Previously, our lab used green fluorescent protein (GFP) reporter systems to track the 
expression of collagen type II alpha 1 chain (COL2A1) in mouse (25) and human (26) iPSCs, 
allowing for the prospective isolation and purification of COL2A1-GFP+ chondrogenic cells 
during the differentiation process. Despite the fact that this approach significantly enhanced 
homogeneity of iPSC chondrogenesis (26), genome editing is required to create a reporter line, 
hindering potential clinical translation. In this regard, the identification of cell surface markers 
that are directly representative of this COL2A1-positive population could greatly enhance the 
prospective isolation and purification of chondroprogenitors, without requiring genetic 
modifications to the cell line.  
In this study, we used a COL2A1-GFP knock-in reporter hiPSC line as a tool to identify 
cell surface markers that are highly co-expressed with COL2A1 to test the hypothesis that this 
sub-population of chondroprogenitor cells will show increased purity and chondrogenic capacity. 
Single-cell RNA sequencing (scRNA-seq) was then used to investigate the gene expression 
profile of this population and to identify subsets within it. Matrix production, cell morphology, 
and gene expression were measured to evaluate chondrogenic ability of unsorted and sorted 
chondroprogenitor cells. This chondroprogenitor population appears to represent an intermediate 
step in the developmental pathway of in vitro hiPSC chondrogenesis in which off-target 
differentiation also occurs. The identification of surface markers to purify this population of 
chondroprogenitor cells via sorting will enhance the efficiency of hiPSC-chondrogenic 




2.3.1 hiPSC lines and culture 
Two hiPSC lines were used in the current study: RVR COL2A1-GFP knock-in line (RVR) and 
BJFF.6 line (BJFF). The RVR line was retrovirally reprogrammed from BJ fibroblasts and 
characterized as previously described (12, 27). Using CRISPR-Cas9 genome editing, a GFP 
reporter allele was added to the COL2A1 gene as previously reported (26). The cells were 
cultured in mTeSR1 medium (StemCell Technologies, Canada, 85857). The BJFF line was 
derived using Sendai viral transfection of foreskin fibroblasts from a newborn male and cultured 
in Essential 8 Flex medium (E8; Gibco, USA, A2858501). Both lines were maintained on 
vitronectin coated plates (VTN-N; Fisher Scientific, USA, A14700) with daily medium changes. 
Cells were passaged at approximately 90% confluency and induced into mesodermal 
differentiation at 40% confluency.  
2.3.2 Mesodermal differentiation 
hiPSCs were induced into mesodermal differentiation in monolayer according to the previously 
published protocol (26). In brief, cells were fed daily with various cocktails of growth factors 
and small molecules driving stepwise lineage differentiation (anterior primitive streak, paraxial 
mesoderm, early somite, sclerotome, and chondroprogenitor) in differentiation medium 
composed of IMDM GlutaMAX (IMDM; Gibco, USA, 31980097) and Ham’s F12 Nutrient Mix 
(F12; Gibco, USA, 11765062) with 1% chemically defined lipid concentrate (Gibco, USA, 
11905031), 1% insulin/human transferrin/selenous acid (ITS+; Corning, USA, 354352), 1% 
penicillin/steptomycin (P/S; Gibco, USA, 15070063), and 450 μM 1-thioglycerol (Sigma–
Aldrich, USA, M6145-25ML).  Upon differentiation into the chondroprogenitor stage, cells were 
dissociated using TrypLE (Gibco, USA, 12563029) at 37ºC followed by neutralization with 
equal parts of DMEM/F-12, GlutaMAXTM (DMEM/F12; Gibco, USA, 10565042) with 10% fetal 
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bovine serum (FBS; Atlanta Biologicals, USA, S11550) and 1% P/S. The dissociated cells were 
used for cell sorting and chondrogenic differentiation as appropriate. 
2.3.3 Fluorescent activated cell sorting (FACS) 
Chondroprogenitor cells were resuspended in FACS Buffer (PBS-/- with 1% FBS and 1% 
penicillin/steptomycin/fungizone (P/S/F; Gibco, USA, 15-240-062) at approximately 40 x 106 / 
mL. The cells were treated with ~6.5% of Human TruStain FcXTM (BioLegend, USA, 422302) 
for 10 min at RT. Approximately 5 x 104 cells in 100 µl were used for each compensation. Cells 
were labeled with appropriate antibodies including an isotype control. A table of the antibodies 
used can be found in Table 2.1. Cells were incubated for 30 minutes at 4ºC and washed with 
FACS buffer twice. Samples were resuspended in sorting medium consisting of DMEM/F12 
with 2% FBS, 2% P/S/F, 2% Hepes (Gibco, USA, 15-630-080), and DAPI (BioLegend, USA, 
422801) at 4 x 106 cells / mL and filtered through a 40 µm cell strainer. Cells were stored on ice 
prior to sorting. 








Marker Color Company 
Catalog Number 
Antibody Isotype 
CD45 FITC BioLegend 304006 400110 
CD166 PE BioLegend 343904 400112 
CD146 PE/Cy7 BioLegend 361008 400126 
PDGFR APC BioLegend 323608 400121 
CD271 PE/Cy7 BioLegend 345110 400126 
CD105 PE BioLegend 323206 400113 
CD73 Pacific Blue BioLegend 244012 400151 
BMPR1 APC R&D Systems FAB5051A IC0041A 
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An Aria-II FACS machine was used to compensate and gate the samples. Sorted cells 
were collected in collection media composed of DMEM/F12, 20% FBS, 1% P/S/F, 1% ITS+, 1% 
MEM non-essential amino acids (NEAA; Gibco, USA, 11140050), and 0.1% ROCK inhibitor 
(Stemcell Technologies, Canada, NC0791122). Data was analyzed using FlowJo software.  
 
2.3.4 10X chromium platform scRNA-seq 
Cells were thawed at 37ºC and resuspended in PBS + 0.01% BSA at concentration of 2,000 
cells/l. Cell suspension were submitted to the Genome Technology Access Center (GTAC 
sequencing core) at Washington University in St. Louis for library preparation and sequencing. In 
brief, 10,000 cells per sample were loaded on a Chromium Controller (10x Genomics, USA) for 
single capture. Libraries were prepared using Single Cell 3′ Library & Gel Bead Kit v2 (10x 
Genomics, USA, 120237) following manufacture’s instruction. A single cell emulsion (Gel Bead-
In-Emulsions, GEMs) is created by making barcoded cDNA unique to each individual emulsion. 
Recovery agent was added to break GEM and cDNA was then amplified. A library is produced 
via end repair, dA-tailing, adaptor ligation, post-ligation cleanup with SPRIselect, and sample 
index PCR. The quality and concentration of the amplified cDNA was evaluated by Bioanalyzer 
(Agilent Technologies, USA, 2100) on a High Sensitivity DNA chip (Agilent Technologies, USA, 
5065-4401). Only cDNA with average library size 260-620 bp were used for sequencing. 
Sequencing was performed by HiSeq2500 (Illumina, USA) with the following read length: 26 bp 
for Read1, 8 bp for i7 Index, and 98 bp for Read2. A species mixing experiment (mouse and 
human) was also performed prior to running on actual sample to ensure good single cell capture 
(i.e., cell doublet rate < 5%). 
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2.3.5 Preprocessing of scRNA-seq data 
Paired-end sequencing reads were processed by Cell Ranger (10x Genomics software, version 
2.0.0). Briefly, reads were aligned to the GRCh38 (version 90) for genome annotation, 
demultiplexing, barcode filtering and gene quantification. Cell Ranger also removes any barcode 
that has less than 10% of the 99th percentile of total unique molecular identifiers (UMI) counts 
per barcode as these barcodes are associated with empty droplets. After this quality control, gene 
barcode matrix for sorted and unsorted cells were generated by counting the number of UMIs for 
a given gene (as row) in individual cell (as column). For sorted cell sample, 8,682 cells with 
19,140 genes were captured, while for unsorted cell sample, we obtained 8,220 cells with 19,604 
genes.   
2.3.6 Unsupervised clustering analysis and cell cluster annotation 
To assess the difference in composition of cell populations due to sorting for selective markers, 
we performed global unsupervised clustering analysis on data sets of scRNA-seq from sorted and 
unsorted cells. First, gene barcode matrices from were input into Seurat R package (version 2.4) 
(28). We then removed the low-quality cells with less than 200 or more than 7,000 detected genes, 
or if their mitochondrial gene content was more than 5%. Genes were filtered out that were 
detected in less than 3 cells. After filtering out low-quality cells or cell doublets, the gene 
expression was then natural log transformed and normalized for scaling the sequencing depth to 
10,000 molecules per cell. Next, to reduce the variance introduced by “unwanted” sources, we 
regressed out variation in gene expression driven by cell cycle stages and mitochondrial gene 
expression with vars.to.regress argument in function ScaleData in Seurat. We then used 
FindVariableGenes function in Seurat to identify highly variable genes across cells for 
downstream analysis. These quality control steps resulted in 4,173 cells with 1,833 highly variable 
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genes for sorted cell sample, and 8,630 cells with 3,009 highly variable genes for unsorted cell 
sample. Dimensionality reduction on the data was then performed by computing the significant 
principal components on highly variable genes. We then performed unsupervised clustering by 
using FindClusters function in Seurat with the resolution argument set to 0.6, and clusters were 
then visualized in t-distributed Stochastic Neighbor Embedding (tSNE) plot (29).   
Differentially expressed genes (DEGs) among each cell cluster were determined using 
FindAllMarkers function in Seurat. DEGs expressing at least in 25% cells within the cluster and 
with a fold change of more than 0.25 in log scale were considered to be marker genes of the 
cluster. To determine the biology functions of the marker genes from a given cluster, we 
performed Gene Ontology (GO) enrichment analysis by using The DAVID Gene Functional 
Classification Tool (http://david.abcc.ncifcrf.gov; version 6.8) (30). By comparing these unique 
biological GO terms with existing RNA-seq datasets and the literature, we were able to annotate 
cell clusters. Additionally, the top 10 enriched GO terms from biological function category with 
associated p values were visualized by GraphPad Prism (version 8.0; GraphPad Software). 
2.3.7 Canonical correlation analysis for integrated analysis of sorted and 
unsorted scRNA-seq data 
To compare cell types and to identify their associated DEGs between sorted and unsorted cells, 
we applied canonical correlation analysis (CCA), a computational strategy implemented in 
Seurat for integrated analysis of multiple datasets, on the scRNA-seq datasets from the cells with 
or without sorting. First, top 1,000 highly variable genes from two datasets were selected. We 
then use RunCCA function to identify common sources of variation between the two datasets and 
to merge the two objects into a single dataset. We next determined the top principal components 
of the CCA by examining a saturation in the relationship between the number of principle 
components and the percentage of the variance explained using the MetageneBicorPlot function. 
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By using selected top principal components, we aligned the CCA subspaces with AlignSubspace 
function, which returns a new dimensional reduction matrix allowing for downstream clustering 
and DEG analyses. DEG analysis was performed on the cells from different datasets but grouped 
in the same cluster (i.e. conserved cell types between two conditions) after CCA alignment. The 
methods for cell clustering, identification of conserved cells types and DEGs as well as 
annotation of cell clusters were similar to the ones mentioned previously. DEGs in each 
conserved cell types in response to sorting were visualized by ComplexHeatmap R package (31). 
2.3.8 Expansion of chondroprogenitor cells 
Sorted and unsorted chondroprogenitor cells were plated on non-coated flasks and cultured in 
MEM alpha media (Gibco, USA, 12571048) with 1% penicillin/streptomycin (P/S; Gibco, USA, 
15070063), 50 μg/ml L-ascorbic acid 2-phosphate (ascorbate; Sigma-Aldrich, USA, A4544), and 
10 ng/ml basic fibroblast growth factor (bFGF; R&D Systems, USA, 233FB001MGC). Cells 
were fed every three days until 80-90% confluency prior to further expansion or chondrogenesis. 
chondroprogenitor cells were passaged up to four times. 
2.3.9 Chondrogenic differentiation 
Sorted, unsorted, and expanded chondroprogenitor cells were re-suspended at 2.5 x 105 cells / 
mL in chondrogenic medium composed of DMEM/F-12, 1% FBS, 1% ITS+, 55 µM -
mercaptoethanol (Gibco, USA, 21985-023), 100 nM dexamethasone (DEX; Sigma-Aldrich, 
USA, D4902), 1% NEAA, 1% P/S, 10 ng/ml human transforming growth factor beta 3 (TGF-3; 
R&D Systems, USA, 24-3B3-200CF), 50 μg/ml L-ascorbic acid 2-phosphate (ascorbate; Sigma-
Aldrich, USA, A4544), and 40 μg/ml L-Proline (proline; Sigma-Aldrich, USA, P5607). 2 mL of 
the cell solution was added to a 15mL conical tube and centrifuged for 5 min at 300g to form a 





 After chondrogenic differentiation, pellets were collected in 10% neutral buffered formalin for 
fixation for 24 hours. Pellets were then transferred to 70% ethanol, dehydrated, and embedded in 
paraffin wax. Wax blocks were sectioned at 8 µm and stained for glycosaminoglycans and cell 
nuclei according to the Safranin-O and hematoxylin standard protocol. 
2.3.11 Immunohistochemistry 
Histologic sections were washed with xylene three times and rehydrated before labeling against 
COL1A1, COL2A1, COL6A1, and COL10A1. Antigen retrieval was performed with 0.02% 
proteinase K for 3 min at 37ºC for COL2A1 and COL6A1 and with pepsin for 5 min at RT for 
COL1A1 and COL10A1 followed by peroxidase quench then serum blocking for 30 min at RT 
each. Samples were labeled for 1 hour with the primary antibody (COL1A1: 1:800 Abcam, UK, 
90395; COL2A1: 1:10 Developmental Studies Hybridoma Bank, USA, II-II6B3-s; COL6A1 
1:1000 Fitzgerald, USA, 70F-CR009X; COL10A1 1:200 Sigma, USA, C7974) and for 30 min 
with the secondary antibody (COL1A1, COL2A1, COL10A1: 1:500 Goat Anti-Mouse Abcam, 
UK, 97021; COL6A1: 1:500 Goat Anti-Rabbit Abcam, UK, 6720). Reagent C was then used for 
enzyme conjugation for 20 min at RT followed by AEC for 2.5 min (COL2A1 and COL6A1) or 
2 min (COL1A1 and COL10A1) at RT. Finally, samples were counterstained with hematoxylin 
to reveal cell nuclei for 45 sec.  
2.3.12 Biochemical analysis 
Pellets were rinsed with PBS after chondrogenic differentiation and digested at 65ºC overnight in 
200 µl of 125 μg/ml papain (Sigma-Aldrich, USA, P4762), 100 mM sodium phosphate (Sigma-
Aldrich, USA, 71507), 5 mM ethylenediaminetetraacetic acid (EDTA; Sigma-Aldrich, USA, 
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ED2SS), and 5 mM L-cysteine hydrochloride (Sigma-Aldrich, USA, C1276) at 6.5 pH. Samples 
were stored at -80ºC before thawing to measure double stranded DNA and sulfated 
glycosaminoglycans (sGAG). The PicoGreen (Invitrogen, USA, P7589) and 1,9-
dimethylmethylene blue (Sigma-Aldrich, USA, 341088), with chondroitin-4-sulfate (Sigma-
Aldrich, USA, C9819) as a standard, assays were used according to the protocols to quantify 
DNA and sGAG respectively.  
2.3.13 Gene expression 
Day 28 pellets were rinsed with PBS-/- and snap frozen in 300 µl of Buffer RL (from Total RNA 
Purification Kit, Norgen Biotek, Canada, 37500) and stored at -80ºC. Samples were thawed and 
homogenized with zirconia beads (BioSpec Products, USA, 11079124zx) and a miniature bead 
beater. RNA was isolated from the samples using the Total RNA Purification Kit according to 
the manufacture’s protocol (Norgen Biotek, Canada, 37500). Reverse transcription of the RNA 
was performed using SuperScript VILO Master Mix (Thermo Fisher, USA, 11755500) to 
maintain cDNA. Fast SYBR Green Master Mix (Thermo Fisher, USA, 4385617) was used for 
quantitative real time polymerase chain reaction (RT-qPCR) according to manufacturer’s 
instructions on the QuantStudio 3 (Thermo Fisher, USA). Gene expression was analyzed using 
the CT method relative to undifferentiated hiPSCs with the reference gene TATA-box-binding 
protein (TBP) (32). Sequences of primers can be found in the Table 2.2.   
Table 2.2 Human primer sequences. Primers were used for RT-qPCR and are listed as 5’ to 3’. 
Gene Forward Sequence Reverse Sequence 
ACAN CACTTCTGAGTTCGTGGAGG ACTGGACTCAAAAAGCTGGG 
COL1A1 TGTTCAGCTTTGTGGACCTC TTCTGTACGCAGGTGATTGG 
COL2A1 GGCAATAGCAGGTTCACGTA CTCGATAACAGTCTTGCCCC 
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COL5A1 GGCTCCCGAGAGCAACCT CGGGACACTCACGAACGAA 
COL6A1 TCAAGAGCCTGCAGTGGATG TGGACACTTCTTGTCTATGCAG 
COL10A1 CATAAAAGGCCCACTACCCAAC ACCTTGCTCTCCTCTTACTGC 
IGFBP5 TCCCCACGTGTGTTCATCTG AAATGGGATGGACTGAGGCG 
NES CAGGGGCAGACATCATTGGT CACTCCCCCATTCACATGCT 
NKX3-2 GCTGGGAGCTTTCTGCACTA TTCGCACCCCTTGGTTACAA 
OTX1 AGACGCATCAGACCCTGAAGGACT CCAGACCTGGACTCTAGACTC 
PRRX1 GCAGGCTTTGGAGCGTGTCT TCCTGCGGAACTTGGCTCTT 
SOX9 CGTCAACGGCTCCAGCAAGAACAA GCCGCTTCTCGCTCTCGTTCAGAAGT 
TBP AACCACGGCACTGATTTTCA ACAGCTCCCCACCATATTCT 
2.3.14 Statistical analysis 
Quantification of surface marker expression was performed 8 separate times with technical 
replicates of n = 3-4 for each experiment.  Biochemical analysis and RT-qPCR were performed 
on the pellets collected from two independent sorting experiments (n = 3-4 samples per group 
per experiment). Gene expression and sGAG/DNA data were tested for normality using the 
Shapiro-Wilk test. An unpaired t-test with Welch’s correction was then performed assuming a 
Gaussian distribution. If data was not normal, an unpaired Kolmogorov-Smirnov test was 
performed. All calculations were performed using GraphPad Prism (GraphPad Software; version 
8.0).  Two-tailed p values were calculated and reported at a 95% confidence interval. 
2.4 Results 
2.4.1 COL2A1-positive chondroprogenitor cells express PDGFR, CD146, and 
CD166 
COL2A1-GFP reporter hiPSCs were differentiated into chondroprogenitor cells along the 
mesodermal lineage for 12 days as previously described (26). After the 12 days of 
differentiation, flow cytometric analysis showed that, on average, 4.27% of the population 
 40 
 
expressed COL2A1 based on GFP expression (Figure 2.1A). The COL2A1-positive cells were 
assumed to be chondroprogenitors with a unique surface marker profile. The cells were labeled 
for surface markers commonly associated with MSCs and/or chondroprogenitors in the 
developing limb bud: BMPR1, CD73, CD105, CD146, CD166, CD271, and PDGFR (22-24). 
Of the total population, less than 1% expressed COL2A1 in addition to either CD271 (0.4%), 
CD105 (0.16%), CD73 (0.09%), or BMPR1 (0%) (Figure 2.1B). Interestingly, 2.32%, 2.17%, 
or 1.32% of the total population co-expressed COL2A1 with PDGFR, CD146, or CD166 
respectively (Figure 2.1C). Since these markers appear to be the most highly correlated with 
COL2A1 expression of the previously identified as MSC and/or chondroprogenitor markers 
selected, cells were sorted based on expression of these markers for this study. Sorting also 
removed cells expressing CD45 (< 15% of total cells) to eliminate any non-chondrogenic 
hematopoietic stem cells potentially derived during mesoderm differentiation (Figure 2.1D). 
2.4.2 PDGFR, CD146, and CD166 enriched chondroprogenitor cells 
The BJFF hiPSC line (wildtype without genome editing) was differentiated into 
chondroprogenitor cells accordingly (12 days in monolayer). Cells either directly underwent 
chondrogenic pellet culture, were expanded, were saved for scRNA-seq, or were labeled for the 
surface markers of interest (Figure 2.1D). Fluorescent activated cell sorting (FACS) was used to 
sort live chondroprogenitor cells negative for CD45 and positively expressing PDGFR and 
CD146, followed by expression of CD166 (Figure 2.1E). Cells not expressing any of these 
surface markers were also analyzed as a negative control. Approximately 16.5% of the total 
chondroprogenitor cell population was triple positive for PDGFR, CD146, and CD166, which 
was significantly higher than the percentage of the cells (7.2% of total cell population) that were 
triple-negative for these markers (Figure 2.1F). As with unsorted cells, sorted cells were also 
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collected and either pelleted for chondrogenesis, expanded, or saved for scRNA-seq, as 
described in Figure 2.1D.  
 
Figure 2.1 Surface marker analysis and sorting strategy to identify progenitors with robust 
chondrogenic potential from heterogenous chondroprogenitor (CP) cells. (A) Flow cytometry 
showed approximately 4.27% of cells expressed COL2A1-GFP. (B-C) Chondroprogenitors were 
labeled for various surface markers and analyzed for co-expression with COL2A1-GFP. (B) 
Most COL2A1-GFP+ cells did not express CD271, CD105, CD73, and BMPR1. (C) PDGFR, 
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CD146, and CD166 were co-expressed with COL2A1-GFP. (D) A schematic representing the 
experimental design. The RVR cell line with the COL2A1-GFP reporter was differentiated into 
chondroprogenitor cells. Surface marker analysis indicated that PDGFR, CD146, and CD166 
expression were highly co-expressed with COL2A1 but not CD45. (E) Cells expressing these 
desired markers were sorted from wildtype BJFF chondroprogenitor cells. To evaluate 
chondrogenic potential of the sorted cells, pellets from the sorted cells were either made 
immediately post-sorting or formed after in vitro expansion. (F) A higher percentage of the total 
cell population (~16.8%) were triple positive for the desired markers compared to the population 
not expressing any of these markers. * p < 0.05. Data represented as mean ± SEM. n = 7-8 
independent experiments. 
2.4.3 scRNA-seq reveals that unsorted chondroprogenitor cells contained 
diverse cell populations  
We next used scRNA-seq to explore the cell diversity and genetic profiles of unsorted 
chondroprogenitor cells. At least 9 distinct cell populations (cell clusters) were observed in 
unsorted chondroprogenitor cells (Figure 2.2A). Among these populations, 5 of them were 
enriched for a variety of neural cell markers such as SOX2, OTX1, NES, and PAX6 (Figure 2.2B), 
likely representing populations of the neurogenic lineage. Of these, SOX2, OTX1, and PAX6 
expression were significantly downregulated with sorting according to RT-qPCR (Figure S2.2A). 
Furthermore, we found that 3 cell populations exhibited high expression levels of several 
mesenchyme markers including PRRX1, COL1A1, COL5A1, and COL6A1 which were 
comparable between sorted and unsorted groups, while only a small cell population (2.3% of 
total cells) expressed chondrogenic markers such as SOX9, COL2A1, IGFBP5, and NKX3-2 
(Figure 2.2B, 2.2C, S2.2B, and S2.2C). Using Gene Ontology (GO) enrichment analysis of the 
gene sets representing each cell cluster (Figure 2.2D and S2.1A) we observed that cells 
expressing SOX9 and COL2A1 demonstrated gene sets enriched for protein translation and 






Figure 2.2 Cell populations and GO enrichment analysis of unsorted chondroprogenitor cells. 
(A) scRNA-seq identified unsorted chondroprogenitor cells contained at least 9 populations, 
which could be further categorized into 3 broad classes: neurogenic cells (blue dashed circle), 
chondrogenic cells (green dashed circle), and mesenchyme (brown dashed circle). (B) 
Expression of signature genes of each cell lineage. (C) GO terms analysis (biological process) of 
each unique population. (D) Percentage of total unsorted chondroprogenitor cells in each unique 
cell population. More than 20% of the unsorted chondroprogenitors were SOX2/TTR/NES+ 
neurogenic cells, while only small number of unsorted cells expressed SOX9 and COL2A1.  
2.4.4 scRNA-seq reveals that sorting enriched SOX9/COL2A1+ cells 
scRNA-seq of sorted chondroprogenitor cells indicated that there were at least 6 cell populations 
consisting of PDGFR+/CD146+/CD166+ cells (Figure 2.3A). Surprisingly, there was still a 
small percentage of cells (4% of total sorted cells) expressing SOX2 and NES, despite the 
stringent sorting regime (Figures 2.3B and 2.3C). We also observed that SOX2/NES+ cells 
exhibited high expression of CD47, an integrin-associated protein (33) (Figure S2.1B). 
Nevertheless, sorting still significantly enriched cells positive for SOX9 and COL2A1 by > 11-
fold (27% of total sorted cells vs. 2.3% of total unsorted cells). Interestingly, overall gene 
expression of these chondrogenic genes was not increased, in fact COL2A1 was decreased with 
sorting when evaluated by RT-qPCR (Figure S2.2C). We observed that sorting slightly increased 
the percentage of the cells expressing ALCAM (22.1% of the unsorted cells vs. 28.3% of the 
sorted cells). However, 9.9% of the total sorted cells were triple positive for 
SOX9/COL2A1/ALCAM, while only 0.8% of the total unsorted cells co-expressed these three 
genes. Interestingly, we also found that ALCAM was also expressed by both chondrogenic and 
neurogenic progenitors (e.g., 31.9% of SOX9/COL2A1+ cells and 44.9% of SOX2/TTR+ cells 
were positive for ALCAM in the sorted group), implying ALCAM alone may not be used as a 
sole marker for chondroprogenitor cells. Additionally, we also observed that gene expression 
levels of the sorting makers were enriched in the sorted population, with ALCAM (CD166) 
highest in the SOX9 and COL2A1 cluster compared to the enrichment of all three in the unsorted 
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mesenchyme population (Figure 2.3D). Similarly, there was enrichment of some previously 
reported pro-chondrogenic markers (18, 19, 21, 24) in the sorted chondroprogenitor population; 
specifically ITGA5 and ENG (CD105) (Figure S2.3). Skeletal system development, as expected, 
emerged as a significant GO term in SOX9/COL2A1+ cells, while HMGB2/TOP2A+ and 






Figure 2.3. Cell populations and GO enrichment analysis of sorted chondroprogenitor cells. (A) 
scRNA-seq identified PDGFR+/CD146+/CD166+ cells contained at least 6 populations. (B) 
Expression of signature genes of each cell lineage. The sorted cells were enriched for 
mesenchymal and chondrogenic genes. (C) Percentage of total sorted chondroprogenitor cells in 
each unique cell population. 27% of the sorted were SOX9/COL2A1. Interestingly, a small 
percentage of cells (4% of total sorted cells) expressing SOX2 and NES was still observed. (D) 
PDGFR+/CD146+/CD166+ sorted cells may belong to mesenchymal population (brown dashed 
circle) in unsorted cells. Green dashed circle indicates the population that was positive for SOX9 
and COL2A1. (E) GO terms analysis (biological process) showing skeletal system development 
was highlighted in SOX9/COL2A1+ cells, while HMGB2/TOP2A+ and LGALS1/PTTG1+ cells 
were enriched in gene sets of cell division. 
2.4.5 Canonical correlation analysis (CCA) demonstrates high enrichment of 
proliferative and mesenchymal genes in sorted chondroprogenitor cells 
CCA, a machine-learning method that performs linear combinations of features across data sets 
that are maximally correlated, was used to integrate scRNA-seq datasets from sorted and 
unsorted cells (28). Five major conserved populations were identified after CCA alignment of the 
sorted and unsorted chondroprogenitor cells (Figure 2.4A). Among these populations, 
HIST1H4C+ cells accounted for the largest conserved population, while the IGFBP5/COL2A1+ 
cluster was the smallest. We next performed differentially expression gene (DEG) analysis to 
explore how sorting enriches or depletes the levels of gene expression within each individual 
population (Figure 2.4B). Within the IGFBP5/COL2A1+ population, sorted cells exhibited 
significantly up-regulated expression of several mesenchymal genes including TPM1, TAGLN 
and TMSB10 (indicated by brown circle), which have been suggested to be essential in 
chondrogenesis (34, 35). Furthermore, within the IGFBP5/COL2A1+ population, sorted cells 
demonstrated significantly down-regulated expression of IGFBP5 (indicated by blue circle), an 








Figure 2.4 CCA for integrated analysis of sorted and unsorted scRNA-seq datasets. (A) Five 
major conserved populations were identified after CCA alignment of the sorted and unsorted 
chondroprogenitor cells (B) DEG analysis indicated that sorted cells exhibited significantly up-
regulated expression of several mesenchymal genes including TPM1, TAGLN and TMSB10 
(brown circle), which have been suggested to be essential in chondrogenesis. Proliferative 
markers including SOX4 (red circle) and TUBA1A (yellow circle) were increased, but IGFBP5 
(blue circle) and several ribosomal genes were decreased in sorted cells. 
2.4.6 Sorting improved matrix production and homogeneity in cartilaginous 
pellets 
Sorted and unsorted cells from both the reporter and wildtype lines underwent chondrogenesis in 
pellet culture for 28 days. Pellets stained with safranin-O for sulfated glycosaminoglycans 
(sGAGs) showed that sorting increased matrix production as well as homogeneity of cell 
morphology (Figure 2.5A and S2.4). Additionally, the layer of non-cartilaginous-like cells 
surrounding unsorted cell pellets was eliminated in the pellets derived from sorted cells. 
Biochemical analysis demonstrated that sorting significantly increased the ratio of sGAGs to 
DNA in pellets by almost 15-fold (unsorted: 1.5 ng/ng vs. sorted: 19.89 ng/ng, Figure 2.6A). 
Similarly, there was an increase in production and homogeneity observed in sorted pellets 
labeled for COL2A1 (Figure 2.5B). In addition, IHC labeling for COL1A1 showed a slight 
decrease at the perimeter of the pellet while the labeling for COL10A1 showed an increase in the 
respective matrix proteins with sorting (Figure 2.5C and 2.5D). Additionally, pellets formed with 
sorted cells had more localized staining of COL6A1 around the cells as shown with IHC 




Figure 2.5 Histology and IHC for matrix proteins in RVR-COL2 and BJFF pellets. (A) Safranin-
O staining for sGAG showing pellets derived from sorted chondroprogenitor cells had more 
robust staining and homogenous cell morphology compared to pellets derived from unsorted 
cells in both lines. (B) Labeling of COL2A1 showed similar results with an increase in COL2A1 
in sorted pellets as opposed to unsorted which has isolated areas of staining. (C) There was little 
labeling of COL1A1 for both unsorted and sorted cell pellets. (D) Labeling for COL10A1 was 
increased with sorting. Scale bar = 200 µm. Inset scale bar = 400 µm. 
2.4.7 Expression of cartilaginous genes was significantly higher in pellets 
derived from triple positive chondroprogenitor cells 
Gene expression in pellets derived from unsorted and triple positive-sorted chondroprogenitor 
cells was analyzed using RT-qPCR. Chondrogenic genes SOX9 (unsorted: 0.88-fold change vs. 
sorted: 6.62 fold change), ACAN (unsorted: 7.22-fold change vs. sorted: 1614-fold change), and 
COL2A1 (unsorted: 0.68-fold change vs. sorted: 1667-fold change) were significantly increased 
in sorted pellets (Figure 2.6B-D). Additionally, COL1A1 (unsorted: 0.74-fold change vs. sorted: 
25.91-fold change) and COL10A1 (unsorted: 2.69-fold change vs. sorted: 54.32-fold change) 
were significantly higher in sorted pellets compared to unsorted (Figure 2.6E-F). Statistical 
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significance was maintained for all genes when analyzed alternatively (Figure S2.6). 
 
Figure 2.6. Quantitative analysis of matrix production and gene expression. (A) Sorting of 
chondroprogenitor cells prior to chondrogenesis significantly increased the sGAG/DNA ratio to 
approximately 20 ng/ng. (B-D) Expression of chondrogenic genes ACAN, SOX9, and COL2A1 
was significantly increased with sorting. (E-F) Sorting significantly unregulated fibrocartilage 
and bone matrix marker COL1A1, and hypertrophic cartilage marker COL10A1. Gene expression 
in reference to undifferentiated hiPSCs with housekeeping gene TBP. * p < 0.05. ** p < 0.01. 
*** p < 0.001. **** p < 0.0001. Data represented as mean ± SEM. n = 6-7 per group: 2 
experimental replicates, 3-4 technical replicates (pellets). 
2.4.8 Chondrogenic capacity was maintained through one passage of unsorted 
and sorted chondroprogenitor cells 
Pellets derived from passage 1 (p1) sorted cells exhibited the most robust and homogenous 
safranin-O staining as compared to the pellets derived from sorted cells of later passages and to 
the pellets derived from unsorted cells of a similar passage (Figure S2.7). Pellets derived from 
p2-4 unsorted and sorted chondroprogenitor cells had comparable staining and cell morphology 




Using a COL2A1-GFP reporter line, we have identified a novel combination of surface markers 
(i.e., PDGFR+/CD146+/CD166+/CD45-) depicting a unique progenitor population with robust 
chondrogenic potential in hiPSC chondrogenesis. This finding was further confirmed by 
significantly increased cartilaginous matrix production of the prospectively isolated cells with 
these selected markers from a wildtype, non-edited hiPSC line. The results of scRNA-seq of 
sorted cells revealed that cells positive for PDGFR, CD146, and CD166 exhibited enhanced 
cell homogeneity with decreased neurogenic subpopulations. These findings support the 
hypothesis that sorting of hiPSC-derived chondroprogenitor cells using surface markers can be 
used to purify progenitor cells with enhanced chondrogenic potential, without the need for 
genetic modification to improve hiPSC chondrogenesis (25, 26). 
 We previously reported that chondroprogenitor cells at the end of mesodermal lineage 
differentiation had high expression of CD146 and CD166 (26). In the present study, we observed 
that these markers were also co-expressed with COL2A1. CD146 and CD166, along with CD105, 
have also been shown to be expressed in chondroprogenitors in articular cartilage (19-21). While 
our chondroprogenitor cells did not co-express CD105 (ENG) with COL2A1, sorting did enrich 
CD105 gene expression. Interestingly, it has been shown that CD105 itself may not indicate 
chondrogenic potential (37). In addition, scRNA-seq showed that sorted cells exhibited increased 
expression of ITGB1 (CD29) and ITGA5 (CD49e), which have been deemed necessary for 
chondrogenic differentiation in progenitor cells and MSCs (18, 19, 38). Nevertheless, our 
chondroprogenitor cells had somewhat different expression profiles than skeletal progenitor cells 
identified previously in vivo (23, 24). Moderate expression of CD164, a surface marker of the 
skeletal stem cell (23), was conserved between the unsorted and sorted chondroprogenitor cells 
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while many other markers described were absent from both populations including 
prechondrocyte markers BMPR1 and CD73 (NT5E) (24). Therefore, the chondroprogenitor 
population described in this study is a distinct, unique subpopulation of iPSCs that possesses 
robust chondrogenic potential. 
Several factors may contribute to the differences in cell surface markers that have been. 
identified as markers of chondrogenesis in these different cell types. First, in our study we used a 
differentiation protocol which follows the paraxial mesodermal lineage of cartilage (26, 39). 
Different types of cartilage follow various developmental pathways (e.g., paraxial mesoderm vs. 
lateral plate mesoderm) and therefore the other studies could be investigating these lineages, thus 
the cells would have different surface marker expression during differentiation (39-41). Another 
explanation may be the time point along the developmental pathway in which the cells are being 
investigated. Our surface marker profiles are based on the expression of COL2A1. While 
COL2A1 is one of the most prominent matrix proteins in articular cartilage (4) and can indicate 
chondrogenic potential and determination of a chondrogenic fate (42), COL2A1 is a relatively 
late marker of chondrogenesis (43). Therefore, differences between the cell surface markers 
identified in our study as compared to other previous work may reflect differences in the 
prescribed differentiation pathway or the specific subpopulation identified. 
In addition to the fact that COL2A1 expression is a later chondrogenic marker, COL2A1 
expression was found throughout the entire unsorted population including neurogenic cells and 
sorting significantly decreased its overall expression indicating that COL2A1+ cells were 
heterogenous. This finding is consistent with studies showing that COL2A1 expression may be a 
broader indicator for the initial lineage specification of a variety of tissues rather than a sole 
marker for chondrogenesis during embryonic development (43-45). Indeed, it has been reported 
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that COL2A1 is expressed in the floor plate of the central nervous system (46), which provides a 
plausible explanation for our observation of COL2A1 expression in neurogenic cells. This may 
also explain why there are many COL2A1 positive cells not expressing the selected surface 
markers. CD146, CD166, and PDGFR may be specific to chondroprogenitors as opposed to 
cells of other lineages also expressing collagen type II thus purifying the population as shown 
with increased COL2A1 IHC labeling when compared to sorting for COL2A1 alone. Following 
sorting for these markers, the size of the chondrogenic SOX9/COL2A1 population was increased 
and, while the neural SOX2 populations were reduced, a SOX2/TTR population remained. In fact, 
this population had high expression of CD47, an integrin-associated and modulating protein (33) 
that could be used as an additional marker for sorting in future experiments to improve 
homogeneity. The expression of nestin and several mesenchyme markers appeared to be 
permissive in sorted cells, suggesting that PDGFR/CD146/CD166 triple-positive cells may still 
have a similar signature as neural crest cells (47, 48) and might come primarily from 
mesenchyme populations in unsorted cells. Nonetheless, despite the presence of 6 unique cell 
clusters, including the SOX2/TTR population, sorted chondroprogenitor cells showed robust 
chondrogenic capacity.  
The sorted chondroprogenitors, which all express PDGFR, CD146, and CD166, were 
found to be localized in the mesenchyme clusters of unsorted cells. Alignment of the unsorted 
and sorted populations by CCA allowed us to compare similarities and differences between the 
two groups. After alignment, the largest cell cluster expressed histone H4 (HIST1H4C). Histones 
are primarily synthesized during the S-phase of the cell cycle to package the replicated DNA 
(49), thus indicating the large portion of cells in both sorted and unsorted populations are 
proliferative. Furthermore, there was a decrease in insulin-like growth factor binding protein-5 
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(IGFBP5) expression in sorted cells among the IGFBP5/CO2A1 population compared to 
unsorted. IGFBP5 plays a role in insulin-like growth factor-1 (IGF-1)-dependent chondrocyte 
proliferation (50) and protects cartilage during OA-induced degeneration (51). This may imply 
that sorted cells may be precursors not fully committed into chondrogenic linage in comparison 
with unsorted cells. This could be further supported by the observation that sorted cells had 
increased expression in neural crest and proliferation markers (i.e., SOX4 and TUBA1A, 
respectively) (52). Indeed, for all populations identified in the sorted cells, we found that they 
exhibited elevated expression in proliferative and mesenchymal genes, further suggesting that 
sorted cells were primarily derived from mesenchyme populations in unsorted cells. Nonetheless, 
subpopulations in sorted cells still expressed unique gene signatures as shown by the clustering. 
This finding implies that chondrocytes may differentiate from mesenchyme cells with a variety 
of transcriptomic profiles if given the correct signaling cues with appropriate timing.  
Cartilaginous pellets derived from sorted chondroprogenitor cells showed a significant 
increase in chondrogenic matrix production and gene expression along with the elimination of a 
surrounding layer of non-chondrocyte-like cells. Despite the increase in COL1A1 gene 
expression, COL1A1 protein, as indicated by IHC labeling, does not reflect its gene expression, 
implying a potential possibility of post-transcriptional regulation of COL1A1 in protein 
translation (53). This results also suggest that the matrix produced by the hiPSC-derived 
chondrocytes is similar to hyaline cartilage instead of fibrocartilage which is rich in COL1A1 
protein. Surprisingly, there was also a relatively small increase in IHC labeling of COL10A1, a 
matrix protein often associated with hypertrophic chondrocytes (54, 55). Interestingly, COL6A1 
was observed to be more localized around the cells in pellets derived from sorted cells. In 
developing neonatal cartilage, COL6A1 is found throughout the matrix, but with maturity it is 
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only found in the pericellular matrix surrounding the chondrocytes (56-58). The increased 
expression in COL10A1 at both mRNA and protein levels alongside the co-localization of 
COL6A1 around chondrocytes suggests that the chondrocytes derived from the sorted cells were 
at more mature stages as compared to the chondrocytes derived from unsorted cells after 28 days 
of chondrogenic culture. With maturity and COL10A1 secretion, there is a possibility that these 
cells may further differentiate into hypertrophic chondrocytes and undergo endochondral 
ossification. Future studies could be done to investigate the differentiation trajectory with more 
time in culture and in vivo.  
As cell sorting can significantly reduce the number of functional cells (59), we also 
examined the effects of cell expansion on differentiation potential of the sorted cells prior to 
chondrogenesis. Cells in the first passage following sorting exhibit high chondrogenic potential 
and sGAG staining in pellet culture.  However, in subsequent passages, cells showed signs of 
dedifferentiation and loss of chondrogenic capacity, similar to that observed in primary 
chondrocytes (60) as well as similarly sorted mouse iPSCs (25).  The decreased chondrogenic 
potential of sorted cells may result from telomere erosion (61), plating density (e.g., cell-cell and 
cell-matrix interactions) (60, 62-64), mechanobiological factors (e.g., plate stiffness and/or 
coating) (65, 66), or culture medium (e.g., low vs. high glucose, growth factors) (62, 65). While 
we used an expansion media similar to MSC expansion media due to similarities of the cells, in 
the future, the media could be altered by changing the glucose level (64) and/or adding growth 
factors such as fibroblastic growth factor (FGF)-2 and FGF-4, bone morphogenic protein (BMP)-
2 and BMP-3, transforming growth factor beta (TGF)-3, heparin-binding epidermal growth 
factor (EGF), and platelet derived growth factor (PDGF)- (62, 65, 67) as these have been 
shown to maintain and improve multipotency and chondrogenic capacity.  
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Figure S2.1 GO enrichment analysis of unsorted and sorted cells. Related to Figure 2 and 3. (A) 
Top 10 GO terms (biological process) that were associated with each population in unsorted 
cells. (B) CD47 was highly expressed in SOX2/TTR+ cells. (C) Top 10 GO terms (biological 
process) that were associated with each population in sorted cells. 
 
Figure S2.2 Overall gene expression of sorted and unsorted chondroprogenitors. Related to 
Figure 2 and 3. RT-qPCR reveals differences between sorted and unsorted chondroprogenitor 
cells in overall expression of (A) neurogenic, (B) mesenchymal, and (C) chondrogenic genes. 
Gene expression in reference to undifferentiated hiPSCs with housekeeping gene TBP. * p < 




Figure S2.3 Expression profiles of pro-chondrogenic genes in sorted and unsorted 
chondroprogenitor cells. Related to Figure 2 and 3. scRNA-seq reveals that sorted and unsorted 
cells had distinct gene expression patterns of several markers that were proposed to be pro-
chondrogenic identified by previous studies. 
 
Figure S2.4 Histology for matrix proteins. Related to Figure 5. Safranin-O staining for sGAG 
showing pellets derived from sorted chondroprogenitor cells had more robust staining and 
homogenous cell morphology compared to pellets derived from unsorted cells in two individual 




Figure S2.5 IHC labeling for COL6A1. Related to Figure 5. There was more distributed labeling 
for COL6A1 in unsorted chondroprogenitor pellets compared to the localization around cells in 
sorted chondroprogenitor pellets. Scale bar = 200 µm. Inset scale bar = 400 µm. 
 
Figure S2.6 Alternative analysis of gene expression. Related to Figure 6. Expression of 
chondrogenic genes ACAN, SOX9, and COL2A1, fibrocartilage and bone matrix marker 
COL1A1, and hypertrophic cartilage marker COL10A1 was significantly increased with sorting. 
CT value of gene of interest was normalized to CT value of housekeeping gene TBP for each 
sample. ** p < 0.01. *** p < 0.001. **** p < 0.0001. Data represented as mean ± SEM. n = 6-7 




Figure S2.7. Histology of pellets derived from in vitro expanded unsorted and sorted 
chondroprogenitors. Chondrogenic capacity was maintained after one passage of both unsorted 
and sorted chondroprogenitor cells as shown by staining for sGAG. There was more robust 
staining in pellets derived from sorted cells. Safranin-O staining for sGAG showed similar loss 





In conclusion, we have identified a unique chondroprogenitor population from hiPSCs which 
expresses PDGFR, CD146, and CD166 and has strong chondrogenic potential. While the 
population does share some characteristics with previously defined chondroprogenitors and 
traditionally defined MSCs, it has a distinct profile. The methods and findings in this study will 
contribute to future cartilage tissue engineering and disease modeling studies to improve 
understanding and treatment of diseases such as osteoarthritis. 
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3.1 Abstract 
The therapeutic application of human induced pluripotent stem cells (hiPSCs) for cartilage 
regeneration is largely hindered by the low-yield of chondrocytes accompanied by unpredictable 
and heterogeneous off-target differentiation of cells during chondrogenesis. Here, we combine 
bulk RNA sequencing, single-cell RNA sequencing, and bioinformatic analyses, including 
weighted gene co-expression analysis (WGCNA), to investigate the gene regulatory networks 
regulating hiPSC differentiation under chondrogenic conditions. We identify specific Wnts and 
MITF as hub genes governing the generation of off-target differentiation into neural cells and 
melanocytes during hiPSC chondrogenesis. With heterocellular signaling models, we further 
show that Wnt signaling produced by off-target cells are responsible for inducing chondrocyte 
hypertrophy. By targeting Wnts and MITF, we eliminate these cell lineages, significantly 
enhancing the yield and homogeneity of hiPSC-derived chondrocytes. Collectively, our findings 
identify the trajectories and molecular mechanisms governing cell fate decision in hiPSC 
chondrogenesis, as well as dynamic transcriptome profiles orchestrating chondrocyte 




Osteoarthritis (OA) is a debilitating joint disease characterized by cartilage degeneration as well 
as pathologic remodeling of other joint tissues. Cartilage has limited intrinsic healing capacity, 
motivating the application of stem cells for regenerative therapies. In this regard, the advent of 
human induced pluripotent stem cells (hiPSCs) has served as a major breakthrough towards 
cartilage regenerative therapies and in vitro disease modeling for OA drug discovery (1). 
However, the development of protocols to consistently differentiate hiPSCs into chondrocytes 
remains challenging. Early studies reported that chondrocytes can be generated from hiPSCs via 
embryoid body formation followed by monolayer expansion of mesodermal cells and three-
dimensional cell pellet culture in chondrogenic induction medium (2, 3). Despite some success, 
this approach was proven difficult to reproduce across different iPSC lines, potentially due to 
variability in lots of fetal bovine serum generally used for cell expansion. Thus, recent strategies 
have sought to use serum-free and chemically defined medium (4-6). By coupling inductive and 
repressive signals required for mesoderm specification in embryonic development (7), we 
established a step-wise hiPSC chondrogenic differentiation protocol that was validated with 
multiple hiPSC lines and in several laboratories (8).  
An important consideration in the differentiation process of hiPSCs is that they are 
considered to be in a primed pluripotent state with increased genome-wide DNA methylation 
compared to ground state naïve pluripotent cells, such as pre-implantation blastocysts (9). 
Therefore, even directed differentiation of hiPSCs can lead to unpredictable formation of off-
target cell populations. However, the gene regulatory networks (GRNs) leading to on- or off-
target differentiation of hiPSCs, as well as the effect of the undesired cells on hiPSC 
chondrogenesis (i.e., heterocellular signaling), remain to be elucidated, particularly at the single 
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cell level.  
Here, we apply bulk RNA sequencing (bulk RNA-seq) and single-cell RNA sequencing 
(scRNA-seq) throughout the process of mesodermal and chondrogenic differentiation of hiPSCs 
to map the dynamics of gene expression. By exploiting single cell transcriptomics, we confirm 
the mesodermal and chondrogenic differentiation of hiPSCs in addition to identifying the GRNs 
and critical hub genes regulating the generation of heterogenous off-target cells. We demonstrate 
that homogeneity of hiPSC chondrogenesis can be significantly improved by inhibiting the 
molecular targets Wnts and MITF. In summary, this study develops and validates an enhanced 
hiPSC chondrogenic differentiation protocol. 
3.3 Methods 
3.3.1 hiPSC lines and culture 
Three distinct hiPSC lines were used in the current study:  STAN, ATCC, and BJFF. STAN line 
was purchased from WiCell (#STAN061i-164-1), ATCC line was acquired from ATCC 
(#ATCCACS-1019), and BJFF was obtained from the Genome Engineering and iPSC Core at 
Washington University in Saint Louis. All three lines were reprogrammed by Sendai virus from 
human foreskin fibroblasts and confirmed to be karyotypically normal and mycoplasma free. 
STAN and BJFF hiPSCs were maintained on vitronectin coated 6-well plates (Thermo Fisher 
Scientific, #A31804) in Essential 8 Flex medium (Thermo Fisher Scientific, #A2858501). ATCC 
hiPSCs were cultured on CellMatrix Basement Membrane Gel coated 6-well plates (ATCC, 
#ACS3035) in Pluripotent Stem Cell SFM XF/FF medium (ATCC, #ACS3002). Cells were fed 
daily, and passaged with ReLeSR (STEMCELL Technologies, #05872). All hiPSC lines were 
maintained below passage 30. Information regarding the cell lines can be found in Table 3.1. 
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3.3.2 hMSCs and culture 
Discarded and deidentified waste tissue from the iliac crests of adult bone marrow transplant 
donors were collected in accordance with the institutional review board of Washington 
University in Saint Louis. Human bone marrow-derived MSCs (hMSCs) were isolated by their 
physical adherence to plastic culture vessels. (10) Cells were expanded and maintained in 
expansion medium consisting of DMEM-low glucose (Thermo Fisher Scientific, #11885092), 
1% penicillin/streptomycin (P/S, Thermo Fisher Scientific, #15140-122), 10% lot-selected fetal 
bovine serum (FBS; Atlanta Biologicals, #S11550), and 1 ng ml-1 basic fibroblast growth factor 
(R&D Systems, #233-FB). Three individual donors were used as biologic replicates in 
subsequent experiments (Table 3.1). 
Table 3.1 Subject details. 
Donor ID Study ID Cell type GenoType Age, Sex 
PHBI-BA-060 STAN iPSC wt/wt 1 yr, M 
SCRC-1041 ATCC iPSC wt/wt Newborn, M 
BJFF.6 BJFF iPSC wt/wt Newborn, M 
hMSC3 Donor 1 MSC wt/wt 51, F 
hMSC4 Donor 2 MSC wt/wt 38, M 
hMSC6 Donor 3 MSC wt/wt 26, F 
3.3.3 Mesodermal differentiation 
hiPSCs were induced into mesodermal differentiation in monolayer at 40% confluency (7). Each 
day, cells were rinsed with wash medium consisting of 50% IMDM GlutaMAX (IMDM, Fisher 
Scientific, #31980097) and 50% Ham’s F12 Nutrient Mix (F12, Fisher Scientific, #31765092) to 
remove previous medium. hiPSCs were then fed daily to sequentially drive mesodermal 
differentiation similar to those identified in embryonic development with various sets of growth 
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factors and small molecules supplemented in mesodermal differentiation medium consisting of 
IMDM and F12 with 1% chemically defined lipid concentrate (Gibco), 1% insulin/human 
transferrin/selenous acid (ITS+, Corning, #354352), 1% P/S (Thermo Fisher Scientific, #15140-
122), and 450 μM 1-thioglycerol (Sigma–Aldrich, #M6145). Cells were induced to the anterior 
primitive streak with 30 ng ml-1 of Activin A (R&D Systems, #338-AC), 4 µM CHIR99021 
(Stemgent, #04-0004), and 20 ng ml-1 human fibroblast growth factor (FGF; R&D Systems, #233-
FB-025/CF) for 24 hours. On the second day, cells were driven to paraxial mesoderm with 2 µM 
SB-505124 (Tocris, #3263), 3 µM CHIR99021, 20 ng ml-1 FGF, and 4 µM dorsomorphin 
(Stemgent, #04-0024). Then, cells were treated with 2 µM SB5, 4 µM DM, 1 µM Wnt-C59 (C59; 
Cellagent Technology, #C7641-2s), and 500 nM PD173074 (Tocris, #3044) to become early 
somite on the third day. For the fourth through sixth days, cells were driven to the sclerotome with 
daily feedings of 2 µM purmorphamine (Stemgent, #04-0009) and 1 µM C59. Finally, for six days, 
cells were driven to the chondroprogenitor stage (Cp) with 20 ng ml-1 of human bone 
morphogenetic protein 4 (BMP4; R&D Systems, #314-BP-010/CF) daily (Figure S3.1A).   
At each stage, some cells were dissociated using TrypLE (Gibco, #12604013) at 37ºC for 
3 mins followed by adding an equal part of neutralizing medium consisting of DMEM/F-12, 
GlutaMAXTM (DMEM/F12; Thermo Fisher Scientific, #10565042) with 10% FBS (Atlanta 
Biologicals) and 1% P/S. The dissociated cells were either used for bulk RNA-seq, scRNA-seq, 
chondrogenic differentiation, or fluorescence-activated cell sorting (FACS) as appropriate.  
3.3.4 Chondrogenic differentiation 
Cells dissociated at Cp stage were re-suspended at 5 x 105 cells per mL in chondrogenic medium 
consisting of DMEM/F-12, 1% FBS, 1% ITS+, 55 µM -mertcaptoethanol, 100 nM 
dexamethasone (DEX; Sigma-Aldrich, #D4902), 1% NEAA (Gibco, #11140050), 1% P/S, 10 ng 
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ml-1 human transforming growth factor beta 3 (TGF-3; R&D Systems, #243-B3-010), 50 μg ml-
1 L-ascorbic acid 2-phosphate (ascorbate; Sigma-Aldrich, #A8960), and 40 μg ml-1 L-Proline 
(proline; Sigma-Aldrich, #P5607). Cells were then centrifuged for 5 min at 300x g to form a 
pellet. Chondrogenic pellets were cultured at 37ºC for up to 42 days.  
On the day of collection for bulk RNA-seq experiments, 3-4 pellets per experimental 
group were pooled together and washed once with PBS, snap frozen in 300 µl of Buffer RL 
(Norgen Biotek), and stored at -80ºC until processing for RNA extraction. At harvesting time 
points for scRNA-seq experiments, 6-8 pellets per experimental group were pooled and digested 
with 0.04% type 2 collagenase solution in DMEM/F12 for 1hr. Cells were washed once with 
PBS, re-suspended in standard freezing medium, and stored in liquid nitrogen until needed.  
3.3.5 C59 and ML329 treatment for Wnt and MITF inhibition 
For C59 treatment for Wnt inhibition during chondrogenesis, pellets were treated with either 10 
ng ml-1 TGF-3 (control group) or a combination of 10 ng ml-1 TGF-3 and 1 M C59 in 
chondrogenic medium from d0 to d42 as appropriate. For C59 and ML329 treatment (ML, Axon 
Medchem, HY-101464) for Wnt and MITF inhibition during chondrogenesis, pellets were 
treated with either 10 ng ml-1 TGF-3 (control group), a combination of 10 ng ml-1 TGF-3 and 
1 M ML, a combination of 10 ng ml-1 TGF-3 and 1 M C59, or a combination of 10 ng ml-1 
TGF-3, 1 M ML and 1 M C59 in chondrogenic medium from d0 to d42 as appropriate. 
3.3.6 Wnt ligands treatment during chondrogenesis 
For Wnt ligands treatment during chondrogenesis, pellets were treated with either 10 ng/ml TGF-
3 (control group) or a combination of 10 ng ml-1 TGF-3 and 100 ng ml-1 individual Wnt ligand 
(Wnt2B, Wnt3A, Wnt4, Wnt5B, or Wnt7B, all from R&D system) in chondrogenic medium 
from d0 to d42 as appropriate. For Wnt ligands treatment during the Cp stage, cells were 
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supplemented with either 20 ng ml-1 BMP4 (R&D Systems, #314-BP-010) alone (control group), 
a combination of 20 ng ml-1 BMP4 and 1 M C59, or a combination of 20 ng ml-1 BMP4 and 
100 ng ml-1 Wnt3A (R&D Systems, #5036-WN-010) in mesodermal differentiation medium 
from d7 to d12. 
3.3.7 Animal experiments 
All animal procedures were approved by Institutional Animal Care and Use Committee (IACUC) 
at Washington University in Saint Louis. Male NSG mice (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ, 
#005557, Jackson laboratory) at age of 18-20 weeks-old were used for human xenograft 
implantation in the in the dorsal region (subcutaneous) or in osteochondral defects in the knee 
joints of mice. Mice were housed under a 12hr light/12hr dark cycle with ambient temperature 
and humidity. NSG mice were anesthetized with 3% isoflurane in oxygen for all surgical 
procedures. For subcutaneous implantation, the skin was shaved and sterilized over the 
implantation site using standard sterile techniques. A mid-scapular incision was made, and a 
hemostat was inserted into the skin incision to create a pocket for implantation. A d14 hiPSC 
chondrogenic pellet was then inserted into the pockets. The incision of the skin was closed with 
8-0 suture with taper point (PolysorbTM, Covidien, #L-2800). Tissue adhesive was applied to 
the skin wound area. For implantation in osteochondral defects in the knee, a 3 mm long medial 
parapatellar incision was made in the left hindlimb, and the knee joint was exposed via lateral 
dislocation of the patella. An osteochondral defect (1 mm in diameter and 1 mm in depth) in the 
trochlear groove of femur was created by a 1 mm micro bone drill (Roboz, #RS-6300A). All 
debris were removed by sterile PBS washes. Mild hemorrhage from the fat pad was controlled by 
epinephrine 1:1000 (International Medication Systems, #491590) followed by sterile PBS wash. 
A d14 hiPSC chondrogenic pellet was implanted into the defect, and the patella was re-
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positioned to its original anatomical location. Mice with osteochondral defects that did not 
receive pellet implantation were used as control group. After implantation, the subcutaneous 
layer and skin were closed with 8-0 suture with taper point followed by the application of tissue 
adhesive to the skin wound area. After surgery, the mice were allowed to move freely within 
their cages. After 14- and 28-days post-implantation, mice were sacrificed for pellet harvest for 
histological analysis.  
3.3.8 RNA isolation, library preparation, and bulk RNA-seq 
To determine transcriptome profiles over the course of differentiation, three hiPSCs lines 
(ATCC, BJFF, and STAN) as biological replicates at various differentiation stages (6 
mesodermal and 5 chondrogenic stages per cell line; i.e., total 33 samples) were collected for 
bulk RNA-seq. Cell samples were thawed on ice, and pellet samples were homogenized with 
zirconia beads (BioSpec Products, # 11079110zx) and a miniature bead beater. RNA was then 
isolated from all samples using the Total RNA Purification Kit according to the manufacture’s 
protocol (Norgen Biotek, #37500). RNA was eluted in 20 l of diethylpyrocarbonate-treated 
water. The quality and quantity of RNA from each sample was evaluated by RNA Analysis 
ScreenTape (Agilent, #5067-5576) on bioanalyzer (Agilent 4200 Tapestation). Only samples 
with a RIN value larger than 0.8 were submitted to the Genome Technology Access Center 
(GTAC sequencing core) at Washington University in St. Louis for library preparation and bulk 
RNA-seq. Libraries were prepared using TruSeq Stranded Total RNA with Ribo-Zero Gold kit 
(Illumina). Sequencing was performed on a HiSeq2500 instrument (Illumina) (1 x 50 bp reads) 
with a sequencing depth of 30 million reads per sample. 
3.3.9 Preprocessing of bulk RNA-seq data 
Reads were processed using an in-house pipeline and open-source R packages as previously 
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described (11). Raw reads were first trimmed using Cutadapt to remove low quality bases and 
reads (12). After trimming, processed reads were aligned to the human reference genome 
GRCh38 (version 90) by STAR (13), and the number of aligned reads to each annotated genes or 
transcripts (GENCODE v21) was performed using featureCounts from the Subread package 
(v1.4.6) (14).  
3.3.10 DEGs and GO enrichment analysis and of bulk RAN-seq data 
After quality control, un-normalized gene counts were read into DESeq2 R package by 
DESeqDataSetFromMatrix function as instructed by the package tutorial (15). Genes that were 
expressed by less than 10 cells were then removed. Next, we used DESeq and results functions 
which implement Wald test in DESeq2 to determine the differentially expressed genes (DEGs) 
between two consecutive differentiation stages. In this process, the estimation of size factors 
(i.e., controlling for differences in the sequencing depth of the samples), the estimation of 
dispersion values for each gene, and fitting a generalized linear model were performed. The 
Gene counts were also averaged from three hiPSC lines. Top 20 DEGs between two consecutive 
stages were selected and visualized using ComplexHeatmap R package. To observe the temporal 
expression of a given gene for each hiPSC line, the count matrix was regularized-logarithm 
transformed via rlog function first, and we used plotCounts function in DESeq2 to visualize the 
expression pattern of the gene. Furthermore, regularized-logarithm transformed counts were also 
used for principle component analysis (PCA) and PCA plots were visualized by ggplot function 
in ggplot2 R package (16). 
We next performed gene ontology (GO) enrichment analysis of the genes in mesodermal 
and chondrogenic stages using GAGE R package (Generally Applicable Gene-set/Pathway 
Analysis), whose algorism evaluates the coordinated up- or down-differential expression over 
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gene sets defined by GO terms (17). Significantly upregulated GO terms with their associated p 
values in biological process, molecular function, and cellular component were plotted by 
GraphPad Prism (version 8.0; GraphPad Software). Furthermore, GAGE analysis also reveals 
that 134 out of 205 genes defined by GO term cartilage development (GO:0051216) were 
significantly increased during our differentiation process. Thus, a heatmap was generated to 
investigate the expression levels of these genes at various stages using ComplexHeatmap R 
package (18). 
3.3.11 10X chromium platform scRNA-seq 
Cells were thawed at 37ºC and resuspended in PBS + 0.04% BSA at concentration of 2,000 cells 
per l. Cell suspensions were submitted to the GTAC sequencing core at Washington University 
in St. Louis for library preparation and sequencing. In brief, 10,000 cells per sample were loaded 
on a Chromium Controller (10x Genomics) for single capture. Libraries were prepared using 
Single Cell 3′ Library & Gel Bead Kit v2 (#120237 10x Genomics) following manufacture’s 
instruction. A single cell emulsion (Gel Bead-In-EMulsions, GEMs) is created by making 
barcoded cDNA unique to each individual emulsion. Recovery agent was added to break GEM 
and cDNA was then amplified. A library is produced via end repair, dA-tailing, adaptor ligation, 
post-ligation cleanup with SPRIselect, and sample index PCR. The quality and concentration of 
the amplified cDNA was evaluated by Bioanalyzer (Agilent 2100) on a High Sensitivity DNA 
chip (Agilent, #5065-4401). Only cDNA with average library size 260-620 bp were used for 
sequencing. Sequencing was performed by Illumina HiSeq2500 with the following read length: 
26 bp for Read1, 8 bp for i7 Index, and 98 bp for Read2. We generally acquired ~180 million 
reads per library (sample).  A species mixing experiment (mouse adipose stem cells and human 
iPSCs, 1:1 mixture) was also performed prior to running on actual sample to ensure good quality 
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of single cell capture (i.e., cell doublet rate < 5%).  
3.3.12 Preprocessing of scRNA-seq data 
Paired-end sequencing reads were processed by Cell Ranger (10x Genomics software, version 
2.0.0). Reads were aligned to the GRCh38 (version 90) for genome annotation, demultiplexing, 
barcode filtering, and gene quantification. Cell Ranger also removes any barcode that has less 
than 10% of the 99th percentile of total unique molecular identifiers (UMI) counts per barcode as 
these barcodes are associated with empty droplets. After this quality control, gene barcode 
matrices for each sample were generated by counting the number of UMIs for a given gene (as 
row) in individual cell (as column). For each sample, ~2,200-2,500 cells were captured.  
3.3.13 Unsupervised clustering analysis and annotation 
To assess the difference in composition of cell populations, we performed global unsupervised 
clustering analysis scRNA-seq datasets. First, gene barcode matrices were input into Seurat R 
package (version 2.4) (19). We then removed the low-quality cells with less than 200 or more 
than 7,000 detected genes, or if their mitochondrial gene content was more than 5%. Note that 
the cutoff criteria were adjusted in few cases due to the sequencing depth and the variations in 
mitochondrial gene content from datasets. Genes that were detected in less than 3 cells were 
filtered out. After filtering out low-quality cells or cell doublets, the gene expression was then 
natural log transformed and normalized for scaling the sequencing depth to 10,000 molecules per 
cell. Next, to reduce the variance introduced by unwanted sources, we regressed out variation in 
gene expression driven by cell cycle stages and mitochondrial gene expression with 
vars.to.regress argument in function ScaleData in Seurat. We then used FindVariableGenes 
function in Seurat to identify highly variable genes across cells for downstream analysis. These 
steps resulted in (1) total 8,547 cells with average 1,882 highly variable genes from stages of 
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hiPSCs, Scl, and CP, (2) total 10,648 cells with average 2,061 highly variable genes from stages 
of TGF-3-treated pellets (d1, d3, d7, d14, d28, and d42), and (3) total 7,997 cells with average 
1,886 highly variable genes from TGF-3+C59-treated pellets (d7, d14, d28, and d42) for 
downstream analysis. Detailed cells numbers passed quality control steps for each stage are listed 
in Table S3.1. Dimensionality reduction on the data was then performed by computing the 
significant principal components on highly variable genes. We then performed unsupervised 
clustering by using FindClusters function in Seurat with the resolution argument set to 0.6 and 
clusters were then visualized in tSNE plot (20).   
DEGs among each cell cluster were determined using FindAllMarkers function in Seurat. 
DEGs expressed in at least 25% cells within the cluster and with a fold change of more than 0.25 
in log scale were considered marker genes of the cluster. To determine the biology functions of 
the marker genes from a given cluster, we performed Gene Ontology (GO) enrichment analysis 
by using The DAVID Gene Functional Classification Tool (http://david.abcc.ncifcrf.gov; version 
6.8) (21). By comparing these unique biological GO terms with existing RNA-seq datasets and 
the literature, we were able to annotate cell clusters. Additionally, the top 10 enriched GO terms 
from biological function category with associated p values were visualized GraphPad Prism 
(version 8.0; GraphPad Software). 
3.3.14 Cell cycle analysis of scRNA-seq data 
CellCycleScoring function in Seurat was used to determine a cell cycle score on each cell 
according to its gene expression of G2/M phase (54 genes) and S phase (43 genes) markers (22). 
Based on this scoring system, fractions of each cell cluster with given cell cycle score in total 




3.3.15 CCA for integrated analysis of multiple scRNA-seq datasets 
To compare cell types and to identify their associated DEGs between distinct experimental 
conditions such as batch effect, C59 treatment, or differentiation stages (i.e., time points), we 
applied canonical correlation analysis (CCA), a computational strategy implemented in Seurat 
for integrated analysis of multiple datasets. First, the top 1,000 highly variable genes from each 
dataset were selected. We then use RunCCA function or RunMultiCCA function (if more than 2 
datasets) to identify common sources of variation resulting from experimental conditions and to 
merge the multiple objects into a single dataset. We next determined the top principal 
components of the CCA by examining a saturation in the relationship between the number of 
principle components and the percentage of the variance explained using the MetageneBicorPlot 
function. By using selected top principal components, we aligned the CCA subspaces with 
AlignSubspace function, which returns a new dimensional reduction matrix allowing for 
downstream clustering and DEG analyses. DEG analysis was performed on the cells from 
different datasets but grouped in the same cluster (i.e., conserved cell types between two 
conditions) after CCA alignment. The methods for cell clustering, identification of conserved 
cell types and DEGs, as well as annotation of cell clusters were similar to the ones mentioned 
previously. DEGs in each conserved cell types in response to differentiation stages or C59 
treatment were visualized by ComplexHeatmap R package (18). In some cases, gene of interests 
such as Wnts and various lineage markers were also visualized using the FeatureHeatmap and 
DotPlot function in Seurat.  
3.3.16 Pseudotemporal ordering and lineage trajectories 
We used Monocle2 R package to reconstruct differentiation trajectories by computing and 
ordering the sequence of gene expression changes of the cells collected from different time 
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points in an unsupervised manner (23, 24). First, scRNA-seq datasets from different timepoints 
underwent several quality control steps as mentioned previously. These multiple scRNA-seq 
datasets were then merged into one single object using MergeSeurat function in Seurat. The 
merged matrix was then converted into Monocle object using importCDS and newCellDataSet 
functions in Monocle2. We then identified a set of DEGs between the cells collected at the 
beginning of the process to those at the end using differentialGeneTest function with argument 
qval < 0.01 in Monocle. The dimensions of the dataset were then reduced using first two 
principal components with ‘DDRTree’ method. Next, we used orderCells function to order the 
cells based on the selected DEGs and the trajectory of the cells was visualized by 
plot_cell_trajectory function in Monocle. The temporal expression of the gene of interests was 
visualized using the plot_genes_in_pseudotime function in Monocle. Additionally, to observe 
dynamic changes in the expression levels of the genes that were branch dependent (i.e., along 
with specific lineage), we used plot_genes_branched_heatmap function in Monocle to construct 
a special type of heatmap in which genes that had similar lineage-dependent expression patterns 
were clustered together.  
3.3.17 WGCNA reconstruction of GRNs and hub genes 
We used Weighted Gene Co-expression Network Analysis (WGCNA), an algorithm 
implemented in WGCNA R package, to reconstruct GRNs and to identify their associated hub 
genes that regulate cell differentiation (38). First, the dataset of interest (e.g., a given timepoint) 
created in Seurat was converted into a plain matrix for a given gene (in column) in an individual 
cell (in row). The dataset was then cleaned by removing cells with too many missing values 
using goodSamplesGenes function in WGCNA. Next, we used pickSoftThreshold function in 
WGCNA to determine the proper soft-thresholding power () that fits the criterion of 
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approximate scale-free topology of the network, and an adjacency matrix was then built with 
soft-thresholding power of 8 in our study. Hierarchical clustering and GRN were constructed by 
using blockwiseModules function with arguments TOMType set to unsigned, networkType set to 
signed, and mergeCutHeight set to 0.25 in WGCNA. Modules containing genes that were highly 
associated with each other were identified in this process. Gene lists of interesting modules were 
extracted and submitted to DAVID for GO term analysis to retrieve their biological process and 
molecular functions. We then identified transcription factors (TFs) and TF regulators from the 
genes based on the GO terms in molecular functions. We then selected top 100 genes that have 
highest weight (i.e., high correlation coefficient) connected to a given TF or TF regulator. 
Finally, the GRN based on these TFs and TF regulators then underwent cluster analysis using 
community cluster (GLay) (25) and was then visualized using Cytoscape (26). Hub genes for 
each GRN were identified as genes with high weight (summed correlation coefficients), high 
degree (summed connectivity, i.e., total numbers genes connected to this specific gene), and high 
betweenness centrality (BC) measure of the network. The hub gene of a given GRN were 
visualized by ComplexHeatmap R package (18).    
3.3.18 Multicellular signaling and ligand-receptor models 
To investigate the ligand-receptor interaction in heterogenous multicellular signaling systems, 
we used a list comprising of 2,557 human ligand–receptor pairs curated by Database of Ligand-
Receptor Partners (DLRP), IUPHAR, and Human Plasma Membrane Receptome (HPMR) (27, 
28). We first quantified the percentage of the cells (i.e., neural cells, melanocytes, and 
chondrocytes) that expressed a specific Wnt ligand and its associated frizzled (FZD) receptors 
using scRNA-seq datasets. To ensure the ligand and receptors are uniquely expressed, we 
required that their expression in fold change needs to more than 0.25 in log scale. We then used 
 82 
 
Circlize R package to visualize the directions of the signaling in the cell type based on 
connections of ligand-receptor pairs (29).  
3.3.19 RNA Fluorescence in situ hybridization (RNA-FISH) 
To validate scRNA-seq findings and to visualize the spatial distribution of Wnts and COL2A1 
within pellets, we performed RNA-FISH for Wnt3A, Wnt4, and COL2A1 expression. d28 pellets 
with or without C59 treatment were harvested (n = 3 time point) and snap frozen in liquid 
nitrogen. Pellets were cryo-sectioned at 10 m thick and fixed using 4% paraformaldehyde in 
PBS on ice for 10 min. Sample pre-treatment and RNA probe hybridization, amplification, and 
signal development were performed using the RNAscope Multiplex Fluorescent Reagent Kit v1 
(Advanced Cell Diagnostics, #320850) following the manufacturer’s instruction. Samples were 
imaged with multi-channel confocal microscopy (Zeiss LSM 880). Tiled images with Z-stacks 
were taken at 20X magnification to capture the entire pellet. Maximum intensity projection, a 
process in which brightest pixel (voxel) in each layer along Z direction is projected in the final 
2D image, was performed using Zeiss Zen Blue (version 2.5).  
3.3.20 Fluorescent activated cell sorting (FACS) for progenitors 
Cells at the Cp stage with treatment of BMP4, a combination of BMP4 and Wnt3A, or a 
combination of BMP4 and C59 were dissociated and resuspended in FACS Buffer (PBS-/- with 
1% FBS and 1% penicillin/steptomycin/fungizone (P/S/F; Gibco) at approximately 40 x 106 cells 
per ml. The cells were treated with Human Tru Stain FC XTM (BioLegend, #422302) for 10 min 
at room temperature. Approximately 10,000 cells in 100 µl were used for each compensation. 
Cells were labeled with appropriate antibodies including their associated isotype control (FITC-
CD45, #304006; PE/Cy7-CD146, #361008; PE-CD166, #343904, all from BioLegend). Cells 
were incubated for 30 minutes at 4ºC and washed with FACS buffer twice. Samples were 
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resuspended in sorting medium consisting of DMEM/F12 with 2% FBS, 2% P/S/F, 2% HEPES 
(Gibco), and DAPI (BioLegend, #422801) at 4 x 106 cells per ml and filtered through a 40 µm 
cell strainer. Cells were stored on ice prior to sorting. Five µl of all antibodies were used per 
million cells in 100 µl staining volume, 10 µl of Tru Stain FC XTM was used per million cells in 
100 µl staining volume. DAPI was used at 3 µM. An Aria-II FACS machine was used to 
compensate the color overlapping and to gate the samples. Data was analyzed using FlowJo 
software (version 10.5.3).  
3.3.21 Histology 
Pellets were collected in 10% neutral buffered formalin for fixation for 24 hours. Pellets were 
then transferred to 70% ethanol, dehydrated, and embedded in paraffin wax. Pellet blocks were 
sectioned at 8 µm thickness and stained for proteoglycans and cell nuclei according to the 
Safranin-O and hematoxylin standard protocol.  
3.3.22 Immunohistochemistry 
Histologic sections (8 m thick) of the pellets were rinsed with xylenes three times and 
rehydrated before labeling. Antigen retrieval was performed with 0.02% proteinase K for 3 min 
at 37ºC for COL2A1 and COL6A1 and with pepsin for 5 min at room temperature for COL1A1 
and COL10A1 followed by peroxidase quench then serum blocking for 30 min at room 
temperature. Samples were labeled for 1 hour with the primary antibody against COL1A1 (1:800 
Abcam #90395), COL2A1 (1:10 Iowa #II-II6B3-s), COL6A1 (1:1000 Fitzgerald #70F-
CR009X), and COL10A1 (1:200 Sigma #C7974) and for 30 min with the secondary antibody 
goat anti-mouse (1: 500, Abcam #97021) or goat anti-rabbit (1:500 Abcam #6720) as 
appropriate. Histostain Plus Kit (Sigma, #858943) was then used for enzyme conjugation for 20 
min at room temperature followed by AEC (ThermoFisher, #001111) for 2.5 min (COL2A1 and 
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COL6A1) or 2 min (COL1A1 and COL10A1) at RT. Finally, samples were counterstained with 
hematoxylin to reveal cell nuclei for 45 sec and mounted with Vector Hematoxylin QS (Vector 
lab, #H3404). Images were taken by Olympus VS120 microscope (VS120-S6-W). 
3.3.23 Biochemical analysis of cartilaginous matrix production 
Pellets were rinsed with PBS after chondrogenic differentiation and digested at 65ºC overnight in 
200 µl papain solution consisting of 125 μg ml-1 papain (Sigma, P4762), 100 mM sodium 
phosphate, 5 mM EDTA, and 5 mM L-cysteine hydrochloride at 6.5 pH. Samples were stored at 
-80ºC before thawing to measure double stranded DNA by Quant-iT PicoGreen dsDNA Assya 
Kit (ThermoFisher, #P11496) and glycosaminoglycans (GAG) by the 1,9-dimethylmethylene 
blue assay at 525 nm wavelength (30). GAG content, as calculated based on the standard curve, 
was normalized to double stranded DNA content. 
3.3.24 RT-qPCR 
RNA of the pellets was isolated using the Total RNA Purification Kit according to the 
manufacture’s protocol (Norgen Biotek, #37500). Reverse transcription of the RNA was 
performed using SuperScript VILO Master Mix (Thermo Fisher, # 11755050). Fast SYBR Green 
Master Mix (Thermo Fisher, # 4385614) was used for reverse transcription quantitative 
polymerase chain reaction (RT-qPCR) according to manufacturer’s instructions on 
the QuantStudio 3 (Thermo Fisher). Gene expression was analyzed using the CT method 
relative to undifferentiated hiPSCs with the reference gene TATA-box-binding protein (TBP). 
Sequences of primers are listed in Table 3.2.  
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Table 3.2 qRT-PCR Primer Sequences. Primers are listed as 5’ to 3’.  
 
3.3.25 Western blots 
To examine the effect of C59 on Wnt inhibition in the pellets at protein levels, Western blot 
analysis was performed on d28 pellets with or without C59 treatments. 6-8 pellets per 
experimental group were pooled and digested with 0.04% type 2 collagenase solution in 
DMEM/F12 for 1hr. Cells were washed once with PBS and lyzed in RIPA buffer (Cell Signaling 
Technology, #9806S) with protease inhibitor (ThermoFisher, #87786) and phosphatase inhibitor 
(Santa Cruz Biotechnology, #sc-45044). Protein concentration was measured using the BCA 
Assay (Pierce). 10 μg of proteins for each well were separated on 10% SDS-PAGE gels with 
prestained molecular weight markers (Bio-Rad, 161-0374). and transferred to a PVDF 
Gene Forward Sequence Reverse Sequence 
ACAN CACTTCTGAGTTCGTGGAGG ACTGGACTCAAAAAGCTGGG 
COL1A1 TGTTCAGCTTTGTGGACCTC TTCTGTACGCAGGTGATTGG 
COL2A1 GGCAATAGCAGGTTCACGTA CTCGATAACAGTCTTGCCCC 
COL10A1 CATAAAAGGCCCACTACCCAAC ACCTTGCTCTCCTCTTACTGC 
MITF AGTTGCTGGCGTAGCAAGAT AAAGTCAACCGCTGAAGAGC 
PAX6 GAGTGCCCGTCCATCTTTG GTCTGCGCCCATCTGTTGCTTTTC 
SOX2 TACAGCATGATGCAGGACCA CCGTTCATGTAGGTCTGCGA 
SOX9 CGTCAACGGCTCCAGCAAGAACAA GCCGCTTCTCGCTCTCGTTCAGAAGT 
TBP AACCACGGCACTGATTTTCA ACAGCTCCCCACCATATTCT 
Wnt2B GTGTCCTGGCTGGTTCCTTA AGCTGGTGCAAAGGAAAGAA 
Wnt3A CCTGCACTCCATCCAGCTACA GACCTCTCTTCCTACCTTTCCCTTA 
Wnt4 GATGTGCGGGAGAGAAGCAA ATTCCACCCGCATGTGTGT 
Wnt5B CTGCCTTTCCAGCGAGAATT AGGTCAAATGGCCCCCTTT 
Wnt7B CCCCCTCCCTGGATCATGCACA GCCACCACGGATGACAGTGCT 
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membrane. The PVDF membrane blots were incubated overnight at 4 °C with the following 
primary antibodies: anti-Wnt2B (1:350, abcam, ab178418), anti-Wnt3A (1:1000, abcam, 
ab81614), anti-Wnt4 (1:500, abcam, ab91226), anti-Wnt5B (1:500, abcam, ab93134), anti-
Wnt7B (1:2000, abcam, ab155313) and anti-GAPDH (1:30000, Proteintech 60004-1-Ig) for 
loading control, respectively. Affinity purified horseradish peroxidase(HRP)-linked goat anti-
rabbit IgG secondary antibody (1:3000, Cell Signaling, #7074) or horse anti-mouse IgG 
secondary antibody (1:3000, Cell Signaling, #7076) was added and incubated for 45 minutes at 
room temperature. Immunoblots were imaged and analyzed using the iBright FL1000 Imaging 
System (Thermo Fisher). After the Wnt proteins were imaged, the blots were then stripped by 
incubating with restore plus Western blot stripping buffer (ThermoFisher Scientific) at room 
temperature for 15 mins.  
3.3.26 Statistical analysis 
All data were presented as mean  SEM. Analyses were performed using SPSS Statistics 
(version 25), with significance reported at the 95% confidence level. In the current study, the 
number of pellets per group or treatment condition are technical replicates, while number of the 
mice per group are biological replicates. 
3.3.27 Data availability 
We acquired RNA-seq datasets of human primary chondrocytes from a previously published 
study (NIH Gene Expression Omnibus (GEO) accession number GSE106292) (31), in which 
embryonic hind limb bud chondrocytes (age: 6 weeks,  n = 2 ), adolescent knee chondrocytes 
(age: 17 weeks, n = 2), adult knee chondrocytes (age: 18-60 years, n  = 2), and growth plate 
chondrocytes (age: 14 weeks, 15 weeks, and 18 weeks, n = 1 per age). For the datasets obtained 
from the previous mentioned study, gene expression counts were averaged if there were more 
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than 2 samples with the same age. We also harvested chondrocytes from human costal cartilage 
and performed bulk RNA-seq on these samples (age: ~70 years, n = 3). However, it was 
challenging to collect rib cartilage from young healthy donors; thus, aged 70-year-old costal 
cartilages were used. To compare the difference between the phenotypes of chondrocytes derived 
from hiPSCs and hMSCs, we also used bulk RNA-seq datasets of hMSC chondrogenesis from 
our recent study (GEO accession number GSE109503) (10). For the present study, our bulk 
RNA-seq and scRNA-seq datasets are available on GEO accession number GSE 160787. 
3.4 Results 
3.4.1 Bulk RNA-seq indicates successful differentiation of hiPSCs 
Previously, we reported a robust differentiation protocol that can drive hiPSCs toward a 
chondrogenic lineage via the paraxial mesoderm (8) (Figure S3.1A-B). To determine 
transcriptome profiles over the course of differentiation, 3 independent hiPSCs lines (ATCC, 
BJFF, and STAN) were collected for bulk RNA-seq at various stages (Figure 3.1A). Principal 
component analysis (PCA) reveals that the 3 hiPSC lines follow similar mesodermal and 
chondrogenic differentiation trajectories (Figure 3.1B-C). Analysis of differentially expressed 
genes (DEGs) between each stage revealed upregulation of stage-specific markers. For example, 
T-box transcription factor T (TBXT) and mix paired-like homeobox (MIXL1) were upregulated at 
the stage of anterior primitive streak (anterior PS) compared to hiPSCs (32) (Figure 3.1D; Table 
3.2). Markers representing mesodermal derivatives including T-box 6 (TBX6), UNC homeobox 
(UNCX), and paired box 9 (PAX9) were upregulated sequentially at the stages of paraxial 
mesoderm, early somite, and sclerotome, respectively (Figure 3.1C).  
Chondrogenic markers such as matrilin 4 (MATN4), aggrecan (ACAN), collagen type VI 
alpha 3 chain (COL6A3), collagen type IX alpha 1 chain (COL9A1), and SRY-box 6 and 9 
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(SOX6 and SOX9) were upregulated as early as at day 7 (d7), while the expression of collagen 
type II alpha 1 chain (COL2A1) was increased at d21 (Figure 3.1E; Table S3.3).  Interestingly, 
microRNA 302a (MIR302A), reportedly down-regulated in osteoarthritic chondrocytes, had 
enhanced expression in d28 pellets (33). Interestingly, neuronal differentiation 4 (NEUROD4), a 
gene encoding a transcriptional activator essential for neuronal differentiation, had increased 






Figure 3.1 DEGs of mesodermal and chondrogenic differentiation of 3 hiPSC lines by bulk 
RNA-seq. (A) Schematic of chondrogenic differentiation protocol for hiPSCs. (B-C) PCA 
indicates that 3 unique hiPSC lines followed similar differentiation trajectories. (D-E) DEGs 
averaged from 3 unique hiPSC lines at each stage of differentiation, respectively. Each column 
of the heatmap represents a comparison between two stages/timepoints, and each gene presented 
was assigned a colored dot (following the gene label). The color of a dot matches the color of the 
timepoint label at the left side of the heatmap. When the color of a gene label and a timepoint 
label match, that gene was significantly upregulated at the corresponding time points and was 
thus detected as a differentially expressed gene. 
3.4.2 in vitro characterization of hiPSC-derived chondrocytes 
While temporal expression of chondrogenic markers such as SOX9 and COL2A1 were 
upregulated in unique hiPSC lines, both the hypertrophic chondrocyte marker collagen type X 
alpha 1 chain (COL10A1) and osteogenic marker collagen type I alpha 1 chain (COL1A1) 
exhibited increased expression over time (Figure 3.2A). It is important to note that COL1A1 is 
also a marker for fibrous tissues, perichondrium, and many other cell types. The d28 pellet 
matrix also demonstrated rich proteoglycan staining using Safranin-O (Saf-O) as well as intense 
labeling for COL2A1 and COL6A1 by immunohistochemistry (IHC). However, little labeling 
for COL10A1 and COL1A1 was observed despite increased gene expression of COL10A1 and 
COL1A1 at later time points (Figure 3.2B).  Gene ontology (GO) enrichment analysis of the 
genes using R package GAGE was performed (17). Significantly upregulated GO terms in 
Biological Process highlighted skeletal system and cartilage development (Figure S3.2A). GAGE 
analysis also revealed that 134 out of the 205 genes defined by cartilage development 
(GO:0051216) were significantly increased. Interestingly, in addition to upregulated SOX5, 6, 
and 9, which are known to be master transcription factors (TFs) governing chondrogenesis, we 
also observed several Wnts, including Wnt2B, had increased gene expression at different stages 
during differentiation (Figure 3.2C).  
To determine the phenotype of hiPSC-derived cartilage, we projected our bulk RNA-seq 
data and publicly available sequencing datasets of primary chondrocytes from a variety of 
 91 
 
cartilaginous tissues and chondrocytes derived from mesenchymal stem cells (MSCs) in a PCA 
plot (Figure 3.2D) (31). We found that hiPSC-derived chondrocytes demonstrated a similar 
phenotype to embryonic limb bud chondrocytes. 
3.4.3 in vivo characterization of hiPSC-derived chondrocytes 
To determine whether hiPSC-derived chondrocytes could maintain their phenotype in vivo, we 
implanted d14 pellets subcutaneously in the dorsal region of immunodeficient NSG (NOD.Cg-
Prkdcscid Il2rgtm1Wjl/SzJ) mice (Figure S3.2B). The d14 pellets represented the earliest time point 
when a chondrocyte-like phenotype was observed in vitro. After 14 days of implantation, pellets 
were harvested and found to retain a cartilage phenotype, with rich proteoglycan and COL2A1 
labeling. No endochondral ossification was observed during this relatively short-term 
implantation period in our study. 
To test whether hiPSC-derived chondrocytes can retain their phenotype within the joint, 
we created an osteochondral defect in the femoral groove of the mouse (Figure 3.2E). Due to the 
small size of the mouse knee, the osteochondral defect model here also involves a growth plate 
defect. The defect was either left empty as a non-repair control group or filled with a d14 pellet. 
Defects left untreated did not exhibit any repair with hyaline cartilage, and only fibrotic tissue 
was observed. However, defects with pellet implantation demonstrated enhanced repair of the 
focal cartilage lesion, which was filled with cartilaginous matrix rich in Saf-O staining at both 
14- and 28-days post-implantation. While this finding provides proof-of-concept of the 
maintenance of the chondrogenic phenotype over 28 days, future studies may wish to investigate 






Figure 3.2 In vitro and in vivo characterization of hiPSC-derived chondrocytes (A) Temporal 
gene expression of chondrogenic markers SOX9 and COL2A1, hypertrophic marker COL10A1, 
and osteogenic marker COL1A1. (B) Pellets showed enriched Saf-O, COL2A1, and COL6A1 
staining. Most COL1A1 staining (green arrow) was located at the edge of the pellets, while faint 
COL10A1 (yellow arrowheads) was observed. Left column scale bar = 400 µm. Right column 
scale bar = 200 µm. Inset scale bar = 50 µm. Experiment was repeated 3 times with similar 
results. (C) Heatmap of 134 significantly upregulated genes identified in GO term cartilage 
development (GO:0051216). Genes in red font are either TFs or transcription regulators. (D) 
hiPSC-derived chondrocytes exhibit similar phenotype to embryonic limb bud chondrocytes. (E) 
hiPSC-derived chondrocytes repaired osteochondral defects in the cartilage of mouse knee joints 
and remained a chondrocyte phenotype 28-days post-implantation. n = 3 mice per group. Top 
row scale bar = 500 µm. Bottom row scale bar = 100 µm. 
3.4.4 scRNA-seq mapping of cellular heterogeneity 
Although our protocol generates a predominantly chondrocyte-like population as shown by IHC 
and bulk RNA-seq (Figure 3.2B), we often observed non-chondrocyte populations and 
occasional focal accumulation of black pigmented regions on the surface of the pellets (Figure 
S3.2C-D). These results suggest the presence of off-target differentiation, prompting us to seek 
their cellular identities. To dissect this cellular heterogeneity, 8 samples from the STAN cell line 
at different differentiation time points were collected for scRNA-seq (Figure 3.3A). Detailed cell 
numbers passed quality control steps and median genes per cell for each stage are listed in Table 
S3.1 (see Methods for quality control steps and criteria). 
Sequencing of mixed species ensured a low cell multiplet rate (2.7%) (Figure S3.3A). To 
verify reproducibility of the differentiation, two batches of d28 samples were collected from 
independent experiments for scRNA-seq. Canonical correlation analysis (CCA) was used to 
align cells from the 2 batches (19) (Figure S3.3B). The cells in the same cluster from different 
batches exhibited high correlation in their gene expression (Spearman’s rank coefficient rs > 0.87 
for all clusters) (Figure S3.3C). Furthermore, genes that were highly conserved in one particular 
cluster (using cluster 0 as an example) showed similar expression patterns in the clusters from 
distinct batches, suggesting that our differentiation is highly reproducible (Figure S3.3D). 
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3.4.5 Lineage bifurcation in hiPSC differentiation trajectory 
We used the Monocle2 R package to reconstruct the differentiation trajectory from the stage of 
hiPSCs to d42 chondrocytes with a total of 19,195 cells that passed quality control (Figure 3.3B) 
(23). While cells following chondrogenic fate expressed chondrocyte markers including ACAN, 
COL2A1, SOX9, and cartilage oligomeric matrix protein (COMP), we found one major 
branchpoint, diverting cell fate toward neural lineage with the expression of neural cell markers 
such as nestin (NES), orthodenticle homeobox 2 (OTX2), SOX2, and Wnt3A (Figure 3.3C). Other 
neural cell markers such as OTX1 and PAX6 were also enriched in this branch (Figure S3.3E). 
The off-target cell differentiation toward neurogenic lineage confirmed our findings of increased 
NEUROD4 in the bulk RNA-seq data.  
To explore distinct cell populations at each stage, scRNA-seq data were subjected to 
unsupervised clustering and visualized using t-distributed stochastic neighbor embedding (tSNE) 
plots (Figure 3.3D). By comparing DEGs with signature genes of cell types in the literature and 
GO term analyses, we annotated broad cell populations by combining clusters expressing similar 
marker genes. For example, 2 of 7 clusters identified at the chondroprogenitor (Cp) stage not 
only had high expression levels of SOX4 and SOX9, but were also enriched in several markers 
resembling neural crest cells including PAX3 and forkhead box D3 (FOXD3) (Figure S3.3F) 
(35). Therefore, these two clusters were assigned to a broad cell population referred to as neural 
crest cells. Similarly, 4 clusters at the Cp stage exhibited markers of neural lineage including 
SOX2, OTX1/2, and PAX6, and thus were annotated as neurogenic lineage cells, while PRRX1, 
COL1A1, and COL3A1 are known markers for mesenchyme (Figure S3.3G) (36). Similar major 
cell populations were also observed in d1 and d3 pellets, although it appeared that the percentage 
of mesenchymal and neural cells increased in d1 and d3 while there was a decreased percentage 
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of neural crest cells (Figure S3.3H-I). 
Of note, a cluster with high expression of melanocyte inducing transcription factor 
(MITF) was observed in d7 and d14 pellets. MITF is a master TF regulating development of 
melanocytes, cells that produce melanin (i.e., pigment) (37). IHC of the pellets labeling for NES 
and MITF further confirmed the presence of neural cells and melanocytes (Figure S3.3J), 
suggesting that the focal black dots observed at the surface of pellets are likely to be the pigment 
accumulation in melanocytes. Nevertheless, as distinct subtypes of hiPSC-derived chondrocytes 
and off-target cells were defined primarily based on marker genes, the complete functionality of 
these population require future investigation. 
3.4.6 WGCNA identifies GRNs of neurogenesis and melanogenesis  
Next, we aimed to improve hiPSC chondrogenesis by decreasing off-target differentiation. We 
performed weighted gene co-expression network analysis (WGCNA) to reconstruct GRNs and 
identify the hub genes that modulate neurogenesis and melanogenesis (38). scRNA-seq data of 
d14 pellets (with a total of 2,148 cells and 3,784 genes) was used for this computation due to the 
earliest presence of both chondrogenic and off-target populations detected. Five major gene 
modules (each containing > 150 genes) were identified, and based on GO enrichment analyses, 
they were categorized into: cell division, cilium movement and assembly, skeletal system 
development, nervous system development, and melanin biosynthetic process. The genes in the 
modules of nervous system development and melanin biosynthetic process were then used to 
build corresponding GRNs and subnetworks by Cytoscape, while hub genes were determined by 
degree (node connectivity), weight (association between two genes), and betweenness centrality 
measure of the network (Figure 3.3E and Figure S3.4A-C) (39).  In the GRN of neurogenesis, 
Wnt4 was strongly associated with several TFs regulating neural differentiation. We also 
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observed that Wnt2B was associated with both MITF and ETS variant 1 (ETV1), a gene whose 






Figure 3.3 scRNA-seq and WGCNA reveal neural cells and melanocytes as off-target cells. (A) 
scRNA-seq was performed at hiPSC, Sclerotome, Cp, and 6 chondrogenic pellet time points. (B) 
Reconstruction of differentiation trajectory reveals an off-target lineage bifurcation toward 
neural cells. A total of 19,195 cells that passed quality control from the stage of hiPSC to d42 
chondrogenic pellet was used to reconstructed differentiation trajectory. (C) Chondrogenic 
markers were enriched in the chondrogenic branch, while neurogenic markers were observed in 
the branch of neurogenesis. (D) Annotated cell populations at different timepoints during hiPSC 
chondrogenesis. Cells that passed quality are used for tSNE plots; Cp: 1,888 cells, d1: 2,216 
cells, d7: 1,200 cells, d14: 2,148 cells, d28: 1,271 cells, and d42: 1,328 cells. (E) WGCNA and 
GO term analysis identified Wnt4 as a hub gene of neurogenesis while Wnt2B was highly 
associated with melanocyte development. scRNA-seq data of d14 pellets (with a total of 2,148 
cells and 3,784 genes) was used for this computation. 
3.4.7 Inhibition of Wnt signaling enhances hiPSC chondrogenesis 
As Wnts were identified as essential genes in the off-target cells, we hypothesized that inhibition 
of Wnt signaling may improve hiPSC chondrogenesis by decreasing undesired cell populations. 
It is known that Wnts are required to properly specify somites from pluripotent cells (41). 
Therefore, we administrated Wnt-C59 (C59), a Wnt inhibitor, at either the Cp stage and/or 
during the chondrogenic pellet culture (i.e., 4 different inhibition regimens; Figure 3.4A). 
Chondrocyte homogeneity, as indicated by Saf-O staining, was increased if Wnt signaling was 
inhibited during pellet culture (Figure 3.4B). This finding was reflected by increased production 
of glycosaminoglycans per cell (GAG/DNA ratio) in the group receiving C59 during the pellet 
culture (Figure 3.4C). However, inhibiting Wnts at the Cp stage severely impaired 
chondrogenesis. Mesenchymal cells that are positive for CD146 and CD166 are proposed to be 
putative chondroprogenitors due to their robust chondrogenic potential (30).  Flow cytometric 
analysis showed that C59 treatment largely decreased the percentage of CD146/CD166+ cells, 
while Wnt3A supplementation increased this population at the Cp stage (Figure 3.4D). Similar 
results were observed using two additional hiPSC lines (ATCC and BJFF) (Figure S3.4D-G).  
Interestingly, pellets derived from hMSCs with Wnt inhibition also exhibited increased Saf-O 
staining (Figure S3.4H-I). Additionally, hiPSC pellets receiving combined administration of C59 
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and ML329 (ML), an MITF antagonist, also exhibited enhanced chondrocyte homogeneity 
compared to standard TGF-3 treatment (Figure S3.4G).  
RNA fluorescence in situ hybridization (RNA-FISH) labeling of Wnts and COL2A1 
within d28 pellets indicated that although some labeling could be detected in the center of the 
pellets, most Wnts were in the perichondral layer, consistent to the inhomogeneous cell 
populations observed via IHC staining. Furthermore, C59-treated pellets showed a more 
homogenous distribution of COL2A1 RNA-FISH labeling versus TGF-3-treated pellets (Figure 






Figure 3.4 Wnt inhibition during pellet culture enhanced homogeneity of hiPSC chondrogenesis. 
(A) Experimental scheme of Wnt inhibition. (B) C59 treatment during pellet culture enhanced 
Saf-O staining and decreased off-target cells (yellow arrowheads) as compared to other Wnt 
inhibition culture regiments. Top row scale bar = 400 µm. Bottom row scale bar = 200 µm. 
Experiment was performed twice with similar results. (C) Pellets treated with C59 in pellet 
culture only exhibited an increased GAG/DNA ratio compared to pellets treated with other 
culture regiments. * p = 0.00001 at d28. # p = 0.0228 at d42. Mean ± SEM. n = 4 pellets per 
group. Statistical significance was determined by one-way ANOVA with Tukey’s post-hoc test 
at specific timepoint. (D) C59 significantly decreased, but Wnt3A significantly increased, 
CD146/CD166+/CD45- progenitors at the Cp stage. Different letters are significantly different (a 
vs. b, p = 0.0005; a vs. c, p = 0.0021; b vs. c, p = 0.0001). Mean ± SEM. n = 3 per group 
(independent experiment). Statistical significance was determined by one-way ANOVA with 
Tukey’s post-hoc test. (E) RNA-FISH of d28 pellets showing C59-treated pellets had decreased 
Wnt3A and Wnt4 staining (green) but more homogenous COL2A1 distribution (red) in the pellets. 
Scale bar = 200 µm. Experiment was performed twice with similar results. 
3.4.8 scRNA-seq confirms Wnt inhibition enhances chondrogenesis 
To determine how Wnt inhibition altered cell populations in chondrogenesis and to identify 
chondrocyte subpopulations, pellets treated with C59 were analyzed using scRNA-seq with a 
total of 12,795 cells from the stage of hiPSC, Cp as well as d7, d14, d28 and d42 C59-treated 
pellets (Figure 3.5A-B). We found the C59-treated pellets comprised two major cell populations: 
mesenchyme and chondrocytes. Mesenchyme exhibited high expression of actin (ACTA2), 
PRRX1, COL1A1, and COL3A1. Most importantly, neural cells and melanocytes were 
significantly decreased with Wnt inhibition. The differentiation trajectory of C59-treated 
chondrogenesis was reconstructed, using scRNA-seq datasets of hiPSC and Cp stages from 
previous sequencing (since they did not involve in C59 intervention) (Figure 3.5C). Compared to 
the trajectory built from TGF-3-treated pellets, C59-treated pellets exhibited little, if any, 
neurogenic markers, but showed enriched expression for chondrogenic markers (Figure 3.5D). In 
pseudotime analysis, we found that C59-treatment led to earlier induction of ACAN expression, 
higher levels of COL2A1 and SOX9 expression, and an earlier decrease in SOX2 expression as 
compared to pellets treated with TGF-3 alone (Figure S3.6A).    
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Chondrocytes in C59-treated pellets comprised several subpopulations as identified by multiple 
CCA alignment of d7-d42 timepoints with a total of 7,997 cells (Figure 3.5E-F and Figure 
S3.6B-C), including one mesenchymal population and four conserved chondrocyte subsets with 
enriched COL2A1 and SOX9 expression. The chondrocyte subset enriched in cell cycling 
markers, such as high mobility group box 2 and cyclin dependent kinase 1 (HMGB2/CDK1+), is 
defined as proliferating chondrocytes (42). The second chondrocyte subset is enriched in IGF-
binding protein-5 (IGFBP5). It has been previously reported that IGFBP5 is highly upregulated 
in early differentiating stage (43). Hence, the IGFBP5+ chondrocyte subset is defined as a 
population of early differentiating chondrocytes. The third chondrocyte subset expresses 
leukocyte cell-derived chemotaxin 1, epiphycan, and frizzled related protein 
(LECT1/EPYC/FRZB+) and had the highest levels of COL2A1 and ACAN expression among 
other chondrocyte subsets. Therefore, the LECT1/EPYC/FRZB+ chondrocyte subset is defined as 
a population of early-mature chondrocytes. Finally, we identified a unique chondrocyte subset 
expressing interferon (IFN)-related genes including ISG15 ubiquitin-like modifier, interferon 
alpha inducible protein 6, and MX dynamin like GTPase 1 (ISG15/IFI6/MX1+). We observed 
that 4.6% of ISG15/IFI6/MX1+ chondrocytes co-expressed terminal hypertrophic differentiation 
markers VEGFA and MMP13; thus, we defined the ISG15/IFI6/MX1+ chondrocyte subset as 
mature-hypertrophic chondrocytes (Figure S3.6D).  
At early timepoint d7, HMGB2/CDK1+ proliferating chondrocytes was the main cell 
population (44.5%) within the pellets (Figure S3.6C). Interestingly, this population also had the 
highest numbers of BMPR1B/ITGA4 double-positive cells, a rare osteochondral progenitor 
population found in articular cartilage (Figure S3.6E-F) (31). When proliferating chondrocytes 
differentiated toward maturity, potentially facilitated by IGFBP5 (43), IGFBP5+ early 
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differentiating chondrocytes and LECT1/EPYC/FRZB+ early-mature chondrocytes became 
dominant (Figure S3.6C). The enriched expression of FRZB, which encodes a secretory Wnt 
inhibitor, in early-mature chondrocytes might help stabilize this population by further 
antagonizing Wnt signaling in addition to C59 treatment (Figure S3.6G). As 
LECT1/EPYC/FRZB+ chondrocytes had the highest levels of COL2A1 and ACAN expression, 
we investigated the DEGs of this particular population at various time points (Figure 3.5G). 
Among several early chondrogenic markers such as COL9A1 and osteogenic markers such as 
COL1A1, IGFBP7 exhibited biphasic upregulation at both early and later time points of 
chondrogenesis.     
The percentage of ISG15/IFI6/MX1+ mature-hypertrophic chondrocytes greatly 
increased at d28 (Figure S3.6C). Although the downstream IFN regulatory molecules including 
STAT1 and PML were elevated in this population, we could not detect any type of IFNs which 
were conventionally believed to be the activators of IFN pathways (Figure S3.6H). Instead, we 
observed that IGFBP3 was enriched in ISG15/IFI6/MX1+ chondrocytes, whereas IGFBP5 was 
highly expressed in early differentiating chondrocytes. In line with the results of previous 
studies, we also observed that IGFBP3 inhibited expression of FOS (C-FOS), a possible driver of 
chondrocyte hypertrophy when it dimerizes with JUN (AP-1) (Figure S3.6I) (44). This result 
may provide some explanations for the finding that ISG15/IFI6/MX1+ chondrocytes had variable 
expression levels of hypertrophic chondrocyte markers (Figure S3.6J) (45).  
During chondrogenic culture, pellets were generally surrounded by a fibrous layer, 
resembling the cartilage anlage enclosed by fibroblastic cells (i.e., perichondrium). To determine 
if the mesenchyme (i.e., ACTA2/PRRX1/COL1A1+ cells) identified in pellets and the 
mesenchyme (i.e., PRRX1+ cells) identified at the Cp stage (monolayer culture) were similar to 
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the perichondrium, we benchmarked these mesenchymal cells, as well as various chondrocyte 
subpopulations, against previously reported markers of perichondrial cells in rats and humans 
(Figure S3.7) (46, 47).  We found that ACTA2/PRRX1/COL1A1+ cells in pellets, but not 
PRRX1+ cells at the Cp stage, were enriched in genes of perichondrium, suggesting that the 
mesenchymal populations at the Cp stage and in pellets had distinct phenotypes, despite their 
shared mesenchymal genes such as COL1A1 and COL3A1. These data were then used 
reconstruct the GRN of hiPSC chondrogenesis, with minimal presence of off-target cells as 






Figure 3.5 scRNA-seq of pellets with Wnt inhibition shows improved chondrogenesis. (A) 
scRNA-seq was performed on the pellets with Wnt inhibition. (B) Chondrocytes and 
mesenchymal cells were two major populations in C59-treated pellets. Cells that passed quality 
are used for tSNE plots; Cp: 1,888 cells, d7: 1,682 cells, d14: 3,076 cells, d28: 1,756 cells, and 
d42: 1,483 cells. (C) Differentiation trajectory of C59-treated pellets. scRNA-seq data with a 
total of 12,795 cells from the stage of hiPSC, Cp as well as d7, d14, d28 and d42 C59-treated 
pellets was used to reconstruct the differentiation trajectory. (D) C59-treated pellets exhibited 
decreased neurogenic markers but increased chondrogenic markers. (E) Multiple CCA alignment 
of d7-d42 pellets. A total of 7,977 cells from d7-d42 timepoints of C59-treated pellets was used 
to performed CCA alignment. (F) Dynamic changes in gene expression and percentages of 
chondrocyte subpopulations over time. (G) Heat map of top 20 DEGs at each timepoint for 
LECT1/EPYC/FRZB+ early-mature chondrocytes. 
3.4.9 Differential gene expression profiles after C59 treatment 
Three major conserved populations were identified after CCA alignment of the d14 cells with or 
without C59 treatment (a total of 5,224 cells analyzed): proliferative cells, mesenchyme 
enriched, and chondrocytes (Figure 3.6A and 3.6B). C59-treated pellets contained more 
mesenchyme and chondrocytes at d14, while non-C59-treated (i.e., TGF-3 only) pellets had 
more proliferative cells at the same time point (Figure 3.6C). Pellets with only TGF-3 treatment 
not only showed elevated expression of MITF but also had more neural cells which were 
clustered in proliferative cells (Figure 3.6D). Chondrocytes and proliferative cells exhibited 
similar profiles of up- and down-regulated DEGs. For instance, both cell populations showed 
upregulated expression of COL2A1 and JUNB, while exhibiting decreased expression of SOX4 
and several ribosomal genes (Figure S3.8B). Interestingly, FRZB was only upregulated in the 
chondrocyte population upon C59 treatment.  
At d28, pellets treated with C59 exhibited increased expression of ACAN and COMP 
compared to the standard-treated pellets (Figure S3.8C-D). Importantly, we also observed that 
IFI6 and ISG15, markers for mature-hypertrophic chondrocytes, were down-regulated in the 




3.4.10 Wnt expression with neurogenesis 
To determine the expression patterns of Wnts and to identify the cells responsible for Wnt 
production, we investigated Wnt expression levels in multiple cell populations of d14 and d28 
pellets (Figure 3.6E and Figure S3.8E; a total of 5,224 d14 cells and a total of 3,027 d28 cells 
analyzed). In TGF-3-treated pellets, several canonical Wnts such as Wnt3, Wnt3A, and Wnt7B, 
as well as non-canonical Wnts including Wnt4, were enriched in the proliferative population 
(where the neural cells clustered), while Wnt2B and Wnt5B could be found in proliferative cells, 
chondrocytes, and mesenchyme.  We did not detect Wnt1, Wnt2, and Wnt8 in any specimens. 
Upon C59 treatment, most Wnts showed decreased expression, particularly in proliferative cells. 
Western blots confirmed that C59-treated pellets had decreased protein levels of Wnt2B, Wnt3A, 
Wnt4, and Wnt7B (Figure 3.6F). Interestingly, C59 only moderately inhibited Wnt5B. We next 
plotted these Wnt ligands along with neurogenic and chondrogenic markers in pseudotime to 
investigate their expression patterns. We observed that Wnt2B, Wnt3A, Wnt4, and Wnt7B 
clustered with neurogenic markers, whereas Wnt5B was upregulated along chondrogenic 
differentiation, implying that individual Wnts may play distinct roles in regulating 






Figure 3.6 CCA analysis reveals that most Wnts, except Wnt5B, were secreted by off-target 
cells. (A) Three major conserved populations in d14 pellets. A total of 5,224 cells from the d14 
pellets with or without C59 treatment was analyzed. (B) Violin plots of the specific markers for 
each conserved population. (C) C59-treated pellets comprised more chondrocytes and 
mesenchymal cells. (D) Expression levels of chondrogenic markers were higher in C59-treated 
pellets while expression of neurogenic markers and melanocyte markers was higher in TGF-3-
treated pellets. (E) Dotplot showing proliferative cells (mainly neural cells) from TGF-3-treated 
pellets had high expression levels of Wnt ligands. Wnt inhibition largely decreased expression 
levels of Wnts in cells. (F) Western blots confirm that Wnt inhibition significantly decreased 
Wnts in cells at protein levels. * p = 0.026, # p = 0.021, $ p = 0.0003, † p = 0.00029, ‡ p = 0.021 
to its corresponding group. Mean ± SEM. n = 3 per treatment condition. Statistical significance 
was determined by two-tailed Student’s t-test for the groups with or without specific Wnt 
inhibition. (G) Most Wnts were upregulated along the lineage of neural cells, where Wnt5B was 
clustered with chondrogenic differentiation in TGF-3-treated pellets. A total of 2,148 cells from 
the TGF-3-treated d14 pellets was analyzed and used to generate the heatmap. 
3.4.11 Wnts alter GAG/DNA and collagen production 
As C59 is a pan-Wnt signaling inhibitor, it therefore remained unknown which Wnt ligand had 
the most severe adverse effect on hiPSC chondrogenesis. To answer this question, we 
administrated a variety of Wnts during pellet culture (Figure S3.9A). RT-qPCR analysis showed 
that only Wnt7B significantly decreased chondrogenic markers (SOX9, ACAN, and COL2A1), 
hypertrophic marker (COL10A1), and osteogenic marker (COL1A1) when compared to TGF-3 
only pellets (Figure 3.7A). Interestingly, the pellets treated with Wnt2B and Wnt3A exhibited 
increased COL2A1, COL1A1, and COL10A1 expression versus TGF-3 pellets. However, only 
the pellets with Wnt3A treatment had a significantly decreased GAG/DNA ratio compared to the 
pellets with TGF-3 only treatment (Figure 3.7B). Wnt2B-treated pellets also showed a trend 
toward increasing expression of neurogenic markers (PAX6 and SOX2), although not statistically 
significant. Furthermore, Wnt2B- and Wnt7B-treated pellets had significantly lower expression 
of MITF relative to TGF-3 pellets. We also observed that Wnt ligands may not only regulate 
their own expression but may also modulate the expression of other Wnt ligands (Figure S3.9B).  
  While all pellets had comparable Saf-O staining, Wnt treatment increased off-target cells 
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within the pellets (Figure 3.7C). Furthermore, these off-target cells exhibited lower production of 
COL2A1 compared to chondrocytes. Additionally, pellets treated with Wnts, particularly 
Wnt3A, exhibited higher intensity of COL1A1 and COL10A1 staining, which was observed near 
off-target cells and perichondrium. On the contrary, C59 pellets had low COL1A1 and 
COL10A1 production and the staining was mainly at the perichondrium. Together, these results 
indicate that Wnts increased non-chondrogenic cells and modulated collagen production. The 
histological images in Figure 3.7C were quantified using a published ImageJ protocol (Figure 
S3.9C) (48). 
3.4.12 Heterocellular Wnt signaling may regulate chondrogenesis 
To investigate which cell populations are the main sources for the endogenous production of 
specific Wnts during chondrogenesis, a heatmap in which the expression of Wnt ligands against 
multiple cell populations at the d28 timepoint was plotted (Figure 3.7D and Figure S3.9D). We 
found that 30% of melanocytes expressed Wnt2B, while Wnt3A, Wnt4, and Wnt7B were mainly 
expressed in neural cells. Wnt5B was expressed primarily by chondrocytes (about 10% of 
chondrocyte population) providing a possible explanation for the upregulation of Wnt5B during 
chondrogenesis. As Wnts are secretory proteins, we next aimed to identify the potential cell 
populations receiving Wnt signaling based on published lists of ligand-receptor pairs (27). We 
found that 31.6% of chondrocytes expressed FZD2, the highest expression of a Wnt receptor in 
chondrocytes (Figure 3.7E). Thus, we created the multicellular signaling for Wnt3A-FZD2 pair 
and identified that 9.9% of neural cells expressed Wnt3A while more than a third of chondrocytes 
(36.1%) were capable of receiving this ligand (Figure 3.7F). Additionally, we also observed that 
although chondrocytes were the major contributor for Wnt5B production, melanocytes (30%) 
might be the main receiving cell type. Furthermore, while 30% of melanocytes may secrete 
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Figure 3.7 Heterogenous multicellular Wnt signaling models. (A-B) RT-qPCR and GAG/DNA 
ratios of pellets treated with various Wnts during pellet culture. Different letters are significantly 
different from each other (p < 0.05). Mean ± SEM. n = 3-4 pellets per group. Statistical 
significance was determined by one-way ANOVA with Tukey’s post-hoc test. (C) Wnt treatment 
increased infiltration of off-target cells (pink arrowheads and white dashed lines) into the pellets, 
decreased COL2A1 staining, but increased COL1A1 (yellow arrowheads) and COL10A1 
staining in the pellets. The pellets with C59 treatment exhibited homogenous COL2A1 staining 
and decreased COL1A1 and COL10A1 staining. Scale bar = 0.2 mm. Experiment was performed 
twice with similar results. (D) Heatmap showing distinct expression levels of various Wnts in 
d14 TGF-3-treated pellets. A total of 2,148 cells from the TGF-3-treated d14 pellets was 
analyzed and used to generate the heatmap. (E) Percentage of the cells expressing Wnt3A and its 
putative receptors in d14 TGF-3-treated pellets. (F-G) Heterogenous multicellular signaling 
models in d14 TGF-3-treated pellets. 
3.4.13 BMP/GDF differential expression after C59 treatment 
While the precise mechanisms of enhanced chondrogenesis remain to be determined, our CCA 
analysis showed that six chondrocyte subpopulations and 1 mesenchymal population were 
conserved between TGF-3 and C59 conditions in d14 pellets: 1) HMGB2/CDK1+ proliferating 
chondrocytes, 2) UBE2C/CCNB1+ proliferating chondrocytes, 3) LECT1/EPYC/FRZB+ early-
mature chondrocytes, 4) ISG15/IFI6/MX1+ mature-hypertrophic chondrocytes, 5) FTL/MT-
CO2+ stressed chondrocytes, 6) BNIP3/FAM162A+ apoptotic chondrocytes, and 
ACTA2/PRRX1/COL1A1+ mesenchymal cells (Figure S3.10A; CCA was performed with a total 
of 1,335 cells from mesenchymal and chondrocyte populations from d14 TGF-3 pellets and 
with a total of 3,047 cells from mesenchymal and chondrocyte populations from d14 C59 
pellets). Interestingly, C59 treatment differentially influenced the expression of various growth 
factors and receptor in the TGF- superfamily essential in regulating chondrogenesis (49) 
(Figure S3.11A-B and Figure S3.12A-B). 
 In addition to exogenous TGF-3 stimulation, endogenous signaling from other members 
of the TGF- superfamily (e.g., bone morphogenetic proteins (BMPs), growth and differentiation 
factors (GDFs)) is also essential for regulating chondrogenesis. To investigate how C59 
 114 
 
treatment alters gene expression profiles of these families and their associated receptors 
(including Type I and Type II receptors), we used CCA to align chondrocytes populations and 
mesenchymal cells from d14 pellets with or without C59 treatment. We also observed that C59 
treatment decreased BMP2, BMP4, BMP6, and BMP7 gene expression, but it increased GDF5 
and GDF10 gene expression. For receptors, C59 treatment enhanced expression levels of 
BMPR1B and ACVR1, but it decreased BMPR2, ACVR2A, and ACVR2B expression (Figure 
S3.11A-B and S3.12A-B). BMP8A, BMP10, BMP11, and BMP15, as well as GDF2, GDF4, 
GDF6, and GDF8 were not detected in our datasets. 
To investigate how C59 treatment affects the percentage of cells expressing genes of 
interest within a specific chondrocyte subpopulation, we used BMP4, GDF5, BMPR1B (type I 
receptor), and BMPR2 (type II receptor) as examples (Figure S3.10B-E). For BMP4, C59-treated 
pellets had a decreased percentage of BMP4-expressing cells within all chondrocyte 
subpopulations except ISG15/IFI6/MX1+ mature-hypertrophic chondrocytes as compared to 
pellets treated with TGF-3 only condition. In addition, C59-treated pellets also demonstrated a 
remarkably increased percentage of GDF5 and BMPR1B expressing cells within all chondrocyte 
populations versus TGF-3-treated pellets. Furthermore, C59 decreased the percentage of the 
cells expressing BMPR2 in LECT1/EPYC/FRZB+ early-mature, ISG15/IFI6/MX1+ mature-
hypertrophic chondrocytes, BNIP3/FAM162+ chondrocytes, and HMGB2/CDK1+ and 
UBE2C/CCNB1+ proliferating chondrocytes. Interestingly, it appeared that C59 treatment did 
not significantly affect the contribution of a chondrocyte subpopulation to the cells expressing a 
given gene (i.e., the cells expressing the genes of interests mainly came from 
LECT1/EPYC/FRZB+ early-mature chondrocytes regardless of the treatments as presented in the 




The therapeutic applications of hiPSCs for cartilage regeneration or disease modeling have been 
limited by the low-yield of bona fide chondrocytes, accompanied by off-target populations 
during chondrogenic differentiation. Our GRN analysis revealed two major off-target cell 
populations, neural cells and melanocytes, which showed high association with Wnt4 and Wnt2B 
signaling, respectively. By building heterocellular signaling models, we showed that off-target 
cells were the main source of several canonical and non-canonical Wnt ligands that were 
implicated in chondrocyte hypertrophic differentiation. Importantly, inhibition of Wnt and 
MITF, the master regulator of melanocyte development, significantly enhanced homogeneity of 
hiPSC chondrogenesis by decreasing off-target cells, circumventing the need for prospective 
sorting and expansion of isolated progenitor cells. 
An important finding of this study was the identification of distinct subtypes of hiPSC-
derived chondrocytes, as shown in depth by the comprehensive transcriptomic profiles of each 
cell type at various differentiation stages. We also observed that inhibition of Wnt signaling 
during chondrogenesis alters gene expression levels of BMPs/GDFs (e.g., decreasing BMP4 and 
BMP7 levels) in chondrocytes, which is consistent with a recent study demonstrating decreased 
BMP activity during MSC chondrogenesis due to Wnt inhibition (50). Another intriguing finding 
is the discovery of ISG15/IFI6/MX1+ mature-hypertrophic chondrocytes as, without scRNA-seq, 
this unique population has not been reported before. Although the signature genes of this 
chondrocyte population (e.g., STAT-1) were generally believed to be downstream of IFN-related 
pathways, we did not detect IFN expression. The high expression of IGFBP3 in 
ISG15/IFI6/MX1+ chondrocytes may provide an explanation for this observation, as IGFBP3 
can activate STAT-1 expression without the presence of IFN molecules in chondrogenesis (51). 
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Additionally, IGFBP3-enriched chondrocytes also had decreased expression of FOS, essential in 
driving chondrocytes toward hypertrophy (44). It has been reported that chondrocyte 
hypertrophy was largely prevented upon IGFBP3 knockdown in the ATDC5 line (52). Thus, low 
FOS expression in ISG15/IFI6/MX1+ chondrocytes provides a plausible explanation for their 
low expression of hypertrophic markers. Nevertheless, the causal relationship between the dual 
function of IGFBP3 in chondrocyte hypertrophy and Wnt inhibition merits further study.   
The finding that melanocytes and neural cells were the major off-target cells imply that 
some, if not all, progenitors may acquire the phenotype of neural crest cells, a transient stem cell 
population that can give rise to neurons and melanocytes. This differentiation pathway likely 
occurs at the Cp stage, where we first observed cell populations expressing several markers of 
neural crest cells. It is likely that the neural crest cells observed in the current study were also 
off-target cells (i.e., non-paraxial mesodermal lineage) generated during early stages of 
mesodermal differentiation and amplified due to BMP4 treatment at the Cp stage. It has been 
reported that the Bmp4-Msx1 signaling axis inhibits Wnt antagonists such as Dkk2 and Sfrp2 in 
dental mesenchyme in mice (53), implying BMP4 activating Wnt signaling that is essential for 
the proliferation of neural crest cells.  
Additionally, our sorting results showed that supplementation of Wnt increased, but 
inhibition of Wnt decreased, the proportion of CD146/CD166+ cells, suggesting that Wnt 
signaling is required to maintain progenitors at the Cp stage. This finding is in agreement with a 
recent study showing that Wnt3A supports multipotency of hMSCs during in vitro expansion 
(54). In our recent publication using a CRISPR-Cas9-edited reporter hiPSC line and scRNA-seq 
techniques, we identified that mesenchymal cells triple-positive for CD146, CD166, and 
PDGFRβ, but negative for CD45, at the Cp stage showed robust chondrogenic potential but little 
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osteogenic capacity compared to unsorted cells, suggesting that CD146/CD166/PDGFRβ+ 
mesenchymal cells may be a unique chondroprogenitor population (55). However, whether the 
CD146/CD166+ progenitor population identified in the current study functions like MSCs with 
multilineage potential warrants future investigation. Furthermore, as distinct subtypes of hiPSC-
derived chondrocytes were defined primarily based on marker genes, the complete functionality 
of these subsets require future investigation.  
An important contribution of this study is the construction of the GRN of hiPSC 
chondrogenesis with the presence of minimal off-target cells, ensuring the hub genes identified 
are truly governing differentiation. In addition to conventional master TFs such as SOX9, we 
also identified several additional hub genes associated with chondrogenesis. For instance, the 
expression levels of complement C1q like 1 (C1QL1) was highly correlated with those of 
COL2A1 in our model. C1QL1 encodes a secreted protein with Ca2+ binding sites that regulates 
synaptogenesis in neuronal cells (56). However, how C1QL1 affects chondrogenesis or if it plays 
a role in synovial joint innervation is currently unknown. Additionally, our finding of the 
melanogenic GRN during hiPSC chondrogenesis suggests an off-target cell fate decision in 
differentiation. This result is further corroborated by the study of Yamashita and colleagues 
demonstrating the presence melanin or lipofuscin on the surface of hiPSC-derived cartilage pellet 
using rigorous histological staining (57). Furthermore, we also revealed the significant 
association between Wnt2B and MITF, providing insights into melanogenesis. Indeed, a recent 
study proposed genetic variants in Wnt2B may serve as a biomarker to predict survival rate of the 
patients with cutaneous melanoma (58). We also identified Wnt4 as a hub gene in the GRN of 
neurogenesis and observed that Wnt3A was enriched in the cell populations expressing neural 
markers. These results are consistent with the previously identified roles for these Wnts in 
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promoting forebrain development (59, 60). 
Heterogenous multicellular signaling models indicate that although most Wnts were 
produced by off-target cells, these ligands may signal though chondrocytes. It is well recognized 
that Wnt signaling not only blocks SOX9 expression in limb bud mesenchymal cells but also 
regulates chondrocyte maturation, driving them toward hypertrophy (61, 62). In agreement with 
these findings, hiPSC-derived chondrogenic pellets treated with individual Wnts exhibited 
increased COL10A1 staining. We also demonstrated that blocking endogenous Wnt signaling 
significantly improved chondrogenesis in hMSCs. These findings reveal the potential 
modulatory effects of off-target cells on chondrocytes through Wnt signaling pathway, indicating 
that inhibition of Wnt has dual beneficial effects on hiPSC chondrogenesis as it not only removes 
off-target cells but also prevents chondrocyte hypertrophy.     
These findings not only identify the mechanisms regulating the heterogeneity in hiPSC 
chondrogenesis but, more importantly, provide an enhanced chondrogenic differentiation 
protocol capable of generating homogenous chondrocytes by removing off-target cells without 
cell sorting. Furthermore, this protocol has been validated in multiple unique lines, 
demonstrating its robustness and efficiency in deriving chondrocytes from hiPSCs. We also 
established a comprehensive map of single-cell transcriptome profiles and GRNs governing cell 
fate decision during hiPSC chondrogenesis. These findings provide insights into dynamic 
regulatory and signaling pathways orchestrating hiPSC chondrogenesis, thereby advancing a 
further step of cartilage regenerative medicine toward therapeutic applications. This approach 
also provides a roadmap for the use of single-cell transcriptomic methods for the study and 
optimization of other in vitro or in vivo differentiation processes. 
3.6 Supplemental Figures and Tables 
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Figure S3.1 Step-wise differentiation of hiPSCs toward chondrocytes via specification of 
mesoderm. (A) Differentiation protocol of hiPSCs into chondrocytes. (B) Cell morphology at 
each stage during mesodermal differentiation. Please note that low cell density at hiPSC stage is 
required to obtain successful mesodermal differentiation. Scale bar = 500 µm. (C) Up-regulation 




Figure S3.2 GO enrichment analysis of bulk RNA-seq data and subcutaneous implantation of 
hiPSC-derived chondrocytes in mice. (A) GO enrichment analysis of bulk RNA-seq data 
showing that up-regulated genes were involved in skeletal system and cartilage development. (B) 
d14 chondrogenic pellets maintained a cartilage phenotype indicated by intense Saf-O and 
COL2A1 staining after 14 days of subcutaneous implantation in mice. n = 3 mice. (C) The off-
target cells (mostly located at the edge of perichondrium, yellow arrowheads) were observed in 
the pellets derived from 3 distinct hiPSC lines. (D) Focal black dots were occasionally observed 






Figure S3.3 Analysis of scRNA-seq data reveals diverse cell populations in hiPSC-derived 
chondrogenic pellets. (A) scRNA-seq of mixed specie samples showing low multiplet rates (< 
2.7%). (B) CCA of scRNA-seq data from d28 chondrogenic pellets from 2 independent 
experiments (i.e., 2 batches). 8 conserved cell clusters were identified in both batches. (C) Cells 
in the same cluster from different batches exhibited high correlation in their gene expression 
(Spearman’s rank coefficient rs > 0.87 for all clusters). (D) Cells in the clusters from distinct 
batches demonstrated similar gene expression patterns. (E) Additional neural cell markers such 
as DCX, MAP2, OTX1, and PAX6 were also enriched in the branch of neurogenic differentiation. 
(F) SOX4+ and SOX4/SOX9+ cells at the Cp stage had high expression of neural crest cell 
markers. A total of 1,888 cells at the Cp stage that passed quality control was analyzed. (G) Cells 
that are enriched for PRRX1, COL1A1, COL3A1, and COL5A1 were annotated as “mesenchyme” 
at the Cp stage. A total of 1,888 cells at the Cp stage that passed quality control was analyzed. 
(H) Three major cell populations observed in d3 pellets. A total of 2,485 cells from d3 pellets 
that passed quality control was used to generate the tSNE plot. (I) Fraction of major cell types 
over the course of differentiation (Cp – d28). A total of 11,208 cells from the Cp stage to d28 
pellets was analyzed. (J) IHC against nestin and MITF confirms the presence of neural cells and 
melanocytes in pellets. (K) Mesenchymal cells in d14 pellets expressed several conventionally 
recognized MSC markers. However, whether these mesenchymal cells exhibit multipotency like 






Figure S3.4 WGCNA reconstructed GRNs of neurogenesis and melanogenesis and identified the 
hub genes in each network. (A-B) GRNs of neurogenesis and melanogenesis. Topological 
analysis (community cluster) was performed to visualize subnetworks. (C) Wnt4 was among the 
hub genes in the GRN of neurogenesis while Wnt2B was associated with the GRN of melanocyte 
development. (D-F) Representative d28 pellet images showing that C59 or a combination of C59 
and ML treatment during pellet culture enhanced the homogeneity of chondrogenesis by 
removing off-target cells. This was validated in 3 unique hiPSC lines. (G) The pellets treated 
with C59 or a combination of C59 and ML treatment exhibited significantly increased 
GAG/DNA ratios compared to the pellets treated with ML and the pellets treated TGF-3. * C59 
vs. TGF-3 (p = 0.01) at a specific timepoint.  # C59 + ML vs. TGF-3 (p = 0.001) at a specific 
timepoint.  Mean  SEM. n = 4 pellets per treatment condition. One-way ANOVA with Fisher’s 
LSD was performed at d28 and d42. (H) hMSCs harvested from 3 distinct donors exhibited 
increased chondrogenesis when treated with C59 during pellet culture. (I) hMSCs harvested 
from donor 1 and donor 3 had significantly increased GAG/DNA ratios when treated with C59 
compared to with TGF-3 alone. # C59 vs. TGF-3 (p = 0.01) at specific time point. Mean  
SEM. n = 4 pellets per treatment condition.  Two-tailed Student’s t-test was performed at d28 
and d42. 
 
Figure S3.5 Semi-quantification of RNA-FISH against Wnts and COL2A1. C59-treated pellets 
showed decreased Wnt3A and Wnt4 expression but increased COL2A1 RNA-FISH labeling 




Figure S3.6 Multiple CCA alignment of d7-d42 pellets reveals that 4 conserved chondrocyte 
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subpopulations and 1 conserved mesenchymal population were observed in C59-treated pellets. 
(A) Jitter plots showing that C59-treated pellets had increased expression of ACAN, COL2A1, 
and SOX9 but decreased SOX2 versus Standard TGF-3-treated pellets. (B) Temporal expression 
profiles of signature genes of each chondrocyte subpopulation. CDK1 and IGFBP5 showed 
transient upregulation while COL9A1 and COL11A1 remained up-regulated once activated. 
MMP13 and MX1 showed increased expression levels at later time points. (C) Dynamic changes 
in the percentage of the cell population within the pellets over the course of differentiation. (D) 
ISG15/IFI6/MX1+ chondrocytes contained 4.6% cells expressing both VEGFA and MMP13. (E-
F) BMPR1B/ITGA4+ progenitors previously identified in articular cartilage were mostly 
observed in HMGB2/CDK1+ proliferating chondrocytes. (G) LECT1/EPYC/FRZB+ early-
mature chondrocytes had the highest levels of COL2A1 and ACAN expression among other 
chondrocyte subpopulations. (H) ISG15/IFI6/MX1+ mature-hypertrophic chondrocytes 
expressed several IFN-related genes. (I) In comparison with IGFBP5+ early chondrocytes, 
ISG15/IFI6/MX1+ mature-hypertrophic chondrocytes showed high expression in IGFBP3 but 
decreased expression in FOS. (J) The expression of various hypertrophic chondrocyte markers. 
For scRNA-seq analysis of C59 treated pellets, total 7,997 cells (from d7-d42) passed quality 
control and thus were analyzed for this figure. (E-F) A total of 7,977 cells from d7-d42 




Figure S3.7 ACTA2/PRRX1/COL1A1+ mesenchymal cells in the pellets, but not mesenchymal 
cells at the Cp stage, exhibit similar gene expression profile to perichondrial cells. (A) 
ACTA2/PRRX1/COL1A1+ mesenchymal cells in the pellets expressed markers of rat 
perichondrial cells. (B) ACTA2/PRRX1/COL1A1+ mesenchymal cells from d7 and d14 pellets 
were enriched with 8 of 15 differentially expressed genes in the perichondrium-like membrane of 
the human chondrogenic pellet.  Particularly, d7 ACTA2/PRRX1/COL1A1+ mesenchymal cells 
had the highest expression of C2orf91, FGF18, GGT7, CHST9, and ZNH354C. Interestingly, we 
also observed that there was gradual shift in the gene expression profile of 
ACTA2/PRRX1/COL1A1+ mesenchymal cells from d28 to d42. For example, d28 
ACTA2/PRRX1/COL1A1+ mesenchymal cells were enriched in NRN1 and CH3L1 while d42 






Figure S3.8 The GRN of hiPSC chondrogenesis. (A) The GRN and hub genes of hiPSC 
chondrogenesis. (B) CCA was used to identify DEGs of each subpopulation between d14 pellets 
with and without C59 treatment. ID2, a neurogenic marker (blue circle), was decreased in 
proliferative cells in C59-treated pellets, while PRG4 (red circle) was increased in mesenchymal 
cells in C59-treated pellets. (C) CCA alignment of cells from d28 pellets with and without C59 
treatment. A total of 3,027 cells from d28 pellets with and without C59 treatment was used to 
performed CCA alignment. (D) CCA was used to identify DEGs of chondrocytes between d28 
pellets with and without C59 treatment. Markers for mature-hypertrophic chondroocytes, such as 
IFI6 and ISG15 (blue circles), were decreased while ACAN and COMP (red circles) were 
increased in C59-treated pellets. (E) Similar to the Wnt expression profiles in d14 pellets, most 




Figure S3.9 Effect of Wnts on chondrogenesis. (A) Schematic of Wnt treatment during 
chondrogenic pellet culture. (B) RT-qPCR of d14 pellets treated various Wnts showing that gene 
expression of Wnts can be modulated by other Wnt ligands. Different letters are significantly 
different from each other (p < 0.05). Mean ± SEM. n = 3-4 pellets per group. Statistical 
significance was determined by one-way ANOVA with Tukey’s post-hoc test. (C) Semi-
quantification of Saf-O and IHC labeling against various collagens. (D) Percentage of the cells 
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expressing a variety of Wnts in d14 pellets treated with TGF-3. For scRNA-seq analysis of d14 




Figure S3.10 Differential expression of BMPs/GDFs and receptors in response to Wnt 
inhibition. (A) CCA alignment of chondrocyte and mesenchymal populations from TGF-3 only 
and C59 conditions. (B) C59-treated pellets had a decreased percentage of BMP4 expressing 
cells within all clusters except within ISG15/IFI6/MX1+ mature-hypertrophic chondrocytes. (C-
D) C59-treated pellets demonstrated a remarkably increased percentage of GDF5 and BMPR1B 
expressing cells within all clusters versus TGF-3-treated pellets. (E) C59 treatment decreased 
percentage of cells expressing BMPR2 in LECT1/EPYC/FRZB+ early-mature chondrocytes, 
ISG15/IFI6/MX1+ mature-hypertrophic chondrocytes, BJIP3/FAM162+ apoptotic chondrocytes, 
as well as HMGB2/CDK1+ and UBE2C/CCNB1/KPNA2+ proliferating chondrocytes. (B-E) 
Note that C59 treatment did not significantly affect the contribution of a cluster to the cells 
expressing BMP4, GDF5, BMPR1B, and BMPR2 as presented in the pie charts. For 
bioinformatic analysis, CCA was performed with a total of 1,335 cells from mesenchymal and 
chondrocyte populations from d14 TGF-3 pellets and with a total of 3,047 cells from 




Figure S3.11 CCA analysis showing differential gene expression with C59 treatment. (A) BMP 
and (B) GDF families in chondrocyte subpopulations due to C59 treatment. Numerical value on 
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top of each bar in the bar graph indicates cell numbers expressing a given gene. For 
bioinformatic analysis, CCA was performed with a total of 1,335 cells from mesenchymal and 
chondrocyte populations from d14 TGF-3 pellets and with a total of 3,047 cells from 




Figure S3.12 CCA analysis showing differential receptor gene expression with C59 treatment. 
(A) Type I and (B) type II receptors for the BMP/GDF family in chondrocyte subpopulations due 
to C59 treatment. Numerical value on top of each bar in the bar graph indicates cell numbers 
expressing a given gene. For bioinformatic analysis, total 2,148 cells from d14 TGF-3 treated 
pellets and total 3,076 cells from d14 C59+TGF-3 treated pellets passed quality control and 





Table S3.1 Numbers of the cells passed quality control (QC) for each stage and associated 































Detected cells Cells passed QC Median genes/cell Highly variable genes 
Monolayer culture 
hiPSC 6258 4798 1688 1651 
Sclerotome 2237 1861 3107 2240 
Cp 2536 1888 3443 1754 
Sum 11031 8547 8238 5645 
Average 3677 2849 2746 1882 
TGF-3 chondrogenic pellets 
d1 2418 2216 3447 2097 
d3 2810 2485 3357 1835 
d7 1369 1200 4049 2302 
d14 2266 2148 3784 2001 
d28 1321 1271 2900 2178 
d42 1355 1328 2324 1955 
Sum 11539 10648 19861 12368 
Average 1923 1775 3310 2061 
TGF-3 + C59 chondrogenic pellets 
 
d7 2191 1682 4030 1733 
d14 3461 3076 2718 1693 
d28 1881 1756 2714 1991 
d42 1926 1483 3003 2126 
Sum 9459 7997 12456 7543 
Average 2365 1999 3116 1886 
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Table S3.2 Top 10 up-regulated genes in fold change in mesodermal phase. Related to Figure 1. 
Ensembl Symbol AP vs hiPSC PM vs AP ES vs Par Scl vs ES ES vs Cp 
ENSG00000113722 CDX1 7.47 1.28 -5.77 -1.90 -2.03 
ENSG00000185155 MIXL1 7.32 -2.67 -4.09 -2.29 0.91 
ENSG00000222033 LINC01124 7.32 0.31 -5.65 -2.48 2.72 
ENSG00000164458 T 7.19 -0.13 -5.22 -2.84 -1.81 
ENSG00000104371 DKK4 7.13 -2.61 -5.28 -0.92 1.07 
ENSG00000274981  6.99 -0.44 -4.38 -2.01 -0.10 
ENSG00000241345 LOC105375483 6.80 1.09 -5.53 -1.25 2.06 
ENSG00000253308  6.75 2.33 -7.08 -1.82 2.23 
ENSG00000106038 EVX1 6.51 0.01 -5.38 -2.44 1.48 
ENSG00000105991 HOXA1 6.34 3.87 -2.36 -1.99 -1.85 
ENSG00000049249 TNFRSF9 1.16 6.93 -5.79 -0.95 3.01 
ENSG00000120094 HOXB1 2.25 6.54 -3.53 -3.39 -0.37 
ENSG00000151379 MSGN1 3.11 6.23 -5.27 -3.42 -0.60 
ENSG00000137252 HCRTR2 0.01 6.01 -2.13 -0.74 1.57 
ENSG00000179111 HES7 0.97 5.54 -2.97 -2.34 -0.34 
ENSG00000253552  2.07 5.13 0.68 -2.19 -0.52 
ENSG00000182742 HOXB4 1.54 4.93 1.00 -1.24 -0.41 
ENSG00000129654 FOXJ1 -2.73 4.73 -2.53 1.02 1.48 
ENSG00000163083 INHBB -2.68 4.55 -0.68 -2.63 1.58 
ENSG00000100678 SLC8A3 -0.89 4.53 -0.27 -0.63 -1.42 
ENSG00000147223 RIPPLY1 -0.02 -0.99 11.49 -8.93 -1.53 
ENSG00000005102 MEOX1 0.06 0.37 9.05 -1.35 -5.05 
ENSG00000164853 UNCX -1.66 0.00 8.92 -0.59 -1.21 
ENSG00000136698 CFC1 -2.67 2.82 8.33 -4.80 -1.36 
ENSG00000224865 LOC101928782 0.07 0.01 8.17 -2.92 -4.34 
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ENSG00000168269 FOXI1 1.00 -0.91 8.12 -4.89 -3.26 
ENSG00000102837 OLFM4 0.99 -0.16 7.77 -4.75 -0.94 
ENSG00000176692 FOXC2 0.89 0.83 7.24 -1.11 -2.23 
ENSG00000176678 FOXL1 -0.32 0.94 7.15 -2.86 -1.48 
ENSG00000213931 HBE1 1.07 0.33 7.12 -1.58 -0.82 
ENSG00000136327 NKX2-8 2.46 -0.32 -2.04 9.99 -3.90 
ENSG00000184302 SIX6 0.22 -1.31 -3.65 8.29 -0.28 
ENSG00000008196 TFAP2B 2.42 0.63 -4.51 7.30 1.47 
ENSG00000274021  -0.86 0.85 -6.19 6.97 -1.09 
ENSG00000064218 DMRT3 0.99 0.80 -2.70 6.97 -3.17 
ENSG00000139318 DUSP6 -0.39 0.72 -6.78 6.96 -1.03 
ENSG00000176165 FOXG1 0.14 0.67 -0.64 6.81 -3.11 
ENSG00000244405 ETV5 -0.05 0.62 -6.23 6.76 -1.15 
ENSG00000152785 BMP3 -0.82 0.49 0.16 6.63 -3.57 
ENSG00000178235 SLITRK1 -0.99 0.33 -2.34 6.62 -2.86 
ENSG00000180828 BHLHE22 2.88 -1.47 -2.00 -3.08 7.73 
ENSG00000167941 SOST -1.11 0.36 5.37 -4.87 7.09 
ENSG00000188620 HMX3 -2.25 -0.08 2.35 -3.91 6.47 
ENSG00000164125 FAM198B 0.87 -0.59 -0.25 1.80 6.30 
ENSG00000163132 MSX1 4.90 0.75 -2.60 -1.44 6.30 
ENSG00000175899 A2M -0.10 -0.72 -0.41 1.55 6.29 
ENSG00000165092 ALDH1A1 -0.27 -1.01 -1.47 0.82 6.20 
ENSG00000109846 CRYAB -1.24 -0.25 -0.09 -0.25 6.12 
ENSG00000107984 DKK1 5.15 -0.85 -3.78 -2.19 6.10 
ENSG00000122641 INHBA -1.45 -1.94 1.50 -0.96 6.07 





Table S3.3 Top 10 up-regulated genes in fold change in chondrogenic phase. Related to Figure 
1. 
Ensembl Symbol d7 vs Cp d14 vs d7 d21 vs d14 d28 vs d21 d42 vs d28 
ENSG00000124159 MATN4 7.69 1.22 0.73 -1.28 -0.68 
ENSG00000181195 PENK 7.65 1.16 -0.23 -0.15 -0.51 
ENSG00000008441 NFIX 7.08 -0.36 1.15 -0.69 0.43 
ENSG00000006611 USH1C 7.01 -0.34 -0.37 -0.64 0.73 
ENSG00000157554 ERG 6.44 -0.47 -0.45 -0.25 -0.51 
ENSG00000171812 COL8A2 6.19 -0.01 0.68 -1.48 0.21 
ENSG00000124134 KCNS1 6.18 0.48 0.42 -0.68 -1.88 
ENSG00000121898 CPXM2 5.87 0.80 1.01 -0.05 0.52 
ENSG00000224765  5.75 -0.37 0.53 -0.83 -0.15 
ENSG00000145708 CRHBP 5.66 -2.59 0.34 0.56 -3.25 
ENSG00000249945  -2.48 5.07 -4.36 -0.50 0.13 
ENSG00000135480 KRT7 -2.54 4.98 1.00 -0.08 -0.17 
ENSG00000278530 CHMP1B2P -0.11 4.80 -4.40 -1.15 -1.39 
ENSG00000234787 LINC00458 -2.38 4.34 -2.06 0.93 -0.91 
ENSG00000182798 MAGEB17 -3.16 4.24 -1.13 -1.02 2.03 
ENSG00000278840  -2.23 4.19 0.70 -0.59 0.73 
ENSG00000253507  -0.90 4.00 -2.28 -0.13 0.48 
ENSG00000187569 DPPA3 0.15 3.96 -1.73 0.95 -0.79 
ENSG00000196767 POU3F4 2.51 3.94 -1.98 -0.60 -2.49 
ENSG00000101842 VSIG1 -1.03 3.81 -1.35 -0.37 2.15 
ENSG00000011083 SLC6A7 -0.34 -1.09 6.22 -1.47 -0.62 
ENSG00000205890 LOC100128770 -2.25 1.60 5.78 -3.33 -1.20 
ENSG00000152213 ARL11 -1.54 -1.42 5.10 -4.03 1.23 
ENSG00000233841 HLA-C -0.97 0.94 5.06 -5.06 1.81 
ENSG00000117091 CD48 0.74 -0.73 4.77 -3.40 -1.04 
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ENSG00000166869 CHP2 -3.55 0.82 4.70 -4.51 1.21 
ENSG00000204121  -3.93 1.36 4.51 -3.57 1.80 
ENSG00000224865 LOC101928782 0.13 -0.54 4.48 -4.29 2.13 
ENSG00000182912  -0.87 -1.29 4.45 -2.86 0.11 
ENSG00000188257 PLA2G2A 2.84 -1.28 4.22 1.86 -0.02 
ENSG00000213931 HBE1 -3.49 1.31 -0.55 3.12 -4.81 
ENSG00000207927 MIR302A -0.72 0.80 -1.84 2.87 0.72 
ENSG00000120094 HOXB1 -0.17 1.40 -1.90 2.82 -3.71 
ENSG00000164746 C7orf57 -0.30 -0.16 -0.92 2.77 -0.75 
ENSG00000183463 URAD -2.49 -0.82 0.69 2.68 -3.05 
ENSG00000203635  -0.46 0.86 -2.09 2.66 -1.49 
ENSG00000131095 GFAP 0.18 0.65 1.11 2.65 0.93 
ENSG00000255282 WTAPP1 -2.90 -1.23 0.75 2.62 -0.60 
ENSG00000101276 SLC52A3 -1.43 1.12 -1.39 2.57 -0.83 
ENSG00000277060 NLRP2 -1.14 1.39 -1.19 2.56 -2.86 
ENSG00000166828 SCNN1G -2.23 0.06 -0.22 0.46 4.32 
ENSG00000129451 KLK10 -2.31 -0.66 1.84 0.73 3.96 
ENSG00000168447 SCNN1B -1.71 0.49 3.90 -3.56 3.84 
ENSG00000176654  -1.05 2.23 1.68 -4.23 3.50 
ENSG00000234745 HLA-B 0.48 -0.20 0.68 -1.09 3.48 
ENSG00000013588 GPRC5A 0.83 -0.05 1.38 0.16 3.45 
ENSG00000105392 CRX 0.14 1.54 -1.45 -1.03 3.32 
ENSG00000137265 IRF4 -1.02 -0.43 3.20 -1.55 3.27 
ENSG00000123689 G0S2 -2.25 0.07 1.75 0.99 3.25 
ENSG00000161652 IZUMO2 -1.81 -1.56 0.78 0.27 3.02 
3.7 Conclusion 
In conclusion, we used next generation sequencing to map the transcriptomic profile of hiPSC 
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chondrogenesis. This allowed us to identify Wnt and MITF as the drivers of off-target 
differentiation resulting in neurogenic and melanocytic cell populations, respectively. By 
inhibiting these signaling pathways during chondrogenesis, we significantly improved the 
homogeneity and robustness of the hiPSC-derived cartilage. The extensive data gathered about 
chondrogenesis via the mesodermal lineage will provide insights and preliminary data for future 
studies investigating chondrogenic differentiation and optimizing cartilage tissue engineering. 
Furthermore, the hiPSC-derived cartilage can serve as an in vitro disease model for 
developmental and degenerative cartilage diseases.  
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Chondrogenic Differentiation of  
Human Induced Pluripotent Stem Cells 
Partially adapted from: Dicks A, Steward N, Guilak F*, Wu CL*. Chondrogenic Differentiation 
of Human Induced Pluripotent Stem Cells. Methods in Molecular Biology. Submitted. 
4.1 Abstract 
The generation of large quantities of genetically defined human chondrocytes remains a critical 
step for the development of tissue engineering strategies for cartilage regeneration and high-
throughput drug screening. This protocol describes chondrogenic differentiation of human 
induced pluripotent stem cells (hiPSCs), which can undergo genetic modification and the 
capacity for extensive cell expansion. The hiPSCs are differentiated in a stepwise manner in 
monolayer through the mesodermal lineage for 12 days using defined growth factors and small 
molecules. This is followed by 28 days of chondrogenic differentiation in a 3D pellet culture 
system using transforming growth factor beta 3 and specific compounds to inhibit off-target 
differentiation. The 6-week protocol results in hiPSC-derived cartilaginous tissue that can be 
characterized by histology, immunohistochemistry, and gene expression or enzymatically 
digested to isolate chondrocyte-like cells. Investigators can use this protocol for experiments 
including genetic engineering, in vitro disease modeling, or tissue engineering. 
4.2 Introduction 
Articular cartilage is the tissue lining the ends of long bones in synovial joints, providing a 
nearly frictionless surface for joint motion while withstanding millions of cycles of loading per 
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year (1, 2). The unique mechanical properties of cartilage (3) are due to the composition and 
structure of the cartilage matrix – predominantly a variety of proteoglycans and collagens as well 
as hyaluronate and fibronectin (4). Glycosaminoglycans (GAGs), largely comprising the large 
aggregating proteoglycan aggrecan (ACAN), make up 4-7% of the tissue (4-6). Due to their 
negative charge, GAGs retain water, which composes 65-80% of the tissue weight, contributing 
to the compressive properties of cartilage (4-6). Type II collagen, making up approximately 10-
20% of cartilage matrix, primarily contributes to the shear and tensile properties of the tissue (4-
6).  
Chondrocytes, the sole cell type in articular cartilage, are responsible for maintaining the 
homeostasis of cartilage matrix proteins in response to genetic and environmental signals, such 
as growth factors or physiologic loading (7, 8). However, under pathologic, injurious loading, the 
chondrocytes shift to a degradative and inflammatory phenotype (9). Since the cartilage is 
avascular and aneural, it is susceptible to degeneration in an inflammatory environment, while 
lacking the ability to regenerate, leading to diseases such as arthritis (4, 10).  
Arthritis is a family of joint diseases characterized degradation of the cartilage matrix, 
which leads to joint space narrowing, along with osteophyte formation, bone remodeling, and 
synovitis. These progressive changes which are associated with pain, swelling, and loss of 
motion (11, 12). There is a variety of types of arthritis, affecting approximately 54 million adults 
in the United States (13), with osteoarthritis (OA) and rheumatoid arthritis (RA) as the most 
common. OA affects the largest number of people with increasing age, female sex, genetics, joint 
injury, and obesity as the primary risk factors (11, 14). RA is an autoimmune disease (12), where 
the immune system leads to the inflammatory environment and onset of degeneration and 
symptoms (12). Unfortunately, current treatment for OA is limited to non-steroidal, anti-
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inflammatory drugs for mild to moderate cases and joint replacements for severe cases (11). 
Disease-modifying antirheumatic drugs have been developed to treat RA; however, they are 
effective in only a fraction of individuals and have been associated with significant side effects 
(12). Therefore, there remains a need for improved therapies for cartilage injury or arthritis. In 
this regard, cartilage tissue engineering not only provides a potential regenerative therapy for 
joint diseases but can also provide in vitro model systems for disease modeling and drug 
development (15-17). Furthermore, such in vitro models can be used to elucidate mechanisms of 
and develop treatments for a variety of other cartilage-associated diseases (18-25). In this regard, 
the availability of large numbers of genetically-defined cells that can be chondrogenically 
differentiated could serve as a critical component in the development of new cell-based therapies 
or in vitro disease models for drug screening.   
4.2.1 Development of the protocol 
This protocol was developed based on a series of previous studies that elucidated the sequence of 
signaling cues required for cartilage development in vivo coupled with various reports of in vitro 
chondrogenic differentiation of mouse and human pluripotent stem cells (26-29). In previous 
studies, we developed a method to derive chondrocytes from hiPSCs in a stepwise manner via 
the paraxial mesodermal lineage (30) based on the mesodermal roadmap developed by Loh, et al. 
using embryonic stems cells and iPSCs (26). The next steps toward directed chondrogenic 
differentiation were induced using bone morphogenic protein 4 (BMP4) and transforming 
growth factor beta 3 (TGF-β3), given their known roles in pre-cartilaginous mesenchymal 
condensation and chondrogenic differentiation (29, 31-36). In this process, hiPSC-derived 
sclerotome cells were treated with BMP4. The resulting chondroprogenitor cells were then 
cultured in a conventional 3D pellet system with TGF-β3 to further specify mesodermal cells 
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into the chondrogenic fate. However, despite the robust generation of chondrocytes from hiPSCs 
using BMP4 and TGF-β3, we and others have shown significant and unpredictable cellular 
heterogeneity within newly formed cartilaginous tissues (30, 37-40).  
To determine the identity of such non-chondrocytic cells, bulk and single-cell RNA 
sequencing were applied at multiple time points throughout the course of hiPSC chondrogenesis. 
These studies revealed that the primary off-target cells were of neural and melanocytic lineages 
(37, 38). With the analysis of the gene regulatory networks, we identified that Wnts and 
melanocyte inducing transcription factor (MITF) are the primary hub genes responsible for off-
target neurogenesis and melanogenesis during hiPSC chondrogenic differentiation, respectively. 
Thus, in the improved protocol, we use small molecules to inhibit Wnt and MITF signaling 
during chondrogenic pellet culture, significantly enhancing the efficiency and homogeneity of 
hiPSC chondrogenesis. We further validated our optimized protocol using multiple hiPSC lines, 
histological and quantitative biochemical analysis of cartilage matrix production, and real-time 
quantitative polymerase chain reaction (RT-qPCR) and single-cell RNA sequencing techniques 




Figure 4.1 Overview schematic of the protocol. hiPSCs undergo mesodermal differentiation in 
monolayer for twelve days. The cells go through the anterior primitive streak, paraxial 
mesoderm, early somite, sclerotome, and finally chondroprogenitor stage. Cells are then cultured 
in a 3D pellet culture to become chondrocytes and synthesize cartilaginous matrix. The protocol 
then has 4 options to either digest the tissue to isolate single cells or validate chondrogenesis 
with histology (Saf-O and IHC), biochemical assays (DMMB for sGAG and PicoGreen for 
dsDNA), and/or RT-qPCR. 
4.2.2 Applications of the protocol 
The hiPSC-derived chondrocytes and tissue-engineered cartilage from this protocol can facilitate 
the development of patient-specific regenerative approaches for a variety of cartilaginous 
disorders including, but not limited to, arthritis, osteochondritis dissecans, relapsing 
polychondritis, chondrocalcinosis, cartilaginous tumors, and arthropathies (41). Particularly, our 
protocol can allow for in vitro disease modeling and high throughput drug screening (15). 
Furthermore, in vitro modeling of specific genetic conditions can be established through targeted 
genome engineering of the cells (e.g., CRISPR-Cas9 genome editing) with isogenic controls or 
patient-derived iPSCs, in conjunction with simulation of a diseased environment (e.g., 
inflammatory cytokines) (16, 42, 43). Furthermore, since the protocol follows the developmental 
lineage, such models allow investigation of the mechanisms underlying developmental disorders, 
 150 
 
such as skeletal dysplasias, chondrodysplasias, collagenopathies, and aggrecanopathies (41). 
Additionally, the protocol can be applied to cartilage tissue engineering and other topics 
in the musculoskeletal field. Studies can be developed to investigate mechanisms that promote or 
repress chondrogenic differentiation to improve tissue engineering and regenerative strategies. 
For example, various forms of loading such as osmotic, compressive, and shear forces can be 
applied at different magnitudes, time points, and regimens to optimize matrix production and 
mechanical properties (44). The similarity between hiPSC-derived chondrocytes and primary 
chondrocytes allows for the study of fundamental questions regarding cell physiology, such as 
mechanisms of chondrocyte mechanobiology (e.g., role of ion channels, integrins, and other 
mechanotransduction pathways) (45, 46), the development and physiology of the chondrocyte 
circadian rhythm, and the cells’ responses to metabolic syndrome and inflammation. 
Furthermore, the rapid expansion of genome engineering in the cartilage field provides the 
opportunity to apply principals of synthetic biology for the development of “smart,” self-
regulating cells or mechanogenetic gene circuits in human cells (45, 47-49). Therefore, the 
ability to generate a large number of chondrogenically differentiated cells from hiPSCs provides 
the opportunity for numerous advances in cartilage research, including other types of 
cartilaginous tissues (50). 
4.2.3 Comparison with other methods 
To tissue-engineer cartilage, a culture system is needed to differentiate and culture chondrocytes 
that can synthesize and accumulate cartilaginous matrix, with or without a biomaterial scaffold 
(6). A variety of cell types have also been used for this purpose including primary chondrocytes, 
adult multipotent stem cells, and pluripotent stem cells (6). While primary chondrocytes can 
synthesize a cartilaginous matrix in 3D, they are limited in their expansion potential and undergo 
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dedifferentiation with passage in monolayer (51). Additionally, harvesting of human 
chondrocytes from a patient results in donor site morbidity, while other sources (e.g., cadaveric, 
surgical waste) are difficult to obtain (6). Therefore, adult stem cells, such as bone marrow-
derived mesenchymal stem cells (52) and adipose-derived stem cells (53), have been used for 
cartilage tissue engineering. While these methods have been optimized to successfully produce 
cartilage-like tissue, adult stem cells represent a heterogeneous population of cells and show 
significant donor-to-donor variability. Furthermore, they have limited in vitro expansion 
capacity, making it difficult to perform gene editing and clonal isolation (54-56). Induced 
pluripotent stems cells have high proliferation and differentiation capacities, allowing for the 
study of genetic perturbations. Furthermore, they can be derived in a patient-specific manner 
with low or no donor morbidity, and they do not have the ethical concerns associated with 
embryonic stem cells (42, 43, 57).  
Previously published chondrogenesis protocols of stem cells, including ours, have greatly 
extended our knowledge in chondrocyte biology and cartilage tissue engineering; however, many 
of these approaches rely on the application of fetal bovine serum (FBS) in culture medium. 
While it may enhance cell viability, FBS may also lead to off-target differentiation because of its 
undefined chemical composition. Furthermore, lot-to-lot variability of FBS may also make the 
protocols difficult to reproduce in different laboratories (34, 35, 58-62). Here, we have 
established a chondrogenic differentiation protocol for hiPSCs, using serum-free, chemically 
defined medium, that we have validated with 8 hiPSC lines with and without genetic mutations. 
4.3 Experimental Design 
4.3.1 Cell source 
hiPSC lines derived from foreskin or skin fibroblasts with either retroviral or Sendai viral 
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induction of the Yamanaka factors (i.e., OCT3/4, SOX2, KLF4, and c-MYC) (56) have been 
tested with this protocol. Sendai-viral hiPSCs are free from genomic integration of the 
Yamanaka factors, unlike retrovirally-transduced hiPSCs, which have the genes integrated in 
their genome (62). The cells are maintained in hiPSC-maintenance medium, avoiding 
overcrowding and spontaneous differentiation. In some cases, cleaning, either colony picking or 
scraping of differentiated cells, can be carried out. hiPSC maintenance, expansion, and 
mesodermal differentiation are performed on vitronectin-coated plates. 
4.3.2 Mesodermal differentiation 
Approximately 48 hours after passaging, when the hiPSCs have reached 30-40% confluency, the 
cells should be induced for mesodermal differentiation in monolayer. The cells are fed every 24 
hours with a defined growth factor and small molecule cocktail to guide differentiation. First, 
basic fibroblast growth factor (FGF) alongside activation of the TGF and Wnt-signaling 
pathways drive the cells into the anterior primitive streak. Wnt activation and FGF are continued 
while the TGF/BMP pathway is inhibited on the second day to derive paraxial mesodermal cells. 
Next, all these pathways (i.e., FGF, Wnt, and TGF/BMP) are inhibited for differentiation into the 
early somite. Wnt inhibition is continued in combination with sonic hedgehog (SHH) activation 
for the next three days achieving sclerotome cells. The following 6 days drive the cells into 
chondroprogenitors by adding BMP4 each day (Figure 4.1). Notably, mesodermal differentiation 
begins along the perimeter of the hiPSC colonies, and cell morphology will change from the 
small, round, colonized hiPSCs into longer, more fibrotic cells which spread throughout the 
culture plate. 
4.3.3 Chondrogenic differentiation 
After the 12-day mesodermal differentiation in monolayer, chondroprogenitor cells are 
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disassociated with TrypLE into single cells. Cells are resuspended at a concentration of 5  105 
cells/mL using complete chondrogenic medium containing TGF-β3. These cells 
are transferred to a 15-mL conical tube and centrifuged to form the 3D chondrogenic pellet 
culture (Figure 4.1). The media is replaced every 3-4 days with complete chondrogenic medium 
until the time point of interest, typically 28 days after chondrogenic induction. 
4.3.4 Chondrogenic validation 
We use five different methods to validate the outcome of the chondrogenic differentiation: 
isolated single cells (chondrocytes), histology, immunohistochemistry (IHC), biochemical 
analysis, and RT-qPCR (Figure 4.1). 
The chondrogenic pellets are digested to obtain hiPSC-derived chondrocytes at the single 
cell level (Figure 4.1). Pellets are washed with DPBS-/- and transferred into a 0.4% (wt/vol) type 
II collagenase solution in a conical tube. The tubes are vortexed and placed on an orbital shaker 
in a 37 ºC incubator. The tubes should be vortexed every 20 minutes until the pellets are 
digested. After pellet digestion, the collagenase solution with single cell suspension is 
neutralized with medium containing 10% FBS. Cells are then resuspended in the appropriate 
serum-free culture medium for follow up experiments.  
Pellets are fixed in 10% neutral buffered formalin overnight, dehydrated in 70% ethanol 
at 4 ºC, processed following standard histological protocol (including multiple dehydration 
steps), and embedded in paraffin wax. Wax blocks containing the pellets are cut into 8 µm 
sections, and sections are placed on microscope slides. Histological slides are stained for the 
nuclei and proteoglycans with hematoxylin and Safranin-O, respectively. For IHC, slides are 
rehydrated, prepared for staining with a primary antibody of interest, visualized with a secondary 
antibody, enzyme conjugation, and a chromogen substrate, and then counterstained for the 
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nucleus. Slides are mounted with paramount and cover slipped for imaging and storage. IHC can 
be semi-quantified using the previously published ImageJ protocol (64).  
For a more quantitative analyses and validation of our protocol, we recommend two 
additional methods. The first is the biochemical assay using dimethylmethylene blue (DMMB) 
and PicoGreen for quantitative measures of sulfated GAG (sGAG) and DNA contents, 
respectively (53). Chondrogenic pellets are washed in DPBS-/-, transferred into a 1.7-mL tube 
containing 200 µL of 125 g/mL papain, vortexed, and digested at 65 ºC overnight to release 
DNA and sGAG content. The following day, the digested samples are vortexed again and can be 
frozen until needed. This protocol measures the sGAG content which can then be normalized to 
DNA. The second method is to quantify gene expression using RT-qPCR (53, 65). Each pellet is 
washed with DPBS-/- and transferred into a 2-mL tube to be snap frozen in liquid nitrogen and 
stored at -80ºC until the RNA isolation. 
4.4 Materials 
4.4.1 hiPSC culture 
1. hiPSC lines. This protocol has been validated with hiPSCs derived from fibroblasts 
reprogrammed using Sendai virus or retrovirus. It has also been successful with CRISPR-
Cas9-edited hiPSCs. 
2. Culture dishes: 6-well cell culture plate or T75 or T225 cm2 cell culture flask 
3. Matrix substrate: 1 µg/mL vitronectin recombinant human protein, truncated (Invitrogen) 
in DPBS. Coat plate at 0.5 µg/cm2 and distribute by rocking plate to ensure surface is 
coated and incubate at room temperature 1 hour. Plates can be used immediately or stored 
at 2-8 °C wrapped in plastic film. If stored, warm for 1 hour at room temperature before 
using. Aspirate vitronectin solution and discard before culturing cells.  
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4. hiPSC culture medium: Essential 8 flex media (E8; Gibco). Prepare according to 
manufacturer instruction and store at 4 ºC for up to 2 weeks. Add 10 µM Y-27632 
(STEMCELL Technologies) to E8 medium for first 24 hours after thawing or passaging. 
5. Disassociation solution: ReLeSR (STEMCELL Technologies). 
6. Cryomedium: PSC cryopreservation kit (Gibco). 
7. 2-ml cryotubes. 
4.4.2 Mesodermal differentiation 
1. Differentiation medium: 242.5 mL Iscove’s Modified Dulbecco’s 
Medium, glutaMAX (IMDM; Gibco), 242.5 mL Ham’s F-12 nutrient 
mix, glutaMAX (F12; Gibco), 5 mL penicillin-streptomycin (P/S; Gibco), 5 mL Insulin-
Transferrin-Selenium (ITS+; Gibco), 19.5 µL 1-Thioglycerol (Millipore Sigma), 
chemically defined concentrated lipids (Thermo Fisher Scientific). Store at 4 ºC for up to 
2 weeks.  
2. Wash medium: 248.5 mL IMDM, 248.5 mL F12, 5 mL P/S. Store at. 4 ºC for up to 2 
weeks. 
3. Anterior primitive streak differentiation medium (day 1): 30 ng/mL activin A protein 
(R&D Systems), 20 ng/mL recombinant human fibroblast growth factor basic protein 
(FGF2; R&D Systems), 4 µM CHIR99021 (Reprocell) in differentiation medium. 
4. Paraxial mesoderm differentiation medium (day 2): 20 ng/mL FGF2, 3 µM CHIR99021, 




5. Early somite differentiation medium (day 3): 2 µM SB505124, 4 µM dorsomorphin, 500 
nM PD173074 (Tocris Bioscience), 1 µM Wnt-C59 (Cellagen Technologies) in 
differentiation medium.  
6. Sclerotome differentiation medium (days 4-6): 1 µM Wnt-C59, 2 µM 
purmorphamine (Reprocell) in differentiation medium.  
7. Chondroprogenitor differentiation medium (days 7-12): 20 ng/mL recombinant human 
bone morphogenic protein 4 (BMP4, R&D Systems) in differentiation medium. 
8. Disassociation reagent: TrypLE Select enzyme (Gibco).  
9. Neutralization medium: 494 mL Dulbecco’s Modified Eagle 
Medium/F12, glutaMAX (DMEM/F12; Gibco), 5 mL fetal bovine serum (FBS; Atlanta 
Biologicals). 
10. Trypan blue stain (Invitrogen). 
11. Cell counter. 
12. 50-mL conical tubes. 
13. Cryomedium: 16 mL FBS, 2 mL DMEM, 2 mL dimethylsulfoxide (DMSO). 
14. 2-ml cryotubes.  
4.4.3 Chondrogenic differentiation 
1. Dexamethasone: 100 µM. Add 19.62 mg dexamethasone powder (Millipore Sigma) to 1 
mL absolute ethanol. Transfer 0.8 mL of the ethanol solution to 39.2 mL DMEM/F12 for 
a 1-mM solution. Transfer 4 mL of the 1-mM solution to 36 mL DMEM/F12 to make a 
100-μM solution. Store aliquots at -80 °C up to 1 year.  
2. Ascorbic acid solution: 50 mg/mL ascorbic acid (Millapore Sigma) in DMEM/F12. Store 
aliquots at -80 ºC for up to 3 months.  
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3. Proline: 40 mg/mL proline (Millapore Sigma) in DMEM/F12. Store aliquots at -80 ºC for 
up to 3 months.  
4. Chondrogenic medium: 483 mL DMEM/F12, 5 mL P/S, 5 mL ITS+, 5 mL Modified 
Eagle Medium (MEM) with nonessential amino acids (Gibco), 0.5 mL dexamethasone, 
0.5 mL 2-Mercaptoethnol (Gibco). Store at 4 ºC for up to 2 weeks. 
5. Complete chondrogenic medium: 10 ng/mL recombinant human transforming growth 
factor beta 3 protein (TGF-β3; R&D Systems), 1 µM Wnt-C59, 1 µM ML329 (Cayman 
Chemical), 0.1% ascorbic acid, 0.1% proline in chondrogenic medium. 
6. 15-ml conical tubes. 
4.4.4 Chondrogenic validation 
Digestion of chondrogenic pellets 
1. DPBS-/-. 
2. Neutralization medium. 
3. Digestion medium: 0.4% wt/vol type II collagenase (Worthington Biochemical, activity 
225 units/mL) in warm neutralization medium. Sterile filter and use immediately. 
4. 15-mL or 50-mL conical tubes.  
5. Orbital shaker. 
Histology preparation 
1. DPBS-/-. 
2. 20-ml glass scintillation vials.  
3. 10% neutral buffered formalin. 
4. Paraffin. 




7. Microscope slides. 
8. Microtome. 
Safranin-O staining 
1. Safranin-O solution (Millipore Sigma). 
2. Harris hematoxylin with glacial acetic acid (Poly Scientific). 
3. Ethanol, 200 proof. 
4. Xylenes. 
5. Differentiation solution (Millipore Sigma). 
6. Permount mounting media. 
7. Glass cover slips. 
Immunohistochemistry 
1. Ethanol, 200 proof. 
2. Xylenes. 
3. COL1A1 antibody (Abcam, cat. no. ab90395).   
4. COL2A1 antibody (Iowa Hybridoma Bank, cat. no. II-II6B3-s). 
5. COL6A1 antibody (Fitzgerald Industries, cat. no. 70F-CR009X). 
6. COL10A1 antibody (Millipore Sigma, cat. no. C7974). 
7. Goat anti-mouse antibody (Abcam, cat. no. ab97021). 
8. Goat anti-rabbit antibody (Abcam, cat. no. ab6720). 
9. Hydrogen peroxide. 
10. Methanol. 
11. 10% goat serum (Thermo Fisher Scientific).  
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12. Pepsin (Thermo Fisher Scientific). 
13. Proteinase K (Millipore Sigma): 0.5% wt/vol in TE buffer. Prepare fresh. 
14. Quenching solution: 3% hydrogen peroxide in methanol. 
15. Histostain Plus Kit (Thermo Fisher Scientific). 
16. AEC substrate solution (Abcam). 
17. Vector hematoxilyn QS counterstain (Vector Laboratories). 
18. VectaMount AQ aqueous mounting medium (Vector Laboratories). 
19. Glass cover slips. 
20. Aluminum foil. 
Biochemical analysis preparation 
1. DPBS-/-. 
2. Papain solution: 125 mg/L papain, pH 6.5. Weigh 125 mg of papain (Millapore Sigma), 
13.8 g of sodium phosphate, 1.46 g ethylenediaminetetraacetic acid (EDTA), and 0.79 g 
cysteine hydrochloric acid (HCl). Mix reagents using a stir bar and plate at room 
temperature with 1 L ultrapure distilled water. Reagents may take 1.5-2 hours to 
dissolve. Adjust pH to 6.5 using approximately 38 mL of 1 N NaOH. Aliquot and store 
at -20°C for up to 3 months.   
3. 1.7-mL tubes. 
RT-qPCR preparation 
1. DPBS-/-. 
2. 2-ml screw-top tubes. 
3. Liquid nitrogen. 
4. Primers. See Table 4.1 for suggested chondrogenic primers.  
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Table 4.1 RT-qPCR primers.  
Target gene Forward primer (5’-3’) Reverse primer (5’-3’) 
ACAN CACTTCTGAGTTCGTGGAGG ACTGGACTCAAAAAGCTGGG 
COL1A1 TGTTCAGCTTTGTGGACCTC TTCTGTACGCAGGTGATTGG  
COL2A1 GGCAATAGCAGGTTCACGTA CTCGATAACAGTCTTGCCCC 
COL10A1 CATAAAAGGCCCACTACCCAAC ACCTTGCTCTCCTCTTACTGC 
SOX9 CGTCAACGGCTCCAGCAAGAACAA GCCGCTTCTCGCTCTCGTTCAGAAGT 
TBP AACCACGGCACTGATTTTCA ACAGCTCCCCACCATATTCT  
4.5 Methods 
4.5.1 hiPSC culture 
≥ 1 hour for coating plate(s), 30 minutes for plating/passaging, 30 minutes for feeding, 2-7 days 
for culture 
1. Coat a 6-well plate with vitronectin. 
2. Thaw a vial of hiPSCs in a 37 ºC water bath.  
3. Transfer the cells using sterile serological plastic pipettes into 10 mL of room-
temperature hiPSC maintenance medium in a 15 mL-conical tube. 
4. Centrifuge cells at 200 g for 5 min at 23 ºC.  
5. Aspirate the supernatant.  
6. Add 13 mL hiPSC maintenance medium containing 10 M of Y-27632 to the cell pellet. 
Do not pipette up and down, instead gently rock the tube back and forth twice. This will 
prevent breaking up the colonies into single cells. 
7. Aspirate the vitronectin-PBS-/- solution from plate.  
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8. Add 2 mL of cell solution to each well. Gently tilt the plate in a circular motion to 
distribute the cells evenly throughout the wells. Failure to do so will cause the cells to 
cluster in one area, preventing proper proliferation, which may lead to spontaneous 
differentiation.  
9. Incubate the plate at 37 ºC.  
10. After 24 hours, aspirate the medium from the plate and feed with hiPSC maintenance 
medium without Y-27632. 
11. Continue cell culture, feeding every day until cells reach approximately 80% confluency. 
Cells can be frozen in cryopreservation medium. We typically freeze cells sufficient for 
one 6-well plate in 1 mL of cryopreservation medium for future passaging. The split ratio 
may vary depending on hiPSC lines.  
12. Before passaging, coat the appropriate number of 6-well plates and/or T225 flasks with 
vitronectin.  
13. Aspirate medium from cell plate. 
14. Wash each well with 2 mL of DPBS-/-.  
15. Add 1.5 mL of ReLeSR for 1 min at RT.  
16. Aspirate off ReLeSR.  
17. Incubate plate for 2 min at 37 ºC. If the cells are ≥ 85% confluent or if there is 
spontaneous differentiation, the time can be shortened to 1 min.  
18. Pipette 2 mL of hiPSC maintenance medium onto the bottom of each well, you should 
see the cells lift off with the medium, and transfer into a conical tube using sterile 
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serological plastic pipettes. Do not pipette up and down.  
19. Tap the plate several times. 
20. Centrifuge cells at 200 g for 5 min at 23 ºC.  
21. Aspirate the supernatant.  
22. Resuspend cells in hiPSC maintenance medium containing 10 M of Y-27632. Do not 
pipette up and down, instead gently rock the tube back and forth twice. This will prevent 
breaking up the colonies into single cells. 
23. Aspirate the vitronectin-PBS-/- solution from plate(s) / flask(s).  
24. Add cell solution to plate(s) / flask(s). Gently tilt the plate(s) / flask(s) in a circular 
motion to distribute the cells throughout the wells. Failure to do so will cause the cells to 
cluster, preventing proper proliferation and leading to spontaneous differentiation  
25. Check cell density in microscope. If too confluent, remove some of the cell solution and 
add up volume with maintenance medium containing Y-27632. 
26. Culture for at least 48 h until 30-40% confluent. Too high cell density inhibits 
mesodermal differentiation. Too low cell density prevents adhesion and increases cell 
death. (see Notes 1-3) 
4.5.2 Mesodermal differentiation 
30 minutes – 1 hour for feeding, 12 days for culture 
1. Warm appropriate volume of wash and differentiation medium in 37 ºC water bath. For 
days 2-12: if fed medium changes from orange to yellow in color after 24 h, suggesting 
high metabolic activity of the cells, increase differentiation medium volume by 1 mL per 
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well and / or 5 mL per flask.  
2. Make the appropriate differentiation medium for the corresponding day by adding the 
correct growth factors. Day 1: anterior primitive streak; day 2: paraxial mesoderm; day 3: 
early somite; days 4-6: sclerotome; days7-12: chondroprogenitor.  
3. Aspirate maintenance media from plate(s) / flask(s). 
4. Rinse plate(s) / flask(s) with wash medium. 
5. Add complete differentiation medium.  
6. Incubate plate at 37 ºC.  
7. Feed the cells every 24 h with mesodermal differentiation medium supplemented with the 
appropriate growth factor and small molecule cocktails. Note that more-than-usual cell 
death may be observed after day 3 due to the inhibition of several major signaling 
pathways. When switching to a new set of the growth factors and small molecules (i.e., 
days 1, 2, 3, 4, and 7), it is critical to feed at the 24-hour time points to ensure proper 
lineage specification. Cells can be harvested after days 1, 2, 3, 6, and 12 if the specific 
lineage stages are of interest to the experiment (e.g., RT-qPCR). (see Notes 4-7) 
8. On day 13, aspirate medium from cell plate(s) / flask(s).  
9. Wash with DPBS-/-  
10. Pipette TrypLE disassociation reagent onto plate(s) / flask(s).  
2 mL per well of 6-well plate and 20-25 mL per T225 flask. 
11. Incubate for 3 min at 37 ºC. 
12. Gently tap plate(s) / flask(s) several times to disassociate cells. You should see cells 
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floating in medium (see Note 8). 
13. Add slightly more than an equal volume of neutralization media. 
14. Pipette half of the medium into a conical tube. 
15. Pipette up and down the other half in the wells / flask(s) twice to lift any remaining cells. 
Transfer to a conical tube.  
16. Rinse the wells / flask(s) twice with neutralization medium and transfer to tubes each 
time.  
17. Centrifuge cell tubes at 300 g for 5 min at 23 ºC.  
18. Aspirate supernatant.  
19. Chondroprogenitor cells can undergo chondrogenesis or frozen in cryomedium for future 
chondrogenesis. 
4.5.3 Chondrogenic differentiation 
1-3 hours for pelleting, 28 days for differentiation 
1. Warm neutralization and chondrogenic medium in 37 ºC water bath.  
2. Add TGF-β3, ascorbate, proline, Wnt-C59, and ML329 to make complete chondrogenic 
medium.  
3. Resuspend chondroprogenitor cells in complete chondrogenic medium. Combine cells if 
you have multiple tubes.  
4. Stain 10 µL of the cell solution with 10 µL of Trypan Blue to count cell number on an 
automated cell counter or hemocytometer.  
5. Using the cell count, calculate the volume needed for a concentration of 5  105 cells per 
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1 mL of complete chondrogenic medium (see Note 9). 
6. Pipette the cell solution to make pellet cultures – 1 mL per 15 mL conical tube.  
7. Centrifuge tubes at 300 g for 5 min at 23 ºC.  
8. Loosen the caps of the tubes in the biosafety cabinet. The tubes must be loosened to 
provide oxygen supply to the cells. The cap should however still be screwed on so that it 
cannot be lifted off to prevent contamination.  
9. Incubate the tubes at 37 ºC.  
10. Check tubes to confirm pellet formation after 24 hours (see Note 10). 
11. Feed pellets every 3 – 4 days.  
12. Warm incomplete chondrogenic medium in 37 ºC water bath.  
13. Add TGF-β3, ascorbate, proline, Wnt-C59, and ML329 to make complete chondrogenic 
medium.  
14. Aspirate medium from the conical tube with a 9” Pasteur pipette. 
15. Use at 12-mL stereological pipette to feed 6 tubes at a time with 2 mL per pellet. Ensure 
lids remain loose (see Notes 11-12). 
16. Chondrogenic pellets can be harvested at various time points as desired. Proceed to 
section 3.4. We recommend weekly harvest on days 7, 14, 21, 28, and 42. In general, 
cells start to deposit matrix 14 days post-chondrogenic induction (i.e., apparent pellet 
enlargement). Additionally, chondrocytes usually can be observed approximately 14-21 
days post-chondrogenic induction. 
17. 28 days after chondrogenic induction, most of the cells should have differentiated into 
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chondrocytes and formed cartilaginous matrix. We recommend digesting the 
chondrogenic pellet to retrieve the chondrocytes at a single cell level (3.4.1) for further 
experimentation or using histology/IHC (3.4.2-4), biochemical assays (3.4.5), and/or RT-
qPCR (3.4.6) to confirm and study chondrogenic differentiation.  
4.5.4 Chondrogenic validation 
Digestion of chondrogenic pellets 
3 hours 
1. Warm neutralization and desired medium for the experiment. If plating the cells, we 
recommend using the neutralization medium.  
2. Prepare digestion medium.  
3. Aspirate medium from pellets.  
4. Wash each pellet with 2-3 mL of DPBS-/-. 
5. Transfer pellets into a tube with digestion medium. Use an equal volume of digestion 
medium to the number of pellets being digested (± 1 mL). A 15-mL or 50-mL tube 
should not exceed 8 mL or 25 mL of digestion medium, respectively.  
6. Vortex the tube(s) and shake manually then place on an orbital shaker (80 RPMs) in a 37 
ºC incubator.  
7. Every 20 min remove the tube(s) from the incubator to vortex and check digestion 
progress.  
8. After approximately 2 h, the matrix of chondrogenic pellets should be mostly digested. 
The length of digestion time needed depends on harvest time point and size of the tube. 
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For example, pellets harvested prior 28 days post-chondrogenic induction may only 
require 1 hr to achieve full digestion. Additionally, we have observed faster digestion 
using 50-mL conical tubes (see Note 13).  
9. Add neutralization medium to the tube(s) bringing the volume to 12 mL or 45 mL.  
10. Centrifuge tube(s) at 300 g for 5 min at 23 ºC.  
11. Aspirate supernatant. 
12. Resuspend in neutralization medium.  
13. Stain 10 µL of the cell solution with 10 µL of Trypan Blue to count on an automated cell 
counter or hemocytometer.  
14. Centrifuge at 300 g for 5 min at 23 ºC.  
15. Resuspend the cells at the desired concentration. The number of cells retrieved per pellet 
may depend on hiPSC lines. On average, we get approximately 6.5  105 cells per pellet. 
The cell recovery rate may be increased if multiple pellets from the same group are 
pooled and digested together. If plating the chondrocytes, we recommend adding the cells 
to desired dish(s) and incubating for 6-8 h. This provides sufficient time for the cells to 
adhere without dedifferentiating and losing their phenotype. 
Histology preparation 
At least 3 days  
1. Transfer pellet(s) into a scintillation vial with 10% (vol/vol) neutral buffered formalin. 
2. Store at 4 ºC overnight. 
3. Remove formalin and add 70% (vol/vol) ethanol. Pellets can be stored in 70% (vol/vol) 
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ethanol at 4ºC long term.  
4. Transfer pellet into a plastic cassette for processing. Biopsy foam pads can be used to 
sandwich the chondrogenic pellet within the cassette to prevent it from falling out. 
Processing can be done by hand or using a tissue processor.  
5. Dehydrate the chondrogenic pellet for 30 min in 80% (vol/vol) ethanol followed by 30 
min in 100% (vol/vol) ethanol. Exchange the 100% (vol/vol) ethanol for another 30 min. 
Pellets can be stored in 100% (vol/vol) ethanol overnight. 
6. Clear the pellet for 30 min with a 1:1 solution of ethanol and xylene followed by 30 min 
of 100% (vol/vol) xylene. Exchange the 100% (vol/vol) xylene for another 30 min. 
7. Begin embedding the pellet for 1 h with a 1:1 solution of xylene and paraffin wax at 60 
ºC followed by 1 h with 100% (vol/vol) paraffin at 60 ºC. Exchange the 100% (vol/vol) 
paraffin for another 1 h at 60 ºC. 
8. Transfer pellet into an embedding tray, place cassette on top, and fill with paraffin wax.  
9. Store for a few hours or overnight at 4 ºC to harden wax. Pellets can be stored in wax 
long term at RT.  
10. Cut the wax blocks in 8-µm-thick sections and place a short ribbon of sections in a 42 ºC 
water bath. 
11. Remove a ribbon of sections from the water bath by allowing it to attach to a microscope 
slide. In general, there should be 3-5 sections per ribbon on each slide. Slides can be 
stored long term at RT.  




13. Perform desired histology such as staining for sGAGs with Safranin-O or labeling of 
collagenous proteins with immunohistochemistry. 
Safranin-O and hematoxylin staining 
1-2 hours 
1. Remove paraffin wax with 3 rounds of soaking slide(s) in xylene for 5 min. 
2. Rehydrate tissue with 100% (vol/vol) ethanol for 2 min followed by 50% (vol/vol) 
ethanol for 2 min. 
3. Rinse slide(s) in tap water for 2 min.  
4. Remove all excess water.  
5. Stain slide(s) with Harris hematoxylin for 3 min (nuclei will be stained purple). Filter 
Harris hematoxylin staining solution before each use to remove potential precipitations 
and avoid deposition of particulates on slide. Do not reuse stain more than ten times.  
6. Rinse slide(s) in tap water for 3 min. 
7. Differentiate slide(s) in differentiation solution (acid alcohol) for 15 sec.  
8. Rinse slide(s) in tap water for 3 min.  
9. Stain slide(s) with Safranin-O for 3-5 min (sGAGs will be stained pink/red). Do not reuse 
stain more than 10 times.  
10. Rinse slide(s) multiple times with 100% (vol/vol) ethanol until no excess stain remains. 
11. Let slide(s) partially dry before rinsing with xylene for 30 sec. 





1. Remove paraffin wax with 3 rounds of soaking slide(s) in xylene for 5 min.  
2. Rehydrate tissue by washing slide(s) with 100% (vol/vol) ethanol for 5 min twice, 95% 
(vol/vol) ethanol for 5 min twice, 70% (vol/vol) ethanol for 5 min, 50% (vol/vol) ethanol 
for 5 min, and then tap water for 5 min. Do not let the slides dry out. Place slide(s) in a 
container with a hydrated paper towel.  
3. Perform antigen retrieval by adding 100 µL of proteinase K or pepsin on the slide and 
incubating (see Table 4.2 for recommended reagent, timing, and temperature). 
4. Wash the slide(s) with DPBS-/- for 5 min twice.  
5. Quench the slide(s) for 1 h in 3% (vol/vol) hydrogen peroxide in methanol.  
6. Wash the slide(s) with DPBS-/- for 5 min three times.  
7. Use a Pap-pen to circle each piece of tissue on the slide(s) to prevent solution spreading. 
8. Perform blocking by adding a couple drops (enough to cover the tissue) of 2.5% (vol/vol) 
goat serum to each piece of tissue for 1 h at RT.  
9. Blot excess serum from bottom of inclined slide. Do not rinse.  
10. Stain tissue with primary antibody for 1 h at RT in hydrated container. See Table 4.2 for 
antibodies and dilutions. Do not add primary antibody to one piece of tissue. Instead add 
more goat serum from step viii to serve as negative control.  
11. Wash the slide(s) with DPBS-/- for 5 min three times.  
12. Add a couple drops (enough to cover the tissue) of the proper secondary antibody at a 
 171 
 
1:500 dilution for 30 min at RT (Table 4.2). 
13. Wash the slide(s) with DPBS for 5 min three times.  
14. Combine 5 mL of ImmPact AEC diluent, 2 drops of AEC reagent 1, 3 drops of AEC 
reagent 2, and 2 drops of AEC reagent 3. Mix well. 
15. Add AEC solution to the slide(s) and incubate at RT. See Table 4.2 for timing (see Note 
15). 
16. Wash the slide(s) with distilled water for 5 min. 
17. Rinse the slide(s) in tap water.  
18. Cover tissue sections with Vector Hematoxylin QS counterstain for 45 sec.  
19. Rinse the slide(s) in tap water for 10 sec. Do not dehydrate slides. 
20. Mount the slide(s) with VectaMount AQ aqueous mounting medium, coverslip, let dry, 
and image.  
Table 4.2 IHC antibodies.  




COL1A1 Mouse Abcam ab90395 Pepsin  
(5 min, RT) 
1:800 2 min 





(3 min, 37 ºC) 
1:10 2.5 min 
COL6A1 Rabbit Fitzgerald 
Industries 
70F-CR009X Proteinase K 
(3 min, 37 ºC) 
1:1000 2.5 min 
COL10A1 Mouse Millipore Sigma C7974 Pepsin 
(5 min, RT) 
1:200 2 min 
Goat anti-mouse 
IgG, biotin 





Goat Abcam ab6720  1:500  
Biochemical assay preparation 
1 day for sample preparation, 2-3 hour for assay 
1. Wash chondrogenic pellets with 2-3 mL of DPBS-/-.  
2. Transfer each pellet into a 1.7-mL tube with 200 µL of papain and vortex.  
3. Digest tissue at 65 ºC overnight and vortex. Use of cap-lock on the tubes may help 
securely seal the tube at high temperatures. Samples can be stored at -20 ºC until analysis.   
4. Follow previously published protocol to determine sGAG/DNA ratio using DMMB and 
PicoGreen Assays (53). 
RT-qPCR Preparation 
1-2 days 
1. Clean work area with RNaseZap solution.  
2. Wash chondrogenic pellets with 2-3 mL DPBS. 
3. Transfer pellet into a tube and snap freeze in liquid nitrogen. We generally use screw-top 
microcentrifuge tubes with O-ring cap. Samples can be frozen at -80 ºC until analysis.  
4. Follow previously published protocol to determine gene expression using RT-qPCR (53, 
65).  
4.6 Anticipated Results 
During regular culture, the hiPSCs have a small, round phenotype, and they grow in dense, round 
colonies (Figure 4.2a). When passaging and plating, caution must be taken to prevent from 
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breaking up the colonies too much as the hiPSCs tend to trigger cell death or spontaneously 
differentiate if cultured as single cells. In our laboratory, most hiPSC lines had optimal survival 
and growth on vitronectin-coated 6-well plates while there was lower viability when cultured on 
10-cm dishes. Some hiPSC lines that were originally maintained on other substrates (e.g., 
Matrigel) were able to be switched onto vitronectin substrate by culturing cells on vitronectin-
coated plates for several passages before mesodermal differentiation. After mesodermal 
induction, hiPSCs begin to differentiate at the edges of the colonies. As the cells become more 
elongated and spread out, the center of the colony begins to differentiate as well (Figure 4.2b-e). 
Some cell death may be observed after the third day of mesodermal induction due to the 
inhibition of multiple essential pathways; however, the remaining cells should recover and 
differentiate as expected. Excess cell death may occur if hiPSCs are induced at too low of a cell 
density. In our previous study, we have demonstrated a decrease in pluripotent genes OCT4 and 
NANOG throughout the mesodermal differentiation with an upregulation of MIXL1 indicating 
anterior primitive streak cells after day 1, MSGN1 indicating the paraxial mesoderm after day 2, 
and PARAXIS indicating the early somite state after day 3 (30). After day 6, the cells are 
committed into the sclerotome lineage with an upregulation of SOX9, PDGFRA, and PDGFRB. 
The upregulation of PDGFRβ continues through the chondroprogenitor stage alongside COL2A1 
expression after day 12 of mesodermal induction (30). We have also demonstrated that the 
chondroprogenitors express the surface markers CD166, CD146, and PDGFRβ, but not CD45, 
using flow cytometric analysis (37). Cells in the chondroprogenitor stage should be fully 
differentiated and spread out throughout the dish with an elongated phenotype (Figure 4.2f). If 
the mesodermal differentiation is induced at too high of a cell density; however, one might 
observe formation of nodules in the center of cell colonies (Figure 4.2g) and/or formation of a 
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cell “sheet” that often spontaneously lifts off the culture plates, resulting into failed mesodermal 
lineage commitment.  
 
Figure 4.2 Phase contrast images of cells throughout mesodermal differentiation. (A) Induce 
cells when they are 30-40% confluent. (B-F) As cells differentiate, from (B) anterior primitive 
streak, (C) paraxial mesoderm, (D) early somite, (E) sclerotome, to (F) chondroprogenitor, they 
spread and become more spindled. (G) If cells are induced at too high of a density, they may not 
fully differentiate and form nodules in the center of the colonies. Scale bar = 1 mm. 
Chondroprogenitor cells in monolayer culture (i.e., day 12 of mesodermal differentiation) 
should be disassociated into single cells to form 3D, chondrogenic pellets for chondrogenesis. 
Cells should lift off the bottom of the culture dish in the TrypLE solution after a 3 min 
incubation and gentle tapping. If cells do not lift off, increase the time of incubation. We have 
tried using cell scrapers in instances where cells do not lift after 8 min of incubation; however, 
the cells had poor viability and failed to form chondrogenic pellets. We average a yield of 6 x 
107 chondroprogenitor cells per T225 flask; however, this value may vary due to different hiPSC 
lines and plating density used. Approximately 24 h after chondrogenic induction, we observe the 
formation of a spherical pellet in the bottom of the conical tube. Occasionally, the pellet may 
need additional time before the proper shape is visible. Pellets that do not form after 48 h should 
be discarded. This may be caused by improper mesodermal differentiation or incompatible 
disassociation reagent (cell line specific). In some cell lines, we have found disassociating 
chondroprogenitor cells in 0.05 mM EDTA and/or differentiating cells on Matrigel has improved 
pelleting and chondrogenesis. As pellet cultures approach 28 days, the medium may begin to turn 
yellow due to increased cellular metabolic activity, which can be prevented by increasing the 
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volume of chondrogenic medium during feeding. In other cases, some excess matrix may have 
formed apart from the pellet in the tube; removing this during feeding will also reduce the rate 
the culture medium is metabolized. If black dots appear on the pellets, suggestive of off-target 
differentiation and presence of melanocytes, increasing the concentration of ML329 will inhibit 
MITF and potential melanin production. Throughout chondrogenic culture, the pellets should 
grow due to accumulation of cartilaginous matrix but maintain a relatively spherical shape. We 
have reported a significant increase in chondrogenic genes SOX9, COL2A1, and ACAN from the 
chondroprogenitor stage through day 42 culture, while fibrocartilage and hypertrophic cartilage 
markers COL1A1 and COL10A1, respectively, remain relatively low until later time points 
(Figure 4.3a-e) (30, 37).  
 
Figure 4.3 Anticipated results – gene expression and matrix quantification. (A-C) Chondrogenic 
transcription factor SOX9 gene expression should increase early, followed by matrix genes 
COL2A1 and ACAN. (D-E) Relative to the expression of COL2A1, lower gene expression of 
fibrocartilage and hypertrophic cartilage markers COL1A1 and COL10A1, respectively, was 
observed. (F) sGAG/DNA ratio should increase throughout chondrogenesis, reaching 20-30 
ng/ng at day 28 and over 40 ng/ng at day 42. Mean ± SEM, n=4. *p<0.05 compared to previous 
time point. 
To obtain hiPSC-derived chondrocytes, day 28 chondrogenic pellets can be digested with 
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type 2 collagenase. Vortexing the tubes every 20 min will facilitate the breakdown of the tissue 
matrix, thus increasing digestion efficiency. However, if the chunks of pellets remain intact after 
a lengthy period of digestion, “smashing” the pellets using a tool with a flat surface (e.g., spatula 
with shovel head, or lid of an Eppendorf tube) in a sterile Petri dish may help break up the tissue 
matrix. We do not recommend digesting for longer than 2.5 h as it may decrease the cell 
viability. Occasionally, small pieces of tissue may still be visible after the digestion process; 
however, most of the cells will be dissociated from the matrix. We average a cell viability of 
85% and approximately 6.5 x 105 cells per digested pellet. We found an increase in viability and 
efficiency when more pellets are digested at a time and 50-mL conical tubes are used.  
To validate and visualize the cartilage matrix produced by hiPSC-derived chondrocytes, 
we use Safranin-O staining to reveal the presence of sGAGs (Figure 4.4a-c), IHC to label various 
types of collagens (Figure 4.4d-f), biochemical DMMB assay to quantify sGAG production 
(Figure 4.3f), and RT-qPCR to analyze gene expression (Figure 4.3a-e). We normally observe 
round chondrocyte-like cells within cartilaginous matrix with robust, homogenous Safranin-O 
staining (Figure 4.4a-c). If cellular heterogeneity is observed, concentration of Wnt-C59 and 
ML329 can be increased to further prevent off-target differentiation. If there is little or no sGAG 
staining, differentiation was unsuccessful, which can be attributed to several issues addressed in 
Notes. If hiPSCs have successfully differentiated into chondrocytes, there should also be 
significant labeling for COL2A1 (Figure 4.4d), with minimal labeling of COL1A1 (Figure 4.4e) 
and COL10A1 (Figure 4.4f). Biochemical analysis and RT-qPCR for these genes can further 
support successful chondrogenesis. Chondrogenic pellets typically have an sGAG/DNA ratio 
between 20-30 ng/ng in day 28 pellet samples, which can continue to increase with more time in 
culture (Figure 4.3f). A significant upregulation of SOX9, COL2A1, and ACAN gene expression 
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should be detected in the pellets at day 28 versus day 0 pellet samples (Figure 4.3a-c), while the 
expression levels of COL1A1 and COL10A1 remain low until later time points (Figure 4.3d-e). 
The hiPSC-derived chondrocytes and cartilage matrix generated using this protocol can be used 
for a variety of experiments including genetic engineering, in vitro disease modeling, and tissue 
engineering. 
 
Figure 4.4 Anticipated results – histology. (A-C) Robust, homogenous safranin-O staining for 
sGAGs in three different cell lines. (D-F) Pellet in panel a with IHC labeling of COL2A1 (D), 
COL1A1 (E), and COL10A1 (F). Scale bar = 500 µm. 
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4.7 Troubleshooting Notes 
1. If hiPSCs are confluent in 2-3 days, the cell concentration of the frozen stock is too high. 
Plate one vial to more than one 6-well plate (e.g., 1.5 or 2 x 6-well plates). 
2. If there is hiPSC death, cells were plated at too low of a density, media was changed too 
soon, Y-27632 was not added, cells were washed and fed too aggressively, or the cell line 
is not compatible with vitronectin. Reduce number of wells and/or flasks you are plating, 
make sure media is changed 24 hours after plating (or try extending the time slightly 
longer than 24 hours), make sure to add Y-27632 to media for the first 24 hours, pipette 
media slowly and onto the side of the dish (not directly on the cells), or try other matrix 
substrates such as Matrigel. 
3. If there is spontaneous differentiation, colonies were not maintained but broken into 
single cells or cells were plated at an incorrect density. Do not pipette up and down when 
plating and passaging hiPSCs or change the number of wells you plate per cell vial/plate. 
You can scrape differentiated cells to clean the wells.  
4. If there is cell death, cells were induced at too low of a density or there was spontaneous 
differentiation. Wait longer after passaging to increase cell density before induction or 
clean wells before passaging by scraping differentiated cells. 
5. If cells are not differentiating or nodules form in the center of colonies, cells were 
induced at too high of a density. Passage cells at a lower density and induce cells 48 
hours after passaging. 
6. If cells lift off the culture surface, cells were induced at too high of a density or were 
washed and fed too aggressively. Passage cells at a lower density, induce 48 hours after 
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passaging, and pipette media slowly on the side of the dish (not directly on cells). 
7. If media is yellow, cells were metabolic and fed too low of a media volume. Increase 
volume by 1 mL per well (6-well plate) or 5 mL per T225 flask. 
8. If cells are still stuck to the dish, they did not fully lift off the plate during disassociation. 
Place dishes with fresh TrypLE back in the incubator for 2 min and increase the force of 
slap without causing media to splash on top of dish.  
9. If you do not have enough cells to create the desired number of chondrogenic pellets, 
reduce the number of cells per chondrogenic pellet (e.g., 2.5 x 105 or 3 x 105). 
10. If pellets have not formed, wait an additional 24 hours to allow them to form. Otherwise, 
dissociation reagent (TrypLE) was too aggressive, cells did not differentiate properly, or 
the cell line is incompatible with vitronectin. Use a milder disassociation reagent (e.g., 
0.05 mM EDTA), decrease cell density at time of mesodermal induction, or try a 
different matrix substrate such as Matrigel.  
11. If media is yellow, pellets have grown significantly and are metabolically active or extra 
matrix is being produced around walls of the conical tube in addition to the pellet. 
Increase chondrogenic medium volume by 1 mL per tube or aspirate away excess matrix 
with Pasteur pipette during aspiration.  
12. If black spots appear on pellet, melanin is being produced. Increase concentration of 
ML329.  
13. If chondrogenic pellets are not fully digested, the collagenase solution is not strong 
enough or the matrix is too dense. Ensure proper ratio of collagenase to medium was used 
and test different lots of collagenase. Remove pellets from tube and place in an empty 
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well of 6-well plate. Use a closed, sterile 1.7-mL Eppendorf to gently “smash” pellets. 
Use collagenase solution to rinse the well and transfer back to tube. Digest an additional 
20 min. 
14. If there is cell and matrix heterogeneity in chondrogenic pellet, Wnt and MITF signaling 
is occurring and causing off-target differentiation. Increase concentrations of Wnt-C59 
and ML329. 
15. If the positive control is not showing stain, development time is too short. Increase time 
of development with AEC. 
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Skeletal Dysplasia-causing TRPV4 Mutations 
Suppress the Hypertrophic Differentiation of 
Human iPSC-derived Chondrocytes 
Partially adapted from: Dicks A, Maksaev GI, Harissa Z, Savadipour A, Tang R, Steward N, 
Liedtke W, Nichols CG, Wu CL*, Guilak F*. Skeletal dysplasia-causing TRPV4 mutations 
suppress the hypertrophic differentiation of human iPSC-derived chondrocytes. 
bioRxiv 2021.06.15.448562; doi: 10.1101/2021.06.15.448562. eLife. Submitted. 
5.1 Abstract 
Mutations in the TRPV4 ion channel can lead to a range of skeletal dysplasias. However, the 
mechanisms by which TRPV4 mutations lead to distinct disease severity remain unknown. Here, 
we use CRISPR-Cas9-edited human induced pluripotent stem cells (hiPSCs) harboring either the 
mild V620I or lethal T89I mutations to elucidate the differential effects on channel function and 
chondrogenic differentiation. We found that hiPSC-derived chondrocytes with the V620I 
mutation exhibited increased basal currents through TRPV4. However, both mutations showed 
more rapid calcium signaling with a reduced overall magnitude in response to TRPV4 agonist 
GSK1016790A compared to wildtype. There were no differences in overall cartilaginous matrix 
production, but the V620I mutation resulted in reduced mechanical properties of cartilage matrix 
later in chondrogenesis. mRNA sequencing revealed that both mutations upregulated several 
anterior HOX genes and downregulated antioxidant genes CAT and GSTA1 throughout 
chondrogenesis. BMP4 treatment upregulated several essential hypertrophic genes in WT 
chondrocytes; however, this hypertrophic maturation response was inhibited in mutant 
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chondrocytes. These results indicate that the TRPV4 mutations alter BMP signaling in 
chondrocytes and prevent proper chondrocyte hypertrophy, as a potential mechanism for 
dysfunctional skeletal development. Our findings provide potential therapeutic targets for 
developing treatments for TRPV4-mediated skeletal dysplasias. 
5.2 Introduction 
Skeletal dysplasias comprise a heterogeneous group of over 450 bone and cartilage diseases with 
an overall birth incidence of 1 in 5000 (1-5). In the specific cases of moderate autosomal-
dominant brachyolmia and severe metatropic dysplasia, among other dysplasias, arthropathies, 
and neuropathies, the disease is caused by mutations in transient receptor potential vanilloid 4 
(TRPV4), a non-selective cation channel (6, 7). For example, a V620I substitution (exon 12, 
G858A) in TRPV4 is responsible for moderate brachyolmia, which exhibits short stature, 
scoliosis, and delayed development of deformed bones (6, 8, 9). These features, albeit more 
severe, are also present in metatropic dysplasia. Metatropic dysplasia can be caused by a TRPV4 
T89I substitution (exon 2, C366T) and leads to joint contractures, disproportionate 
measurements, and, in severe cases, death due to small chest size and cardiopulmonary 
compromise (6, 9, 10). Both V620I and T89I TRPV4 mutations are considered gain-of-function 
variants (11, 12). Given the essential role of TRPV4 during chondrogenesis (13) and cartilage 
homeostasis (14), it is hypothesized that TRPV4 mutations may affect the cartilaginous phase of 
endochondral ossification during skeletal development.  
Endochondral ossification is a process by which bone tissue is created from a cartilage 
template (2, 10, 15, 16). During this process, chondrocytes transition from maintaining the 
homeostasis of cartilage, regulated by transcription factor SRY-box containing gene 9 (SOX9) 
(16-19), to hypertrophy. Hypertrophy is driven by runt related transcription factor 2 (RUNX2) 
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and bone morphogenic protein (BMP) signaling (16, 18, 19) and leads to chondrocyte apoptosis 
or differentiation into osteoblasts to form bone (16, 18, 19). However, how TRPV4 and its 
signaling cascades regulate endochondral ossification remains to be determined.  
The activation of TRPV4 increases SOX9 expression (13) and prevents chondrocyte 
hypertrophy and endochondral ossification (18, 20-23). One study found that overexpressing 
wildtype Trpv4 in mouse embryos increased intracellular calcium (Ca2+) concentration and 
delayed bone mineralization (24), a potential link between intracellular Ca2+, such as with gain-
of-function TRPV4 mutations, and delayed endochondral ossification. Our previous study also 
observed increased expression of follistatin (FST), a potent BMP inhibitor, and delayed 
hypertrophy in porcine chondrocytes overexpressing human V620I- and T89I-TRPV4 (12, 25). 
While previous studies have greatly increased our knowledge of the influence of TRPV4 
mutations on chondrogenesis and hypertrophy, most of them often involved animal models (12, 
24) or cells (2, 8, 10, 11) (12) overexpressing mutant TRPV4. Therefore, these approaches may 
not completely recapitulate the effect of TRPV4 mutations on human chondrogenesis.  
Human induced pluripotent stem cells (hiPSCs), which are derived from adult somatic 
cells (26), offer a system for modeling human disease to study the effect of mutations throughout 
differentiation (27, 28). In fact, two studies have used patient-derived hiPSCs with TRPV4 
mutations to study lethal and non-lethal metatropic dysplasia-causing variants I604M (29) and 
L619F (30), respectively. However, patient samples are often challenging to procure due to the 
rarity of skeletal dysplasias. In this regard, CRISPR-Cas9 technology allows the creation of 
hiPSC lines harboring various mutations along with isogenic controls (i.e., wildtype; WT).  
The goal of this study was to elucidate the detailed molecular mechanisms underlying 
how two TRPV4 gain-of-function mutations lead to strikingly distinct severities of skeletal 
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dysplasias (i.e., moderate brachyolmia vs. lethal metatropic dysplasia). To achieve this goal, we 
used CRISPR-Cas9 gene-edited hiPSC lines bearing either the V620I or T89I TRPV4 mutation, 
and their isogenic WT control, to delineate the effects of TRPV4 mutations on chondrogenesis 
and hypertrophy using RNA sequencing and transcriptomic analysis. We further examined the 
effects of the mutations on channel function and matrix production and properties. We 
hypothesized the V620I and T89I TRPV4 mutations would enhance chondrogenesis with 
differing degrees of altered hypertrophy. This study will improve our understanding of the role 
of TRPV4 in chondrocyte homeostasis and maturation and lay the foundation for treatment and 
prevention of TRPV4-mediated dysplasias. 
5.3 Methods 
5.3.1 hiPSC culture 
The BJFF.6 (BJFF) human iPSC line (Washington University Genome Engineering and iPSC 
Center (GEiC), St. Louis, MO), was used in this study as the isogenic-wildtype control. 
CRISPR-Cas9 gene editing was used to create the V620I and T89I mutations in the BJFF cell 
line as described previously (31). The hiPSCs were maintained on vitronectin (VTN-N; cat. num. 
A14700; Thermo Fisher Scientific, Waltham, MA)-coated plates in Essential 8 Flex medium 
(E8; cat. num. A2858501; Gibco, Thermo Fisher Scientific, Waltham, MA). Medium was 
changed daily until cells were passaged at 80-90% confluency (medium supplemented with Y-
27632 [cat. num. 72304; STEMCELL Technologies, Vancouver, Canada] for 24 hours) or 
induced into mesodermal differentiation at 30-40% confluency. 
5.3.2 Mesodermal differentiation 
The hiPSCs were differentiated through the mesodermal pathway as previously described (31-
33). In brief, cells were fed daily with different cocktails of growth factors and small molecules 
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for twelve days in mesodermal differentiation medium and driven through the anterior primitive 
streak (1 day; 30 ng/ml Activin [cat. num. 338-AC; R&D Systems, Minneapolis, MN], 20 ng/ml 
FGF2 [cat. num. 233-FB-025/CF; R&D Systems, Minneapolis, MN], 4 µM CHIR99021 [cat. 
num. 04-0004-02; Reprocell, Beltsville, MD]), paraxial mesoderm (1 day; 20 ng/ml FGF2, 3 µM 
CHIR99021, 2 µM SB505124 [cat. num. 3263; Tocris Bioscience, Bristol, UK], 4 µM 
dorsomorphin [DM; cat. num. 04-0024; Reprocell, Beltsville, MD]), early somite (1 day; 2 µM 
SB505124, 4 µM dorsomorphin, 500 nM PD173074 [cat. num. 3044; Tocris Bioscience, Bristol, 
UK], 1 µM Wnt-C59 [cat. num. C7641-2s; Cellagen Technologies, San Diego, CA]), and 
sclerotome (3 days; 1 µM Wnt-C59, 2 µM purmorphamine [cat. num. 04-0009; Reprocell, 
Beltsville, MD]) into chondroprogenitor cells (6 days; 20 ng/ml BMP4 [cat. num. 314-BP-
010CF; R&D Systems, Minneapolis, MN]). Mesodermal differentiation medium had a base of 
Iscove’s Modified Dulbecco’s Medium, glutaMAX (IMDM; cat. num. 31980097; Gibco, 
Thermo Fisher Scientific, Waltham, MA) and Ham’s F-12 nutrient mix, glutaMAX (F12; cat. 
num. 31765092; Gibco, Thermo Fisher Scientific, Waltham, MA) in equal parts supplemented 
with 1% penicillin-streptomycin (P/S; cat. num. 15140122; Gibco, Thermo Fisher Scientific, 
Waltham, MA), 1% Insulin-Transferrin-Selenium (ITS+; cat. num. 41400045; Gibco, Thermo 
Fisher Scientific, Waltham, MA), 1% chemically defined concentrated lipids (cat. num. 
11905031; Thermo Fisher Scientific, Waltham, MA), and 450 µM 1-thioglycerol (cat. num. 
M6145; Millipore Sigma, St. Louis, MO). The chondroprogenitor cells were then disassociated 
for chondrogenic differentiation. 
5.3.3 Chondrogenic differentiation with 3D pellet culture 
Cells were differentiated into chondrocytes using a high-density, suspension pellet culture (31-
33). In summary, cells were resuspended in chondrogenic medium: Dulbecco’s Modified Eagle 
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Medium/F12, glutaMAX (DMEM/F12; cat. num. 10565042; Gibco, Thermo Fisher Scientific, 
Waltham, MA), 1% P/S, 1% ITS+, 1% Modified Eagle Medium (MEM) with nonessential amino 
acids (NEAA; cat. num. 11140050; Gibco, Thermo Fisher Scientific, Waltham, MA), 0.1% 
dexamethasone (Dex; cat. num. D4902; Millipore Sigma, St. Louis, MO), and 0.1% 2-
Mercaptoethnol (2-ME; cat. num. 21985023; Gibco, Thermo Fisher Scientific, Waltham, MA) 
supplemented with 0.1% L-ascorbic acid (ascorbate; cat. num. A8960; Millipore Sigma, St. 
Louis, MO), 0.1% L-proline (proline; cat. num. P5607; Millipore Sigma, St. Louis, MO), 10 
ng/ml human transforming growth factor-β3 (TGFβ3; cat. num. 243-B3-010/CF; R&D Systems, 
Minneapolis, MN), 1 µM Wnt-C59, and 1 µM ML329 (cat. num. 22481; Cayman Chemical, Ann 
Arbor, MI) at 5 x 105 cells/mL. One mL of the cell solution was added to a 15 mL-conical tube 
(cat. num. 430790; Corning, Corning, NY) and centrifuged to form the spherical pellets. Pellets 
were fed every 3-4 days with complete chondrogenic medium until the desired time point. 
Several timepoints of the chondrogenic pellets were used to study chondrocyte maturation (7, 14, 
28, and 42 days), mechanical properties (28 and 42 days), hypertrophy (28 days) or, after 
digestion to single cell day-28 chondrocytes, on Ca2+ signaling in response to pharmacological 
activation of TRPV4. 
5.3.4 BMP4 treatment to promote hypertrophic differentiation 
Some day-28 pellets were also further differentiated for an additional 4 weeks to examine the 
effects of the mutations on chondrocyte hypertrophy. Pellets were cultured with complete 
chondrogenic medium with either TGFβ3 (10 ng/mL) alone, BMP4 (50 ng/mL) alone, or a 
combination of TGFβ3 (10 ng/mL) and BMP4 (50 ng/mL). 
5.3.5 Dissociation of chondrogenic pellets to obtain single cell hiPSC-derived 
chondrocytes 
To isolated hiPSC-derived chondrocytes, day-28 chondrogenic pellets were rinsed and placed in 
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an equal volume (1 pellet per 1 mL) of digestion medium (0.4% w/v type II collagenase [cat. 
num. LS00417; Worthington Biochemical, Lakewood, NJ] in DMEM/F12 with 10% fetal bovine 
serum [FBS; cat. num. S11550; Atlanta Biologicals, R&D Systems, Minneapolis, MN]). The 
tubes were placed on an orbital shaker at 37ºC and vortexed every 20 minutes for approximately 
2 hours. Once the tissue was digested and could no longer be seen by the naked eye, the 
digestion medium was neutralized in DMEM/F12 medium containing 10% FBS. These cells 
were used for patch clamping and confocal experiments. 
5.3.6 TRPV4 agonists and antagonists  
Solutions were prepared immediately before experiments and held at room temperature. 
GSK1016790A (GSK101; cat. num. G0798; Sigma Aldrich, St. Louis, MO) and/or GSK205 (cat. 
num. AOB1612 1263130-79-5; AOBIOUS, Gloucester, MA), in addition to DMSO for a vehicle 
control, were added to assay buffer (Hanks' Balanced Salt Solution [HBSS; cat. num. 14025076; 
Gibco, Thermo Fisher Scientific, Waltham, MA] with 2% HEPES [cat. num. 15630130; Gibco, 
Thermo Fisher Scientific, Waltham, MA]) at 2x the desired concentration (20 nM GSK101, 40 
µM GSK205). Solutions were made at 2x the desired concentration because they would be 
mixed at an equal volume of assay buffer after capturing a baseline fluorescence in Ca2+ 
signaling experiments. 
5.3.7 Patch clamping 
Isolated chondrocytes were kept on ice and used for patching within 36 hours. Patch-clamp 
experiments were carried out at RT under two conditions. Single-channel measurements were 
made in excised inside-out membrane patches in a symmetric potassium chloride (KCl) solution 
(148mM KCl, 1mM K2EDTA, 1mM EGTA, 10mM HEPES, pH 7.4). Channel activation was 
achieved by bath perfusion with the same buffer solution containing 10 nM GSK101. Blocking 
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was performed using the same buffer solution supplied with both 10 nM GSK101 and 20 µM 
GSK205. Recordings were made at -30mV membrane. Whole-cell currents were recorded using 
an external sodium chloride (NaCl) solution (150 mM NaCl, 5 mM KCl, 1 mM EGTA, 10 mM 
Glucose, 10 mM HEPES, and 10 µM free Ca2+) and KCl pipette solution as used for single-
channel recordings. Inhibition of basal currents was performed by pre-incubation of the cells in 
external solution supplied with 20 µM GSK205 for 20 min before patching; the drug was also 
present in the bath at the same concentration during the experiment. Data were acquired at 3 
kHz, low-pass filtered at 1 kHz with Axopatch 1D patch-clamp amplifier and digitized with 
Digidata 1320 digitizer (Molecular Devices, San Jose, CA). Data analysis was performed using 
the pClamp software suite (Molecular Devices, San Jose, CA). Pipettes with 2.0-4.0 MOhm 
resistance in symmetric 150 mM KCl buffer were pulled from Kimble Chase 2502 soda lime 
glass with a Sutter P-86 puller (Sutter Instruments, Novato, CA). 
5.3.8 Confocal imaging of Ca2+ signaling 
hiPSC-derived chondrocytes from digested pellets were plated in DMEM medium containing 
10% FBS at 2.1 x 104 cells/cm2 in 35 mm-dishes for 6-8 hours to allow the cells to adhere 
without dedifferentiating. Cells were then rinsed and stained for 30 min with Fluo-4 AM (cat. 
num. F14201; Thermo Fisher Scientific, Waltham, MA), Fura Red AM ((cat. num. F3021; 
Thermo Fisher Scientific, Waltham, MA), and sulfinpyrazone ( cat. num. S9509-5G; Sigma 
Aldrich, St. Louis, MO) with 20 mM GSK205 or 1000x DMSO (vehicle control). The dye 
solution was replaced with assay buffer before imaging cells on a confocal microscope (LSM 
880; Zeiss, Oberkochen, Germany) at baseline for the first 100 frames (approximately 6 min). 
Then, an equal volume of a 2x solution of GSK101 or GSK101 and GSK205 was added, and 
imaging continued for an additional 300 frames (approximately 20 min). Fiji software (ImageJ, 
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version 2.1.0) was used to locate cells and quantify the ratiometric fluorescence intensity 
(Intensityfluo-4/Intensityfura red). In brief, .czi files were imported into Fiji and the channels were 
split. After applying the median filter, the image calculator divided the green channel by the red. 
A Z-projection was performed based on the maximum fluorescence of the red channel (to ensure 
that all cells were identified even in groups were there was no increase in Ca2+ signaling). A 
threshold and watershed binary were then applied, and measurements were set for a cell size of 
100-infinity. Outlines were projected, and the mean fluorescence of each cell was measured over 
time. The average fluorescence was plotted for all the cells in the group over time. Area under 
the curve and time of response were calculated to quantify differences between groups. Cells 
were classified as responders if they had a fluorescence greater than the baseline mean plus 3 
times the standard deviation in at least a quarter of the frames. Time of response was the time of 
the first frame in which the cell responded for at least 2 consecutive frames. The fluorescence 
was measured for all the cells in the frame of view as technical replicates for 2 experimental 
replicates. 
5.3.9 AFM measurement of neocartilage mechanical properties  
Day-28 and day-42 hiPSC-derived pellets were rinsed in PBS and snap frozen in optimal cutting 
temperature (OCT; cat. num. 4583; Sakura Finetek, Torrance, CA) medium and stored at -80 ºC. 
Pellets were cryosectioned using cryofilm (type 2C(10); Section-Lab, Hiroshima, Japan) in 
multiple different regions of the pellet (i.e., zones). The 10 µm cryosection with cryofilm was 
fixed on a microscope slide using chitosan and stored at 4 ºC overnight. The next day, 
cryosections were mechanically loaded using an atomic force microscopy (AFM, MFP-3D Bio, 
Asylum Research, Goleta, CA) as previously described (34). Briefly, the samples were tested in 
PBS at 37 ºC to maintain hydration and mimic physiologic conditions, respectively. The sections 
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were mechanically probed using a silicon cantilever with a spherical tip (5μm diameter, k~7.83 
N/m, Novascan Technologies, Ames, IA). An area of 10 μm2 with 0.5 μm intervals (400 
indentations) was loaded to 300 nN with the loading rate of 10 μm/sec. Multiple locations from 
different sites of each zone and pellet were loaded as replicates. The curves obtained from AFM 
were imported into a custom written MATLAB code to determine the mechanical properties of 
the pellets. Using contact point extrapolation, the contact point between the cantilever’s tip and 
the tissue was detected, and the elastic modulus was calculated using a modified Hertz model 
(34-38). 
5.3.10 Histology 
Chondrogenic pellets at days 7, 14, 28, 42, and 56 (with and without BMP4) were fixed and 
dehydrated in sequential steps of increasing ethanol and xylene solutions until embedded in 
paraffin wax. Wax blocks were cut into 8 µm sections on microscope slides for histological and 
immunohistochemical analysis. Slides were rehydrated in ethanol and water and the nuclei were 
stained with Harris hematoxylin and sGAGs with Safranin-O. Antigen retrieval was performed 
on rehydrated slides followed by blocking, the addition of primary and secondary antibodies, and 
AEC development to label collagen proteins (COL1A1, COL2A1, COL6A1, and COL10A1) and 
Vector Hematoxylin QS counterstain.  
5.3.11 Biochemical analysis 
Chondrogenic pellets at days 7, 14, 28, and 42 were washed with PBS and digested in papain 
overnight at 65ºC. sGAG and dsDNA content were measured using the dimethylmethylene blue 
(DMMB) and PicoGreen assays (Quant-iT™ PicoGreen™ dsDNA Assay Kit; cat. num. P7589; 
Thermo Fisher Scientific, Waltham, MA) respectively. sGAG content was normalized to 




5.3.12 Western blot 
Day-56 pellets treated with TGFβ3, TGFβ3+BMP4, or BMP4 were digested to single cells, as 
described above, and lysed in RIPA buffer (cat. num. 9806S; Cell Signaling Technology, 
Danvers, MA) with protease inhibitor (cat. num. 87786; Thermo Fisher Scientific, Waltham, 
MA). Protein concentration was then measured using the BCA Assay (Pierce). Twenty 
micrograms of proteins for each well were separated on 10% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis gel with pre-stained molecular weight markers (cat. num. 
161-0374; Bio-Rad, Hercules, CA) and transferred to a polyvinylidene fluoride (PVDF) 
membrane. The PVDF membrane blot was cut through the line at 50 kD. Two blots were 
incubated overnight at 4 °C with the primary antibodies: anti-COL10A1 (1:500; cat. num. PA5-
97603; Thermo Fisher Scientific, Waltham, MA) and anti-GAPDH (1:30000; cat. num. 60004-1-
Ig; Proteintech, Rosemont, IL), as the loading control. TidyBlot-Reagent-HRP (1:1000; cat. num. 
147711; Bio-RAD, Hercules, CA) and horse anti-mouse IgG secondary antibody (1:3000; cat. 
num. 7076; Cell Signaling, Danvers, MA) were then used respectively. Immunoblots were 
imaged and analyzed using the iBright FL1000 Imaging System (Thermo Fisher Scientific, 
Waltham, MA). 
5.3.13 RNA isolation 
Chondrogenic pellets at days 7, 14, 28, 42, and 56 were washed with PBS, lysed, snap frozen, 
and homogenized. RNA was isolated using the Total RNA Purification Plus Kit (cat. num. 




5.3.14 Gene expression with RT-qPCR 
Isolated RNA was reverse transcribed into cDNA. The cDNA was used to run real-time, 
quantitative PCR using Fast SYBR green. Gene expression was analyzed using the ∆∆CT method 
with hiPSC as the reference time point and TBP as the housekeeping gene (39). Three to four 
independent experiments were performed with 3-4 technical replicates per group. Primers can be 
found in the Table 5.1.  
Table 5.1 Primers for RT-qPCR.  
Gene Forward Primer (3’) Reverse Primer (5’) 
ACAN CACTTCTGAGTTCGTGGAGG ACTGGACTCAAAAAGCTGGG 
COL1A1 TGTTCAGCTTTGTGGACCTC TTCTGTACGCAGGTGATTGG 
COL2A1 GGCAATAGCAGGTTCACGTA CTCGATAACAGTCTTGCCCC 
COL10A1 CATAAAAGGCCCACTACCCAAC ACCTTGCTCTCCTCTTACTGC 
FST TGTGCCCTGACAGTAAGTCG GTCTTCCGAAATGGAGTTGC 
S100B AGGGAGGGAGACAAGCACAA ACTCGTGGCAGGCAGTAGTA 
SOX9 CGTCAACGGCTCCAGCAAGAACAA GCCGCTTCTCGCTCTCGTTCAGAAGT 
TRPV4 AGAACTTGGGCATCATCAACGAG GTTCGAGTTCTTGTTCAGTTCCAC 
TBP AACCACGGCACTGATTTTCA ACAGCTCCCCACCATATTCT 
5.3.15 Genome-wide mRNA sequencing 
Isolated RNA was treated with DNase (cat. num. 25720; Norgen Biotek, Thorold, Canada) and 
cleaned (cat. num. 43200; Norgen Biotek, Thorold, Canada) according to manufacturer 
instructions prior to submitting to the Genome Technology Access Center at Washington 
University in St. Louis (GTAC). Libraries were prepared according to manufacturer’s protocol. 
Samples were indexed, pooled, and sequenced at a depth of 30 million reads per sample on an 
Illumina NovaSeq 6000. Basecalls and demultiplexing were performed with Illumina’s bcl2fastq 
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software and a custom python demultiplexing program with a maximum of one mismatch in the 
indexing read. RNA-seq reads were then aligned to the Ensembl release 76 primary assembly 
with STAR version 2.5.1a (40). Gene counts were derived from the number of uniquely aligned 
unambiguous reads by Subread:featureCount version 1.4.6-p5 (41). Isoform expression of known 
Ensembl transcripts were estimated with Salmon version 0.8.2 (42). Sequencing performance 
was assessed for the total number of aligned reads, total number of uniquely aligned reads, and 
features detected. The ribosomal fraction, known junction saturation, and read distribution over 
known gene models were quantified with RSeQC version 2.6.2 (43). 
5.3.16 Transcriptomic analysis of sequencing datasets 
R and the DESeq2 package were used to read un-normalized gene counts, and genes were 
removed if they had counts lower than 200 (44). Regularized-logarithm transformed data of the 
samples were visualized with the Pheatmap package (45) function on the calculated Euclidean 
distances between samples or with the ggplot2 package (46) to create a principle component 
analysis (PCA). The transformed data was also used to determine the top 5000 most variable 
genes across the samples. The replicates, from DESeq data, for each group were averaged 
together, and the up- and down-regulated differentially expressed genes (DEGs) were 
determined. The total number of DEGs was plotted using GraphPad Prism. At day 28, the V620I 
and T89I lines were compared to WT. At day 56, TGFβ3-treated V620I and T89I were 
compared to TGFβ3-treated WT, and BMP4-treated groups were compared to their respective 
TGFβ3-treated group of the same line (e.g., BMP4-treated WT vs. TGFβ3-treated WT). Genes 
were considered differentially expressed if adjusted p value (padj) < 0.1 and log2(fold change) ≥ 1 
or ≤ -1. The intersecting and unique DEGs were determined and plotted with the intersect and 
setdiff, and venn.diagram (VennDiagram package (47)) functions. The fold changes of common 
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chondrogenic, hypertrophic, growth factor, Ca2+ signaling, and off-target genes, in the top 5000 
most variable genes, were plotted using the pheatmap function. The top 25 most up-regulated 
and down-regulated for each group, based on log2(fold change), and the log2(fold change) of that 
gene for the other group(s) were also plotted with the pheatmap. Gene lists (e.g., intersected 
genes, genes upregulated with BMP4 treatment) were entered into g:profiler to determine 
associated Gene Ontology (GO) Biological Processes, Molecular Functions, Cellular 
Components, KEGG pathways, Reactome pathways, and Human Phenotype (HP) Ontologies 
(48). The negative log10 of the adjusted p value for each term was plotted with GraphPad Prism 
or using a function to scale circle diameter to the p value in Illustrator.  
The gap statistic method determined the ideal number of clusters resulting from BMP4 
treatment was either 1 or 9. We then performed k-means clustering with 9 clusters and plotted 
the gene expression trends for each gene within the cluster with the average expression trend 
overlaying for each cell line of the largest cluster using the tidyverse package (49). The genes in 
each cluster, with the normalized counts for each group, are listed in Table S5.1. The largest 
cluster was plotted using the Cytoscape String app’s protein interaction to create a protein-
protein network (50, 51). Using the average log fold change with BMP4 treatment across lines, 
the network was propagated using the Diffusion app, and functional enrichment with 
EnrichmentMap was performed on the network (52). We then created a network connecting the 
genes to their associated genes with black lines and to their associated Gene Ontology processes 
using grey lines. We colored the gene circles with three colors representing the log fold change 
of that gene in each line. The white arrows were added to the color scale legend to indicate 
maximum log fold change for each line. 
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5.3.17 Statistical analysis 
Data were graphed and analyzed using GraphPad Prism (Version 9.1.0). Outliers were removed 
from the data using the ROUT method (Q = 1%), and the data were tested for normality with the 
Shapiro-Wilk test (  = 0.05). For RT-qPCR, normally distributed data were analyzed within 
each time point using a Brown-Forsythe and Welch one-way ANOVA with multiple 
comparisons (mean of each column, cell line, with every other column). A Kruskal-Wallis test 
was used if data was not normally distributed. For biochemical analysis, mechanical properties, 
and area under the curve, and time of response, data were analyzed using an ordinary two-way 
ANOVA, comparing each cell with all other cells, with Tukey’s post-hoc test. Area under the 
curve was quantified for plots over time considering a baseline of Y=0, ignoring peaks less than 
10% of the distance from minimum to maximum Y, and all peaks going over the baseline. 
5.4 Results 
5.4.1 Mutant TRPV4 has altered response to chemical agonist GSK101 
We first assessed TRPV4 channel function and alterations in Ca2+ signaling due to the V620I and 
T89I mutations in day-28 hiPSC-derived chondrocytes using electrophysiology and fluorescence 
imaging. Using whole-cell patch clamping, we measured the basal membrane current of the 
hiPSC-derived chondrocytes from the mutated and WT lines. V620I-TRPV4 had the highest 
basal currents at both 70 and -70 mV (70/-70 mV pA/pF – WT: 18.52/5.93 vs. V602I: 
77.79/55.33 vs. T89I: 40.97/50.13; Figure 5.1A). However, when TRPV4 was inhibited with 
GSK205 (53), TRPV4-specfic chemical antagonist, the three lines had similar, decreased 
currents (70/-70 mV – WT: 18.72/14.36 pA/pF vs. V620I: 13.55/9.15 pA/pF vs. T89I: 
29.27/13.8 pA/pF; Figure 5.1A). To capture the specific current through TRPV4, we took the 
difference of the basal current (no GSK205) and the average TRPV-inhibited current (with 
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GSK205). TRPV4 inhibition caused a significant change in current in V620I at both 70 and -70 
mV (70 mV – V620I: Δ64.28 vs. WT: Δ -0.19, p=0.0379 and T89I: Δ11.67, p<0.0001; -70 mV – 
V620I: Δ46.13 vs. WT: Δ -8.47, p<0.0001 and T89I: Δ36.33, p=0.0057; Figure 5.1B). 
Interestingly, T89I-TRPV4 was not significantly different from WT despite also causing a gain-
of-function in recombinant channels (11).  
Next, we activated WT and mutant TRPV4 with chemical agonist GSK1016790A 
(GSK101) (54) and found that the mutations decreased the cellular response to the agonist, 
resulting in reduced Ca2+ signaling. These results were supported using two methods: inside-out 
excised patches and confocal imaging of Ca2+ signaling (Figure 5.1C-D). The representative 
traces of inside-out patches showed increased current through the patch with the addition of 
GSK101 and the attenuation by GSK205 (Figure 5.1C). GSK205 continued to block the channel 
and prevented another increase in current despite the addition of GSK101. Though the unitary 
currents were indistinguishable (8 pA at -30mV) among WT and mutants, in excised inside-out 
patches WT typically produced higher GSK101-induced currents than the mutants (WT: 290 pA 
vs. V620I: 87.1 pA and T89I: 62.3 pA at -30mV), potentially indicative of more channels per 
patch (Figure 5.1C). In the confocal imaging experiments, a ratiometric fluorescence indicated 
Ca2+ signaling of the hiPSC-derived chondrocytes in response to either 10 nM GSK101 or a 
cocktail of 10 nM GSK101 and 20 µM GSK205. WT cells had significantly higher fluorescence, 
and therefore Ca2+ signaling, in response to GSK101 according to the plots and their area under 
the curve (AUC; WT: 1470 vs. V620I: 1114 and T89I: 1044; p<0.0001; Figure 5.1D-E). The 
presence of GSK205 attenuated this response for all three lines, confirming the Ca2+ influx was 
due to the TRPV4 ion channel (WT: 366 vs. V620I: 460 vs T89I: 358). We also evaluated the 
response time of the cells to GSK101 and GSK101+GSK205. We considered a cell to be 
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responding if more than a quarter of its frames, after stimuli, had a fluorescence higher than the 
mean baseline plus 3 times the standard deviation. The mutants responded faster to GSK101 than 
the WT (WT: 46.2 sec vs. V620I: 12 sec, p=0.0048 and T89: 10.8 sec, p=0.0097; Figure 5.1F). 
Interestingly, the addition of GSK205 did not significantly slow the response of WT, but it did 
slow the response of the mutants, with the severe mutation slower than the moderate (WT: 35.4 




Figure 5.1 Differences in TRPV4 electrophysiological properties of WT and mutant hiPSC-
derived chondrocytes. (A) Whole-cell currents were higher, on average, in mutant hiPSC-derived 
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chondrocytes than WT at 70 and -70 mV. TRPV4 inhibition with 20 µM GSK205 reduced 
mutant currents to similar levels as WT. Mean ± SEM. n=20-40 cells. (B) The difference 
between the current through TRPV4 without GSK205 from the average current through inhibited 
channels was significantly higher in V620I. There was no difference between no drugs and 
GSK205 in WT. Mean ± SEM. n=20-40 cells. Kruskal-Wallis test with multiple comparisons 
comparing cell lines at 70 mV and -70 mV. *p<0.05, **p<0.01, ****p<0.001. (C) Inside-out 
excised patches of WT had a higher current in response to 10 nM GSK101 (indicated by *) than 
mutants. The addition of 10 nM GSK101 + 20 µM GSK205 (indicated by ) decreased the 
current and continued to block the channel when GSK101 alone was re-introduced (*). 
Representative plots with average unitary current and current in response to GSK101. Mean ± 
SEM.  n=5, 9, and 8 for WT, V620I, and T89I, respectively. (D) Mutant TRPV4 decreased the 
channels’ sensitivity to activation with GSK101 as shown with confocal imaging of ratiometric 
fluorescence indicating Ca2+ signaling. GSK205 attenuated GSK101-mediated signaling. Mean ± 
95% CI. N = 3 experiments with a total of 158-819 cells per line. (E) Quantification of the area 
under the curve of (D). Mean ± SEM. n=158-819 cells from N=3 experiments. Ordinary two-
way ANOVA with Tukey’s post-hoc test. Interaction, cell line, and treatment p<0.0001. (F) 
Time of initial response of each responding cell (≥25% of frames for that cell are responding) 
measured from the addition of stimulus. Mutant TRPV4 responded faster to GSK101, but the 
response was significantly slowed by GSK205. Responding frames were considered to have a 
fluorescence greater than the mean plus three times the standard deviation. Mean ± SEM. 
Ordinary two-way ANOVA with Tukey’s post-hoc test. Interaction, cell line, and treatment 
p<0.0001. 
5.4.2 Chondrogenic differentiation of WT and mutant hiPSC lines  
To confirm if the hiPSCs with dysplasia-causing mutations would undergo proper 
chondrogenesis, we differentiated CRISPR-Cas9-edited hiPSCs with mutant TRPV4 alongside an 
isogenic wildtype (WT) using our previously published protocol (31, 33). After 12 days of 
monolayer mesodermal differentiation, the cells underwent 42 days of chondrogenic 
differentiation, and pellets were collected at days 7, 14, 28, and 42. At day 28, the three lines had 
similar chondrogenic matrix as shown with Safranin-O staining for sulfated glycosaminoglycans 
(sGAGs) and collagen type 2 alpha chain 1 (COL2A1) labeling with immunohistochemistry 
(IHC; Figure 5.2A-B). All three lines had little to no labeling of fibrocartilage marker COL1A1 
and hypertrophic cartilage marker COL10A1 with IHC (Figure 5.2C-D). To quantitatively 
confirm the matrix production throughout chondrogenesis, we performed biochemical assays to 
measure sGAG production and normalize it to double-stranded DNA content. As expected, 
 204 
 
differences in matrix production were significant between time points (p<0.0001; Figure 5.2E). 
The sGAG/DNA ratio increased in WT by 8-fold and in V620I and T89I by 5- to 5.5-fold from 
day 14 to 28 (p<0.0001). V620I pellets also increased in matrix content by 150% from day 28 to 
42 (p=0.0163) with all three lines reaching an sGAG/DNA ratio of approximately 30. However, 
there were no differences in sGAG/DNA ratios among the three cell lines at any time point (cell 
line: p=0.1206; interaction: p=0.7426).  
Atomic force microscopy (AFM) was then used to measure the mechanical properties of 
the hiPSC-derived cartilaginous matrix deposited by the WT and two TRPV4 mutated cell lines. 
The elastic modulus ranged from 14 to 20 kPa, consistent with mouse iPSC-derived cartilage 
(55). At day 28, the three lines had similar properties (WT: 14.4 kPa vs. V620I: 15.9 kPa vs. 
T89I: 14.8 kPa); however, at day 42, V620I had a significantly decreased elastic modulus 
(V620I: 10.32 kPa vs. WT: 20.0 kPa, p=0.0004 and T89I: 17.5 kPa, p=0.0328; Figure 5.2F). 
These experiments indicated that all three lines could properly differentiate into chondrocytes 
and had similar cartilaginous matrix production by day 28. Therefore, we used the day 28 time 




Figure 5.2 Mutant TRPV4 had little effect on chondrogenic matrix production. (A-D) WT, 
V620I, and T89I day-28 pellets exhibit similar matrix production shown by staining for sGAGs 
with Safranin-O and hematoxylin (A) and labeling with IHC for COL2A1 (B), COL1A1 (C), and 
COL10A1 (D). Scale bar = 500 µm. (E) The sGAG/DNA ratio increased in all three lines from 
day 14 to 28 of chondrogenesis. There were no differences between lines at each time point. 
Mean ± SEM. n = 11-16 from 3-4 different experiments. ****p<0.0001 Statistical significance 
determined by an ordinary two-way ANOVA with Tukey’s post-hoc test. (F) There were no 
differences in the elastic modulus of the matrix at day 28. Day-42 V620I had a significantly 
lower elastic modulus than WT and T89I. Mean ± SEM. n=11-14 from 3 experiments. *p<0.05, 
***p<0.001 Statistical significance determined by an ordinary two-way ANOVA with Tukey’s 
post-hoc test. 
5.4.3 TRPV4 mutations altered chondrogenic gene expression in hiPSC-
derived chondrocytes 
RT-qPCR analysis throughout differentiation shows that mutants had higher ACAN expression 
compared to WT at day 28; however, expression decreased at day 42 in T89I (day-42 fold 
changes; V620I: 5933 vs. WT: 2687, p=0.0016 and T89I: 2631, p=0.0058; Figure 5.3A). 
 206 
 
COL2A1 expression was similar among the three lines at day 28 but significantly lower in T89I 
at day 42 (day-42 fold changes; T89I: 2798 vs. WT: 9209, p=0.0144 and V620I: 7177, 
p=0.0007; Figure 5.3B). Throughout chondrogenesis, V620I significantly increased expression 
of chondrogenic transcription factor SOX9 (day-42 fold changes; V620I: 195.3 vs. WT: 44.29, 
p<0.0001 and T89I: 32.19, p=0.0003; Figure 5.3C) and TRPV4 (day-42 fold changes; V620I: 
168.5 vs. WT: 48.82, p<0.0001 and T89I: 44.72, p<0.0001; Figure 5.3D). On the other hand, 
T89I significantly increased expression of pro-inflammatory, calcium binding protein S100B 
(56) throughout chondrogenesis (day-42 fold changes; T89I: 1363 vs. WT: 362.0, p=0.0018 and 
V620I: 507.8, p=0.0439; Figure 5.3E). T89I also had significantly higher expression of 
fibrocartilage marker COL1A1 at days 7, 14, and 28 than the other two lines, and both mutations 
had increased expression at day 42 compared to WT (day-42 fold changes; WT: 32.47 vs. V620I: 
76.42, p=0.01.58 and T89I: 74.23, p=0.0132; Figure 5.3F). In contrast, hypertrophic marker 
COL10A1 was significantly higher in the WT line than the mutants at days 28 and 42 (day-42 
fold changes; WT: 615.7 vs. V620I: 71.00, p=0.0001 and T89I: 83.07, p=0.0015; Figure 5.3G). 
Surprisingly, there was not a significant increase in follistatin (FST) expression in mutants at 
later time points (day-42 fold changes; WT: 0.5342 vs. V620I: 0.6808, p=0.6882 and T89I: 




Figure 5.3 V620I and T89I had differing effects on gene expression during chondrogenic 
differentiation. (A) T89I and V620I had increased ACAN gene expression at day 28 and 42, 
respectively, compared to WT. (B) Day-42 T89I chondrocytes had decreased expression of 
COL2A1. (C-D) V620I increased expression of SOX9 (C) and TRPV4 (D) throughout 
chondrogenesis. (E-F) T89I increased expression of S100B (E) and COL1A1 (F) throughout 
chondrogenesis. (G) Both mutations decreased COL10A1 gene expression at day 28 and 42, 
compared to WT. (H) There were no differences in FST expression at later time points day 28 
and 42. Mean ± SEM. n=10-12. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 Significance 
determined by one-way ANOVA with Tukey’s post-hoc test for each time point. 
To obtain comprehensive transcriptomic profiles of WT and TRPV4 mutated cell lines, 
we performed bulk RNA sequencing of day-28 chondrogenic pellets. We compared V620I and 
T89I gene expression to WT and plotted the log2 fold change in heatmaps (Figure 5.4A-B). 
While many chondrogenic and hypertrophic genes had similar levels of expression between the 
lines, the mutants had increased expression of cartilage ECM genes cartilage oligomeric matrix 
protein (COMP), collage type 6 alpha chains 1 and 3 (COL6A1, COL6A3), growth differentiation 
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factor 5 (GDF5), high-temperature requirement A serine peptidase 1 (HTRA1), and secreted 
protein acidic and cysteine rich (SPARC) (Figure 5.4A). In contrast, the mutants had decreased 
expression of hypertrophic markers COL10A1, secreted phosphoprotein 1 (SPP1), and alkaline 
phosphatase, biomineralization associated (ALPL) in addition to SST (Figure 5.4B). The 
mutations up-regulated expression levels of bone morphogenic protein 6 (BMP6), transforming 
growth factor 3 (TGFB3), nuclear factor of activated T-Cells C2 (NFATC2), Twist family BHLH 
transcription factor 1 (TWIST1), ADAM metallopeptidase with thrombospondin type 1 motif 4 
(ADAMTS4), and Wnt3A (Figure 5.4B). The mutations also downregulated osteoblastogenesis 
transcription factors SOX2 and SOX11 and previously identified genes governing off-target 
differentiation during hiPSC chondrogenesis including nestin (NES), orthodenticle homeobox 2 
(OTX2), Wnt7A, and Wnt7B (Figure 5.4B). Interestingly, BMP4 was downregulated to a greater 
extent in V620I than T89I when compared to WT. 
5.4.4 V620I and T89I mutants demonstrate similar gene expression profiles  
First, to evaluate the similarities and differences in transcriptomic profiles between the hiPSC-
derived chondrocytes with and without the TRPV4 mutations, we computed the Euclidean 
distance between day-28 samples of each cell line. The WT samples clustered away from the 
mutants, and the V620I samples were the most variable. (Figure 5.4C). In terms of total 
differentially expressed genes (DEGs) compared to WT, V620I had 8% fewer DEGs than T89I 
(2459 vs. 2671; Figure 5.4D). Mutants had only about half of the number of up-regulated genes 
compared to down-regulated genes (V620I: 884 vs. 1575, T89I: 978 vs. 1693; Figure 5.4D). The 
majority of the down-regulated DEGs were shared between the two mutants when compared to 
WT, comprising 76% and 71% of V620I’s and T89I’s total down-regulated DEGs, respectively 
(Figure 5.4E). We plotted the top 25 most down-regulated DEGs for each line in a heatmap. 
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These included antioxidant catalase (CAT), anti-inflammatory nucleotide-binding and leucine-
rich repeat receptor family pyrin domain containing 2 (NLRP2), and kruppel like factor 8 (KLF8) 
(Figure 5.4F). Interestingly, many of the down-regulated DEGs, both unique and shared between 
V620I and T89I, were associated with Gene Ontology (GO) terms related to nervous system 
development, including many potassium channel genes (i.e., KCN family; Figure 5.4G).  
In contrast, 686 up-regulated DEGs were shared by both mutants, while 22% of V620I’s 
and 30% of T89I’s up-regulated DEGs were unique to each mutation (198 vs. 292; Figure 5.4H). 
A heatmap of the top 25 up-regulated DEGs showed that several homeobox (HOX) genes were 
highly expressed in chondrocytes with the TRPV4 mutations (Figure 5.4I). These included 
HOXA2 to HOXA7, HOXA-AS2, HOXB2 to HOXB4, and HOXB-AS1, which are associated with 
morphogenesis and anterior patterning (57). Furthermore, the shared, up-regulated DEGs 
between two mutants are associated with extracellular matrix production and organization and 
growth factor binding in GO term analysis, while V620I genes were associated with type I 
interferon (Figure 5.4J). These data highlight an early morphogenic genetic profile in hiPSC-
derived chondrocytes with the V620I and T89I mutations. 
5.4.5 The severe T89I mutation inhibits chondrocyte hypertrophy more than 
moderate V620I mutation  
Following an additional 4 weeks of chondrogenic culture, we performed RNA sequencing to 
investigate how the differences between the WT and the two mutants change with further 
differentiation. Using Euclidean distances, we compared the WT, V620I, and T89I hiPSC-
derived chondrocytes at both day 28 and 56 (Figure 5.4K). WT clustered together at both day 28 
and 56; however, the mutants clustered by time point. Again, there were more down-regulated 
genes than up-regulated at day 56 (Figure 5.4L). T89I had the most DEGs, and the number 
increased from day 28 to 56. In contrast, V620I’s DEGs decreased at day 56. 74% of V620I up-
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regulated DEGs, but only 24% of T89I DEGs, were shared between the two lines (424 total 
genes; Figure 5.4M). These intersecting, up-regulated genes were associated with the biological 
processes of skeletal development, morphogenesis, and patterning due to the up-regulation of 
many HOX genes (Figure S5.1A). Most of the top up- and down-regulated genes were consistent 
between day 28 and 56 (Figure S5.1A-B), including both anterior and  posterior HOX genes (i.e., 
HOXA1 to HOXA7, HOXB2 to HOXB4, HOXB6 to HOXB8, HOXC4, HOXD8, HOXA-AS2-3, 
and HOXB-AS1-2)(57). Although V620I and T89I TRPV4 mutants continued to share the up-
regulated HOX genes, which may be responsible for dysfunctional chondrogenic hypertrophy 
compared to WT cells, our results also indicate that these two mutated lines started to 




Figure 5.4 Dynamic changes in transcriptomic profiles of V620I and T89I mutants during 
chondrogenesis. (A-B) Heatmaps comparing the log2 fold change of common chondrogenic and 
hypertrophic genes (A) and growth factor and signaling genes (B) in day-28 V620I and T89I 
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chondrocytes compared to WT. (C) Clustering of the samples using Euclidean distances reveals 
that V620I and T89I hiPSC-derived chondrocytes are more similar to each other than WT. (D) 
The number of up- and down-regulated DEGs in V620I and T89I day-28 chondrocytes compared 
to WT. (E-G) Analysis of the down-regulated genes compared to WT. (E) A Venn diagram 
reveals the number of similar and different down-regulated DEGs between V620I and T89I, 
where most genes are shared. (F) A heatmap showing the log2 fold change, compared to WT, of 
the top 25 down-regulated genes for each line. (G) The top 3 GO Terms (biological process) 
associated with the DEGs unique to V620I, shared between V620I and T89I, and unique to T89I. 
(H-J) Analysis of the up-regulated genes compared to WT. (H) A Venn diagram reveals the 
number of similar and different up-regulated DEGs between V620I and T89I, where most genes 
are shared. (I) A heatmap showing the log2 fold change, compared to WT, of the top 25 up-
regulated genes for each line. (J) The top 3 GO Terms (biological process) associated with the 
DEGs unique to V620I, shared between V620I and T89I, and unique to T89I. (K) Clustering of 
the day-28 and day-56 samples using Euclidean distances reveals that the WT chondrocytes, at 
both day 28 and 56, cluster together while mutants cluster by time point. (L) The number of up-
regulated and down-regulated DEGs for V620I and T89I compared to WT at day 28 and day 56. 
(M) A Venn diagram reveals the number of similar and different up-regulated DEGs between 
V620I and T89I, with T89I becoming more unique at day 56. 
5.4.6 TRPV4 mutations exhibit dysregulated BMP4-induced chondrocyte 
hypertrophy 
To evaluate how TRPV4 mutations may affect hypertrophy, BMP4 was added to the 
chondrogenic medium with and without TGFβ3 to stimulate hypertrophic differentiation starting 
at day 28 of chondrogenic pellet culture (58). At day 56, Safranin-O staining indicated the 
BMP4-treated WT had developed a more hypertrophic phenotype compared to TGFβ3- and 
TGFβ3+BMP4-treated pellets with enlarged chondrocytes (cell diameter; WT-BMP4: 27.6 µm 
vs. WT-TGFβ3: 11.8 µm, V620I-BMP4: 12.5 µm, and T89I-BMP4: 11.3 µm; p<0.0001; Figure 
5.5A-B). This phenotype was not present in any of the groups from the V620I and T89I lines. 
Western blot further confirmed this with an increase in hypertrophic cartilage protein COL10A1 
secretion in the WT-BMP4 group (Figure 5.5C), consistent with the day-28 gene expression data 
(Figure 5.3G, 5.4A). RNA sequencing and PCA revealed that the WT line was more sensitive to 
BMP4, as indicated by the arrows (Figure 5.5D).  Given that the BMP4-treated WT 
chondrocytes had the most apparent hypertrophic phenotype, later analyses were performed 




Figure 5.5 WT chondrocytes are more sensitive to BMP4 treatment. (A) WT chondrocytes 
treated with BMP4 developed a hypertrophic phenotype with enlarged lacunae, which was not 
present in the mutant cell lines or other conditions, as shown by Safranin-O and hematoxylin 
staining. Scale bar = 500 µm. (B) Cell diameter was significantly increased in the WT with 
BMP4 treatment compared to all other groups indicating a hypertrophic phenotype. Mean ± 
SEM. n = 249-304 cells from 2 pellets. Different letters indicate statistical significance (p<0.05) 
between groups as determined by Kruskal-Wallis test with multiple comparisons since data was 
not normally distributed. (C) Western blot shows that WT had increased production COL10A1 
in response to BMP4 treatment. (D) PCA of bulk RNA-seq reveals an increased sensitivity to 
BMP4 (and TGFβ3+BMP4) treatment in WT hiPSC-derived chondrocytes compared to V620I 
and T89I. 
Hierarchical K-means clustering of gene expression profiles of BMP4- and TGFβ3-
treated chondrocytes resulted in 9 unique clusters, as determined using the gap statistics method 
(Figure 5.6A). Most of the clusters, including the largest (i.e., cluster 1), showed up-regulation of 
gene expression with BMP4 treatment, while clusters 4, 5, and 9 showed down regulation. The 
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gene expression per group for each cluster is listed in Table S5.1. Overall, WT responded to 
BMP4 treatment with the largest number of DEGs, over 2500, with only 22% of them shared 
among all three lines (Figure 5.6B). Although cluster 1 shows an overall increase in gene 
expression with BMP4 treatment, WT had a larger increase in expression than the mutants 
(Figure 5.6C). In fact, some of the genes that were up-regulated with BMP4 treatment in WT 
may have no change or down-regulation in mutants (cluster 1, Figure 5.6A).  
As cluster 1 represents the primary response to BMP4 treatment and may highlight how 
the TRPV4 mutations inhibit chondrocyte hypertrophy, we constructed a gene network of this 
cluster (Figure 5.6D). The log fold change of each gene per cell line is represented by a color 
scale, which is consistent with WT having overall higher expression of the genes (as indicated by 
the white arrows in the legend; Figure 5.6D). With GO term analysis, the cluster 1 gene network 
is highly associated with ossification, biomineral tissue development, skeletal system 
development, tissue development, and osteoblast differentiation (Figure 5.6D). Alkaline 
phosphatase, biomineralization associated (ALPL), amelogenin X-linked (AMELX), fibroblast 
growth factor receptor 3 (FGFR3), interferon induced transmembrane protein 5 (IFITM5), Indian 
hedgehog (IHH), parathyroid hormone 1 receptor (PTH1R), and noggin (NOG) were connected 
to at least 4 of the top 5 GO terms. Of those, ALPL, AMELX, and IFITM5 showed much higher 
expression in WT than the mutants alongside antioxidant glutathione S-transferase alpha 1 
(GSTA1) and bone ECM proteins integrin binding sialoprotein (IBSP) and matrix extracellular 
phosphoglycoprotein (MEPE). Lack of expression of these key genes may be responsible for the 
inhibited hypertrophy in TRPV4 V620I- and T89I-mutated chondrocytes.  
We next investigated and plotted the top 25 up-regulated genes for each line with BMP4 
treatment (compared to their respective TGFβ3 control) (Figure 5.6E). 88% of these genes were 
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also present in cluster 1. The key genes ALPL, AMELX, IFITM5, GSTAI, IBSP, and MEPE had 
distinctly higher expression in WT than mutants, in agreement with the network analysis. Both 
mutants showed higher expression than WT of ankyrin repeat and SOCS box containing 10 
(ASB10), GTPase, IMAP family member 6 (GIMAP6), and adhesion G protein-coupled receptor 
D1 (ADGRD1) when compared to their corresponding TGFβ3 control group. GO term analysis 
was further performed on all BMP4 up-regulated DEGs for each line (Figure 5.6F). WT was 
highly associated with skeletal system development, ossification, endochondral ossification, and 
extracellular structure organization, followed by V620I mutants, while T89I showed little to no 






Figure 5.6 V620I and T89I had an inhibited hypertrophic response to BMP4 treatment. (A) 
There are 9 clusters of genes based on expression and hierarchical k-means clustering of the 
samples. (B) Venn diagram shows similar and distinct DEGs in response to BMP4 treatment in 
all three lines. (C) Cluster 1 represented increasing in expression from TGFβ3-treatment to 
BMP4-treatment (left to right on x-axis). Y-axis scale (-1.5 to 2) represents the scaled mean 
counts. (D) A protein-protein interaction network with functional enrichment analysis of cluster 
1 reveals the top regulating genes and their associated concepts. Connections between protein-
coding genes and GO processes are based on the average log fold change between cell lines. 
Coloring of the protein-coding gene circles is divided into three to represent the log fold change 
for each cell line as shown in the legend. The white arrows in the legend indicates the location of 
the maximum log fold change for each respective cell line. The grey boxes represent the top 5 
GO terms (biological process) identified for the network with the log10(false discovery rate) 
underneath the term. (E) A heatmap of the top 25 up-regulated genes, and their log2 fold change, 
in each line compared to their respective TGFβ3 controls. (F) The top GO terms and biological 
pathways associated with the up-regulated DEGs with BMP4 treatment. Symbol color represents 
the cell line, and size represents the -Log10(padj). 
5.5 Discussion 
To elucidate the detailed molecular mechanisms underlying the distinct severity of skeletal 
dysplasias caused by two TRPV4 mutations (brachyolmia-causing V620I vs. metatropic 
dysplasia-causing T89I), we used CRISPR-Cas9 gene editing to generate hiPSC-derived 
chondrocytes bearing these two mutations. We observed that day-28 chondrocytes exhibited 
differences in channel function and gene expression between the mutants and WT control. 
Differences in transcriptomic profiles between V620I and T89I and from WT became more 
apparent with maturation following 4 additional weeks of culture with TGFβ3 or hypertrophic 
differentiation with BMP4 treatment. Of note, WT was significantly more sensitive to BMP4-
induced hypertrophy. At the transcriptomic level, TRPV4 mutations inhibited chondrocyte 
hypertrophy, particularly with the T89I mutation, whereas V620I exhibited a milder phenotype, 
consistent with the clinical presentation of these two conditions. Our results suggest that skeletal 
dysplasias may be, at least in part, resulting from improper chondrocyte hypertrophy downstream 
of altered TRPV4 function. Furthermore, with our genome-wide RNA sequencing analysis, we 
also identified several putative genes that may be responsible for these dysregulated pathways in 
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human chondrocytes bearing V620I or T89I TRPV4 mutations. 
Our findings are generally consistent with previous non-human models of V620I and 
T89I mutations. Two other models that have studied the V620I and T89I mutations include X. 
laevis oocytes injected with rat TRPV4 cRNA (11) or primary porcine chondrocytes transfected 
with human mutant TRPV4 (12). Both reports and our current study investigated the baseline 
currents of the mutant TRPV4 compared to WT. Here, we used patch clamping and observed 
high basal currents in V620I with a significant decrease when TRPV4 was inhibited. However, 
this characteristic was trending, but not significant, in T89I, despite both V620I and T89I being 
reported as gain-of-function mutations (8, 10). Both the X. laevis oocyte and porcine chondrocyte 
models confirmed high basal currents through V620I-TRPV4 (11, 12). Interestingly, X. laevis 
oocytes, but not the humanized porcine chondrocytes, showed an increase in basal Ca2+ signaling 
through T89I (11, 12). Furthermore, our results were consistent with a summary of TRPV4 
channelopathies reporting an increase in conductivity in V620I but no change in T89I (6). The 
conflicting basal current results could be due to the species of the TRPV4, but this was not the 
case regarding channel activation. As mentioned, the hiPSC-derived chondrocytes with V620I 
and T89I TRPV4 had reduced currents and Ca2+ signaling in response to chemical agonist 
GSK101. However, our previous study showed the porcine chondrocytes with mutant human 
TRPV4 had increased peak Ca2+ signaling in response to hypotonic changes (12). This 
discrepancy could be due to the mode of activation of TRPV4 (i.e., osmotic vs. chemical 
agonist). In contrast, the oocytes with mutant rat TRPV4 had lower currents in response to both 
hypotonic and chemical (GSK101) TRPV4 activation compared to WT-TRPV4, consistent with 
our findings.  It can be speculated that there is decreased sensitivity to the antagonist because the 
mutated hiPSC-derived chondrocytes are compensating for the increased basal activity by 
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reducing the number of TRPV4 channels, or other ion channels and signaling transducers as 
shown with the RNAseq data and associated GO terms. The increased basal currents and 
decreased channel sensitivity to TRPV4 agonist GSK101 with mutated TRPV4 is also likely due 
to an increased open probability of TRPV4 making the channels less likely to open due to an 
agonist (11). The obvious differences in both resting and activated states confirm functional 
differences with TRPV4 mutations that may ultimately lead to changes downstream of the 
channel, which alter joint development and result in skeletal dysplasias.  
It was hypothesized, in the porcine chondrocyte study, that the increased Ca2+ signaling 
due to the V620I and T89I TRPV4 mutations increased FST expression that inhibited BMP 
signaling and hypertrophy (12, 25). Surprisingly, we found no differences in FST expression in 
mutant hiPSC-derived chondrocytes compared to WT. However, our previous study used non-
human cells, which could alter the effects of the human TRPV4 mutations and downstream gene 
expression. Another previous hypothesis made was that the altered TRPV4 signaling increased 
SOX9 expression, a known regulator of resting and proliferating chondrocytes upregulated by 
TRPV4 activation (13), thus decreasing hypertrophy (8). SOX9-knockin mice exhibit a dwarfism 
phenotype (20), and SOX9 overexpression inhibits hypertrophy and endochondral ossification 
(22, 23), likely via parathyroid hormone-related protein (PTHrP) (18, 20). However, PTHrP was 
not strongly regulated in our data set. Furthermore, our RT-qPCR revealed that only V602I 
significantly upregulated SOX9, and the RNAseq data showed that SOX9 had a smaller fold 
change compared to other chondrogenic genes, such as GDF5, COL6A1, COL6A3, and COMP. 
In fact, these genes, which were upregulated in V620I- and T89I-hiPSC-derived chondrocytes, 
have a pro-chondrogenic but anti-hypertrophic phenotype (59-61). Therefore, these results 
suggest additional and alternative pathways to FST and SOX9 that are responsible for the V620I 
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and T89I skeletal dysplasias.  
Our results are also generally consistent with previous reports on the effects of other 
TRPV4 mutations such as lethal and non-lethal metatropic dysplasia-causing I604M (29) and 
L619F (30). The data also reveal potential differences in the effects of these varying TRPV4 
mutations on cell electrophysiology or differentiation. For example, we saw an increase in SOX9 
expression in V620I, while no change in T89I. Gain-of-function mutation L619F also increased 
SOX9 expression (30), while I604M, which has been reported to not alter conductivity like T89I 
(6), decreased SOX9 (29). I604M also decreased COL2A1, COL10A1, and RUNX2 expression 
consistent with our T89I results (29). Intriguingly, the L619F mutation was reported to increase 
Ca2+ signaling with activation via a TRPV4 agonist (30). However, we observed that V620I and 
T89I had significantly reduced Ca2+ signaling compared to WT in response to chemical agonist 
GSK101, as confirmed by both confocal imaging and patch clamping. These results highlight 
that TRPV4 mutations have heterogeneous effects on downstream signaling pathways and thus 
lead to diverse disease phenotypes, despite similar classification of these mutations as “gain-of-
function.” It is also important to note that in previous studies, chondrogenic differentiation of 
iPSCs (29) or dental pulp cells (30) were performed in short-term micromass culture, and not 
long-term pellet culture as in our study, potentially leading to different levels of chondrogenesis 
and maturation of the cells.  
Our transcriptomic analysis showed significant changes in various HOX family genes due 
to TRPV4 mutations, suggesting a potential role of these genes in maintaining the immature, 
chondrogenic phenotype in the mutated lines. At both day 28 and 56, the top 25 up-regulated 
genes in the V620I and T89I lines included genes from the anterior HOX family (57, 62). The 
high expression of anterior HOX genes indicates that the mutants are maintaining the 
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chondrocytes in an early developmental stage with axial patterning. At day 28 and 56, HOXA2, 
HOXA3, and HOXA4 were in the top upregulated genes, with HOXA4 having the largest fold 
change. Interestingly, gain-of-function mutations or overexpression of HOXA2, HOXA3, and 
HOXA4 impair chondrogenesis, limit skeletal development, decrease endochondral ossification 
regulators, and delay mineralization in animal models (57, 63-67). HOXA5 was also highly 
upregulated at both day 28 and 56, and mutations in this gene showed disordered patterning of 
limb bud development (68). Finally, the rib and spine phenotypes associated with brachyolmia 
and metatropic dysplasia could be contributed to the altered expression of HOXA4 to HOXA7 as 
it has been shown that these genes are associated with rib and spine patterning, and alterations in 
expression have led to defects (69, 70). The only up-regulated posterior HOX genes were 
HOXC8 and HOXD8 at day 56 (57, 62). The absence of posterior HOX9, HOX11, and HOX13, 
which are associated with limb development and hypertrophic RUNX2/3 expression (68, 71), 
may be at least partially responsible for the improper development in skeletal dysplasias. 
Interestingly, many links have been identified between HOX genes and TGFβ3-family signaling, 
specifically through SMAD proteins, both within skeletal development and other processes (e.g., 
murine lung development) (67, 72, 73). 
In fact, TRPV4 and TGF-β signaling have recently been shown to interact, with effects 
specific to the order in which they occur (14, 74, 75). Consistent with previous finding with 
hiPSCs housing the I604M TRPV4 mutations (29), the altered TRPV4 activity in our hiPSC-
derived chondrocytes could be altering their response to the TGFβ3 and BMP4 treatments. 
Furthermore, the V620I and T89I mutations increased expression of HTRA1, which has been 
shown to bind to and alter the response to members of the TGFβ family (76). Furthermore, 
TGFβ3 and TWIST, which is downstream of TGFβ3-signaling, were both upregulated in TRPV4-
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mutated hiPSC-derived chondrocytes. It has been reported that TGFB3 expression and signaling 
prevent osteoblastogenesis of mesenchymal stem cells (18, 21), while TWIST inhibits 
hypertrophy regulators RUNX2 and FGFR2 (77, 78). Therefore, another mechanism of 
hypertrophic dysregulation with these mutations could be altered response to TGFβ family 
signaling.  
Furthermore, significantly lower expression of ALPL, AMELX, IFITM5, GSTA1, IBSP, 
and MEPE in mutated chondrocytes compared to WT suggest that mutated cells had altered 
response to BMP4-induced hypertrophy. Indeed, mutations in ALPL have been shown to lead to 
hypophosphatasia with deformed long bones (79), while mutations in IFITM5 lead to osteogenic 
imperfecta (80). Our results indicate a connection between these genes and delayed 
endochondral ossification in chondrocytes bearing V620I and T89I mutations; however, how the 
expression levels of these genes are associated with TRPV4 function and mutations still warrants 
further investigation.  
Another gene increased in BMP4-treated WT, but less in mutants, was GSTA1, which 
produces the antioxidant glutathione (81, 82). The TRPV4-mutated chondrocytes also had 
significant downregulation of catalase (CAT), another antioxidizing gene (82). Interestingly, 
BMP4 treatment of T89I-mutated chondrocytes was able to significantly increase CAT 
expression, potentially indicating an association between antioxidant expression and maturation. 
One study observed that chondrocyte maturation is associated with decreasing catalase (83). 
However, many others report that reactive oxygen species (ROS; e.g., H2O2), which can be 
removed by CAT and GSTA1, prevent endochondral ossification, potentially via inhibition of the 
hedgehog pathways (82, 84, 85). Interestingly, IHH also had the lowest expression level in our 
T89I mutant chondrocytes. These findings suggest that decreased expression of CAT and GSTA1 
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in TRPV4 mutants may also be involved in dysregulating endochondral ossification in these 
cells.  
The decrease in mechanical properties with increased basal current of the V620I mutant 
was unexpected since TRPV4 activation was previously shown to increase matrix production and 
properties (14). Furthermore, genes uniquely upregulated in V620I were associated with 
interferon type I (IFNβ). IFNβ has been reported to decrease inflammatory markers and matrix 
degradation (86-89), despite the decrease in moduli observed in the day-42 V620I chondrogenic 
pellets. Interestingly, a study comparing bone marrow-derived MSCs from healthy and systemic 
lupus erythematous patients found that IFNβ inhibited osteogenesis via suppression of RUNX2 
and other osteogenic genes (90). Highlighting a potential, unique regulator of the delayed 
hypertrophy in V620I leading to brachyolmia. In contrast, T89I became more unique at later time 
points of chondrogenesis and was not associated with many of the same biological processes as 
WT and V620I, especially those regarding endochondral ossification, when treated with BMP4. 
This, in conjunction with the high number of unique DEGs, represents a potential inhibition of 
hypertrophy, particularly in response to BMP4 treatment, with the T89I mutation leading to 
severe metatropic dysplasia. 
 Here, we present multiple putative genes and pathways that could be involved in 
delaying, and potentially inhibiting, chondrocyte hypertrophy in V620I- and T89I-TRPV4 
mutants. It should be noted, however, that this study has some potential limitations. It is well-
recognized that Wnt/β-catenin signaling plays an important role in chondrocyte hypertrophy (78, 
91, 92). However, we may be preventing some hypertrophy since our chondrogenic protocol uses 
a pan-Wnt inhibitor to prevent off-target differentiation and promote a homogenous chondrocyte 
population (33). Nevertheless, our WT chondrocytes, but not TRPV4 mutants, exhibited 
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hypertrophic differentiation with BMP4 treatment, suggesting that DEGs/pathways detected in 
our sequencing analysis are still robust. Since this study focuses on TRPV4 gain-of-function 
mutations, future studies could fully or partially inhibit TRPV4 signaling to determine if that 
would increase similarity between the mutant and WT lines at various stages of chondrogenic 
and hypertrophic differentiation. Additionally, this study only activated TRPV4 using the 
pharmacological activator GSK101. Other future experiments could activate the channel 
osmotically or with mechanical loading to investigate additional differences in TRPV4 function 
leading to skeletal dysplasias during development. 
5.6 Supplemental Figures and Tables 
 
Figure S5.1 Top DEGs of V620I and T89I chondrocytes compared to WT remain from day 28 
to day 56. (A) The top 25 up-regulated genes, and their log2 fold change, for day-56 TGFβ3-
treated V620I and T89I chondrocytes compared WT. (B) The top 25 down-regulated genes, and 
their log2 fold change, for day-56 TGFβ3-treated V620I and T89I chondrocytes compared WT. 
 
Table S5.1 Clustering of BMP4 treatment. The top 10 genes of each cluster with normalized 
gene counts for each group. The top upregulated genes were determined for the group with the 
highest expression in that cluster: 1 – WT BMP4, 2 – T89I BMP4, 3 – T89I BMP4, 4 – T89I 
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TGFβ3, 5 – WT TGFβ3, 6 – WT TGFβ3, 7 – V620I BMP4, 8 – T89I BMP4, and 9 – WT 
TGFβ3. Related to Figure 5.6A.  













Cluster 1        
ENSG00000136630 HLX -0.4407717 2.0402195 -0.5407056 -0.3272783 -0.535553 -0.4414497 
ENSG00000134215 VAV3 -0.4322642 2.0374974 -0.5033759 -0.389187 -0.4886749 -0.4664525 
ENSG00000154143 PANX3 -0.4953438 2.03064846 -0.4974411 -0.3205407 -0.4982932 -0.4578532 
ENSG00000162551 ALPL -0.4919204 2.03056528 -0.5327131 -0.2125114 -0.5488725 -0.5036349 
ENSG00000103056 SMPD3 -0.1974815 2.02602223 -0.5671042 -0.2903093 -0.6396414 -0.6310159 
ENSG00000176842 IRX5 -0.465913 2.02293985 -0.5606691 -0.2921023 -0.5380299 -0.4085238 
ENSG00000170962 PDGFD -0.1915284 2.01873261 -0.659709 -0.4009481 -0.6770205 -0.3392717 
ENSG00000153446 C16orf89 -0.4773729 2.01744291 -0.5845101 -0.2737777 -0.5435154 -0.3791925 
ENSG00000163501 IHH -0.5298648 2.01702244 -0.5431994 -0.2002987 -0.5405259 -0.4519113 
ENSG00000101280 ANGPT4 -0.5302453 2.01695715 -0.5428197 -0.1350517 -0.603895 -0.4542005 
Cluster 2        
ENSG00000134061 CD180 -0.4622938 -0.5288295 -0.3577376 -0.3482325 -0.1581304 2.35438578 
ENSG00000230815  -0.4489383 -0.8685342 0.18583502 -0.1584488 -0.2552786 2.12243149 




0.24000783 -0.9939455 -0.1426133 -0.1043512 -0.3913171 1.80875466 
ENSG00000129422 MTUS1 -0.4016571 0.49891994 -0.654169 0.56752143 -1.3036937 1.50604821 
ENSG00000231104  0.29347029 -1.0471918 0.46399309 0.15234796 -0.817868 1.42832896 
ENSG00000261997  -0.3339501 -0.7616808 -0.1494389 0.64731428 -0.4849139 1.39374618 
ENSG00000148680 HTR7 0.36576125 -0.0299804 -0.5503075 0.4317182 -1.371105 1.35511546 
ENSG00000232903 LINC01166 0.37813758 0.11002898 -0.8602688 0.50836176 -1.3454177 1.32545463 
ENSG00000243175 RPSAP36 0.13741559 -0.890453 -0.0641273 0.59088704 -0.7695273 1.30636422 
Cluster 3        
ENSG00000162078 ZG16B -0.8551802 -0.1800379 -0.930196 0.12377608 0.12377608 1.98041735 
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ENSG00000116455 WDR77 -1.2364286 -0.3366992 -0.5494202 0.15785895 0.34689005 1.97392514 
ENSG00000170006 TMEM154 -1.2573605 -0.0147801 -0.5923283 0.10134896 0.15941346 1.94083253 
ENSG00000136943 CTSV -0.8907691 -0.6416754 -0.7378985 0.30115571 0.41522664 1.82598136 
ENSG00000171428 NAT1 -0.9289641 -0.097933 -0.8605664 0.29193349 0.12777919 1.67014557 
ENSG00000169504 CLIC4 -1.4859539 0.13092627 -0.3119891 0.22835859 0.11867718 1.65597823 
ENSG00000153029 MR1 -1.4531496 -0.1979707 -0.5965094 0.31339853 0.56036661 1.63298287 
ENSG00000155918 RAET1L -0.6734798 -1.1691676 -0.4812131 0.34493311 0.64234574 1.62170451 
ENSG00000114450 GNB4 -1.3812791 0.4524834 -0.3327172 0.18743492 -0.2225245 1.61789756 
ENSG00000203392  -0.880589 -0.5792242 -0.9690578 0.62794695 0.35569132 1.60395769 
Cluster 4        
ENSG00000142661 MYOM3 -0.1800364 -0.5676659 -0.3980397 -0.6631954 2.02449127 -0.420085 
ENSG00000265190 ANXA8 -0.4662521 -0.6012199 -0.2862952 -0.5472328 2.01715398 -0.2503038 
ENSG00000188015 S100A3 -0.4862037 -0.7025085 -0.2076937 -0.4734799 2.01614534 -0.2642439 
ENSG00000164764 SBSPON -0.6366146 -0.4165159 -0.5056698 -0.4938291 2.01153508 -0.1137641 
ENSG00000065325 GLP2R -0.4285246 -0.7675511 -0.1872943 -0.5589194 2.00985763 -0.1525224 
ENSG00000196154 S100A4 -0.3852601 -0.5834099 0.04349122 -0.6381075 2.0018262 -0.5702228 
ENSG00000007171 NOS2 -0.3798747 -0.5060131 -0.2511371 -0.4794094 2.00161854 -0.5972914 
ENSG00000174946 GPR171 -0.2568739 -0.6297553 -0.0524796 -0.6711866 2.00113036 -0.5386065 
ENSG00000214688 C10orf105 -0.4068724 -0.7431708 -0.1763876 -0.3974435 1.99436058 -0.4194443 
ENSG00000177283 FZD8 -0.396451 -0.7014113 -0.0357477 -0.6369388 1.98680373 -0.3002558 
Cluster 5        
ENSG00000244953  1.93036295 -0.4874654 -0.1516559 -0.4744663 -0.42247 -0.5762924 
ENSG00000125869 LAMP5 1.9113851 -0.3544688 -0.2506172 -0.5999363 -0.2128529 -0.7415522 
ENSG00000259881 LOC101927793 1.88877557 -0.4321825 0.15904637 -0.4519634 -0.4255889 -0.9311006 
ENSG00000263155 MYZAP 1.84143074 -0.751481 -0.3599587 -0.5963496 -0.0644702 -0.2122145 
ENSG00000141750 STAC2 1.75760823 -0.8245062 -0.3863292 -0.6367161 0.24311552 -0.3330061 
ENSG00000101938 CHRDL1 1.72579926 -0.1375551 -0.2522428 -0.8218159 0.09439777 -0.8955253 
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ENSG00000120057 SFRP5 1.70244888 -0.2222804 0.03070915 -0.944713 0.20955956 -1.0240626 
ENSG00000139292 LGR5 1.65667334 -0.5917232 0.15125745 -0.8029446 0.11975952 -0.6602775 
ENSG00000270228  1.64512369 -0.0663858 -0.3402273 -0.0663858 -0.1804865 -1.4355934 
ENSG00000106327 TFR2 1.64094873 -0.7710817 0.04517224 -0.4726389 0.42422017 -1.1404366 
Cluster 6        
ENSG00000185742 C11orf87 1.54928318 0.52412284 -0.068401 -0.5339555 -0.6750326 -1.0841562 
ENSG00000122254 HS3ST2 1.54484352 0.69539965 -0.1085645 -0.4269226 -0.8670489 -1.1531311 
ENSG00000125804 FAM182A 1.49677851 0.46950232 0.61491584 -0.6562798 -0.9517976 -1.0925204 
ENSG00000184828 ZBTB7C 1.48468335 0.81548377 -0.2924263 -0.6119857 -0.6213616 -1.1300001 
ENSG00000239268  1.47666919 0.59588969 0.12571513 -0.7540006 -0.5880567 -1.0997172 
ENSG00000129151 BBOX1 1.41603923 0.14942686 -0.1857581 -0.6965929 0.00922931 -0.9850453 
ENSG00000187135 VSTM2B 1.37532225 0.98960864 -0.5246744 -0.5675315 -0.6103885 -1.0580068 
ENSG00000133636 NTS 1.34744728 0.67247136 -0.4800385 -0.4433051 -0.4708552 -0.9943059 
ENSG00000184492 FOXD4L1 1.33955469 0.06928731 -0.3541351 -0.9151699 0.51388089 -0.9892688 
ENSG00000243319 FGF14-IT1 1.31866392 0.56172241 0.18599419 -0.3268611 -1.273038 -0.5599772 
Cluster 7        
ENSG00000183644 HOATZ -0.8453249 -0.4201194 -0.3940103 1.73947729 -0.10681 -0.0956204 
ENSG00000154342 Wnt3A -1.0716829 -0.5651792 -0.01912 1.72421754 -0.2873257 0.28574702 
ENSG00000138356 AOX1 -0.7979798 -0.4018139 -0.6671427 1.7178925 -0.6232867 0.80739331 
ENSG00000141448 GATA6 -1.0975583 -0.402573 0.21816165 1.71356796 -0.3802979 0.00432003 
ENSG00000189001 SBSN -1.1766072 -0.414439 0.04404355 1.69481709 0.06058673 -0.263187 
ENSG00000152669 CCNO -1.0056734 -0.2531982 -0.0784151 1.67736047 -0.4030122 0.05777953 
ENSG00000120949 TNFRSF8 -0.8457057 -0.525458 -0.5571943 1.67473023 -0.5462308 0.88074675 
ENSG00000256673  -0.7951926 -0.4642983 -0.5650053 1.66493452 -0.6800989 0.9312124 
ENSG00000212993 POU5F1B -0.8110902 -0.48146 -0.3129823 1.6501491 -0.3276325 0.27302709 
ENSG00000115363 EVA1A -1.3417184 -0.2438053 -0.5302174 1.60919416 0.35505632 0.02524845 
Cluster 8        
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ENSG00000154080 CHST9 0.79674683 -0.3558075 -0.6039268 -0.8960673 -0.4158364 1.76521261 
ENSG00000109193 SULT1E1 -0.2211121 0.92346818 -1.0657016 -0.7472498 -0.3088017 1.5372955 
ENSG00000268089 GABRQ 1.05785547 0.0056823 -0.5794371 -0.4526902 -1.1845235 1.34433826 
ENSG00000129159 KCNC1 1.14171692 -0.402278 -0.2372079 -0.0078783 -1.3714752 1.09042729 
ENSG00000162645 GBP2 1.23597668 -0.4515684 0.04491227 -0.5396142 -1.060552 1.042765 
ENSG00000164093 PITX2 -0.1260545 1.24124219 -1.0665402 -1.0719021 0.1184503 0.85089238 
ENSG00000129824 RPS4Y1 0.35003319 0.82149811 -1.3769648 -1.3832455 0.60788477 0.8487374 
ENSG00000175084 DES 1.28288386 -0.2443785 -1.1495016 -1.0843542 0.30456241 0.80455019 
Cluster 9        
ENSG00000171722 SPATA46 1.97614501 -0.3838787 0.08643424 -0.5006111 -0.6071928 -0.732384 
ENSG00000087250 MT3 1.97175135 -0.2804736 -0.0235548 -0.5370286 -0.5806975 -0.7411808 
ENSG00000146360 GPR6 1.96269185 -0.2126427 0.00307151 -0.5245186 -0.6531674 -0.7662224 
ENSG00000257126  1.94280226 -0.1402269 -0.232513 -0.57529 -0.5621063 -0.6543924 
ENSG00000115155 OTOF 1.936001 -0.0992158 -0.3563582 -0.3942778 -0.6555677 -0.6928948 
ENSG00000100078 PLA2G3 1.93320458 -0.2334559 0.10590057 -0.4635004 -0.6641775 -0.8686616 
ENSG00000144119 C1QL2 1.93116843 -0.3228628 -0.1106777 -0.4724358 -0.6324442 -0.5605564 
ENSG00000186960 LINC01551 1.92885289 -0.2396521 -0.1617074 -0.512869 -0.5768657 -0.6375806 
ENSG00000105509 HAS1 1.92860762 0.15041891 -0.5956422 -0.5807668 -0.4880813 -0.7512624 
ENSG00000127329 PTPRB 1.92160498 0.00830095 -0.3770758 -0.5227041 -0.6449196 -0.6393005 
5.7 Conclusion 
In summary, our study found that dysregulated skeletal development in the V620I- and 
T89I-TRPV4 dysplasias is likely due, at least in part, to delayed and inhibited chondrocyte 
hypertrophy. The gain-of-function mutations may lead to increased HOX gene expression, 
altered TGFβ signaling, decreased hypertrophic and biomineralization gene expression (e.g., 
ALPL, AMELX, IFITM5, IBSP, and MEPE), and genes regulating hedgehog pathways and ROS 
accumulation (e.g., GSTA1, CAT). These findings lay a foundation for the development of 
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therapeutics for these diseases and give insights into the regulation of endochondral ossification 
via TRPV4. 
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Skeletal Dysplasia-causing TRPV4 Mutations 
Increase Mechanosensitivity of  
Human iPSC-derived Chondrocytes 
6.1 Abstract  
Transient receptor potential vanilloid 4 (TRPV4) is a mechanically sensitive ion channel highly 
expressed in chondrocytes. Mutations in TRPV4 prevent proper skeletal development and cause 
skeletal dysplasias, such as V620I and T89I that lead to brachyolmia and metatropic dysplasia, 
respectively. However, how these mutations alter mechanotransduction and inhibit chondrocyte 
hypertrophy and endochondral ossification has yet to be elucidated. Therefore, we 
chondrogenically differentiated human induced pluripotent stem cells (hiPSCs) harboring the 
moderate V620I and severe T89I TRPV4 mutations. We cultured the derived chondrocytes in an 
agarose hydrogel prior to compressive loading of 10% strain at 1 Hz for 3 hours. Using mRNA 
sequencing and bioinformatic analyses, we assessed the transcriptomic response of chondrocytes 
0, 3, 12, and 24 hours after loading. hiPSC-derived chondrocytes synthesized cartilaginous 
matrix in agarose hydrogels. We observed an increased mechanosensitivity of mutant TRPV4 
with higher fold changes and more differentially expressed genes compared to the wildtype 
control. From the transcriptomic data, we propose that TRPV4 mutations V620I and T89I 
increase cell cycle regulating genes (e.g., E2F1, TP53, NFKB1) resulting in continued 
proliferation of chondrocytes and inhibition of hypertrophy, ultimately leading to the 




Articular cartilage lines the ends of long bones and provides a nearly frictionless surface for joint 
movements (1). Interestingly, not only does cartilage withstand millions of cycles of loading, but 
loading maintains the homeostasis of the tissue (2, 3). Chondrocytes, the primary residing cell 
type, synthesize and degrade extracellular matrix (ECM) proteins, including glycosaminoglycans 
(GAGs) and type II collagen (COL2A1), in response to physiologic loading (1, 4). Chondrocyte 
mechanotransduction occurs as compressive, shear, hydrostatic pressure, and osmotic forces are 
filtered through the pericellular matrix surrounding the chondrocyte to mechanosensors, such as 
integrins, primary cillium, and ion channels (5, 6). The signal is then converted into downstream 
pathways (e.g., Indian hedgehog, Wnt, TGFβ, MAPK-ERK) and results in transcriptomic 
changes (5). One mechanosensor of particular interest is ion channel transient receptor potential 
vanilloid 4 (TRPV4).  
 TRPV4 is a non-selective cation channel activated by, but not limited to, heat, acidity, 
chemical agonists (e.g., 4α-phorbol 12,13-didecanoate, ruthenium red, GSK1016790A), 
osmolarity, and mechanical loading (7, 8). The channel is expressed throughout the body with 
high expression in chondrocytes (7). In fact, TRPV4 is essential to the development and 
homeostasis of cartilage. TRPV4 activation increased expression of chondrogenic transcription 
factor SRY-box transcription factor 9 (SOX9) promoting chondrogenesis in ATDC5 cells (9) and 
increased matrix production and Young’s modulus in primary porcine chondrocytes (4). 
However, knockout of TRPV4 in murine adipose-derived stem cells decreased chondrogenic 
potential (10). To better understand the downstream effects of TRPV4 activation on 
chondrocytes, our recent study identified the shared transcriptome between TRPV4 activation via 
loading and chemical agonist GSK1016790A (GSK101; 11). The primary porcine chondrocytes 
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had increased gene expression associated with rheumatoid arthritis, TGFβ signaling, and PPAR 
signaling (11). These results highlight the essential function of mechanical loading on cartilage 
development and homeostasis, particularly via TRPV4 and its downstream signaling cascades. 
 In fact, mutations in TRPV4 have been shown to cause skeletal dysplasias, diseases of 
improper skeletal development (12, 13). For example, the V620I substitution causes moderate 
autosomal dominant brachyolmia, and the T89I substitution causes severe, neonatally lethal 
metatropic dysplasia. Both mutations lead to a disproportionate skeletal phenotype with scoliosis 
and deformed long bones (14, 15). Previous studies, including ours, showed increased basal 
membrane currents with V620I and T89I TRPV4 (16-18). However, there have been conflicting 
results as to whether the mutant channel has increased or decreased sensitivity to activation via 
chemical agonist GSK101 and hypotonic solutions (16-18). Using human induced pluripotent 
stem cells (hiPSC)-derived chondrocytes, we found that V620I and T89I mutations decrease 
channel sensitivity to GSK101 and delay and inhibit chondrocyte hypertrophy (18). However, 
how the mutations alter the response to mechanical, compressive loading, has not been 
elucidated. Here, we investigate the transient, transcriptomic response of hiPSC-derived 
chondrocytes to physiologic, cyclic loading and the differences in the response due to dysplasia-
causing gain-of-function mutations. These results will provide insights into TRPV4 
mechanotransduction, hiPSC-derived tissue-engineered cartilage optimization, and skeletal 
dysplasia treatments. 
6.3 Methods 
6.3.1 hiPSC culture 
BJFF.6 (BJFF; Washington University Genome Engineering and iPSC Center (GEiC)) was the 
isogenic, wildtype control hiPSC line used in this study. V620I and T89I substitutions were 
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added to BJFF using CRISPR-Cas9 to create the two mutated hiPSC lines as previously 
described (19). The hiPSCs were cultured on vitronectin (VTN-N; Fisher Scientific, A14700)-
coated plates and fed Essential 8 Flex medium (E8; Gibco, A2858501) daily. For expansion, 
cells were passaged at 80-90% confluency using ReLeSR (STEMCELL Technologies, 05872) 
and cultured with rock inhibitor Y-27632 (STEMCELL Technologies, 72304) for 24 hours. For 
mesodermal differentiation, cells were induced at 30-40% confluency. 
6.3.2 Mesodermal differentiation 
The hiPSCs were differentiated along the mesodermal lineage to chondroprogenitors in 
monolayer for 12 days as previously described (19-21). In brief, the cells were fed daily with 
mesodermal differentiation medium: Iscove’s Modified Dulbecco’s Medium, glutaMAX 
(IMDM; Gibco, 31980097) and Ham’s F-12 nutrient mix, glutaMAX (F12; Gibco, 31765092) in 
equal parts supplemented with 1% penicillin-streptomycin (P/S; Gibco, 15140122), 1% Insulin-
Transferrin-Selenium (ITS+; Gibco, 41400045), 1% chemically defined concentrated lipids 
(Thermo Fisher Scientific, 11905031), and 450 µM 1-thioglycerol (Millipore Sigma, M6145). 
Various combinations of growth factors and small molecules were used each day for specified 
differentiation: day 1, anterior primitive streak, 30 ng/ml Activin (R&D Systems, 338-AC), 20 
ng/ml FGF2 (R&D Systems, 233-FB-025/CF), 4 µM CHIR99021 (Reprocell, 04-0004-02); day 
2, paraxial mesoderm, 20 ng/ml FGF2, 3 µM CHIR99021, 2 µM SB505124 (Tocris Bioscience, 
3263), 4 µM dorsomorphin (DM; Reprocell, 04-0024); day 3, early somite, 2 µM SB505124, 4 
µM dorsomorphin, 500 nM PD173074 (Tocris Bioscience, 3044), 1 µM Wnt-C59 (Cellagen 
Technologies, C7641-2s); days 4-6, sclerotome, 1 µM Wnt-C59, 2 µM purmorphamine 
(Reprocell, 04-0009); and days 7-12, chondroprogenitor cells, 20 ng/ml BMP4 (R&D Systems, 
314-BP-010CF)). The chondroprogenitor cells were then disassociated with TrypLE™ Select 
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Enzyme (1X), no phenol red (Gibco, 12563029) for chondrogenic differentiation. 
6.3.3 Chondrogenic differentiation 
Chondroprogenitor cells were chondrogenically differentiated for 28 days in a high-density, 3D 
pellet culture as previously described (19-21). Chondroprogenitor cells were resuspended at 5 x 
105 cells/mL in chondrogenic medium: Dulbecco’s Modified Eagle Medium/F12, glutaMAX 
(DMEM/F12; Gibco, 10565042), 1% P/S, 1% ITS+, 1% Modified Eagle Medium (MEM) with 
nonessential amino acids (NEAA; Gibco, 11140050), 0.1% dexamethasone (Dex; Millipore 
Sigma, D4902), and 0.1% 2-Mercaptoethnol (2-ME; Gibco, 21985023) supplemented with 0.1% 
L-ascorbic acid (ascorbate; Millipore Sigma, A8960), 0.1% L-proline (proline; Millipore Sigma, 
P5607), 10 ng/ml human transforming growth factor beta 3 (TGFβ3; R&D Systems, 243-B3-
010/CF), 1 µM Wnt-C59, and 1 µM ML329 (Cayman Chemical, 22481). Pellets were formed by 
centrifuging 1 mL of the cell solution in a 15-mL conical tube and fed every 3-4 days. 
6.3.4 Digestion of chondrogenic pellets to obtain hiPSC-derived chondrocytes 
A 0.4% w/v type II collagenase (Worthington Biochemical, LS00417) digestion solution was 
created in DMEM/F12 with 10% fetal bovine serum (FBS; Atlanta Biologicals, S11550). Day-28 
chondrogenic pellets were then rinsed and digested in an equal volume of digestion solution (1 
mL per pellet) on an orbital shaker at 37 ºC. Digestion solution with pellets was vortexed every 
20 minutes until tissue was no longer visible and was neutralized with an equal volume of 
DMEM/F12 with 10% FBS. 
6.3.5 Casting of hiPSC-derived chondrocytes in agarose 
A 4% (w/v) agarose (low gelling temperature Type VII-A; Sigma, A0701) solution was made in 
PBS and autoclaved. hiPSC-derived chondrocytes were resuspended in chondrogenic medium at 
6 x 107 cells/mL and mixed with an equal volume of 60 ºC agarose. The 3 x 107 cells per 1 mL of 
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2% agarose solution was cast in a mold for 10 min at room temperature before creating disks 
with a 3 mm diameter biopsy punch. Agarose constructs were fed every 3-4 days with 
chondrogenic medium for 2 weeks to allow for matrix production. 
6.3.6 Inhibition of TRPV4 during culture 
Some agarose constructs were continued in culture for an addition 2 weeks. The chondrogenic 
medium was supplemented with 20 µM GSK205 (cat. num. AOB1612 1263130-79-5; 
AOBIOUS, Gloucester, MA) or an equal volume of DMSO for 1 hour per day, 5 days per week 
for 2 weeks. 
6.3.7 Analysis of elastic modulus  
Agarose constructs were transferred to PBS and stored at 4 ºC for mechanical testing. Using the 
ELF 3220 (ELectroForce with WinTest Software, EnduraTEC Systems Corporation), a 2 g tare 
was applied to the constructs before undergoing a stress relaxation test with a 10% displacement 
at a rate of 1 µm/s for 20 min to calculate the elastic modulus of the constructs. 
6.3.8 Histology 
Agarose constructs were fixed and dehydrated in sequential steps of increasing ethanol and 
xylene solutions until embedded in paraffin wax. Wax blocks were cut into 8 µm sections on 
microscope slides, and slides were rehydrated in ethanol and water. Nuclei were stained with 
Harris hematoxylin and sGAGs with Safranin-O. Antigen retrieval was performed on rehydrated 
slides followed by blocking, the addition of primary and secondary antibodies, and AEC 
development to label type II collagen proteins and Vector Hematoxylin QS counterstain. 
6.3.9 Biochemical analysis 
Agarose were rinsed in PBS and digested in a papain solution at 65 ºC overnight. Sulfated 
glycosaminoglycan (sGAG) content was measured using a dimethylmethylene blue (DMMB) 
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solution. Double-stranded DNA (dsDNA) was measured using the PicoGreen assay (Quant-iT™ 
PicoGreen™ dsDNA Assay Kit, P7589). sGAG content was normalized to dsDNA. 
6.3.10 Sinusoidal compressive loading 
After 2 weeks, agarose constructs were switched to chondrogenic medium without TGFβ3. 
Constructs were sinusoidally loaded with a 10% peak-to-peak strain at 1 Hz for 3 hours at 37 ºC 
alongside a free swelling control. The loading was performed with a custom-made bioreactor (4, 
11). The loaded agarose constructs were incubated until harvested in chondrogenic medium 
without TGFβ3. Agarose constructs were rinsed and snap frozen 0, 3 (2 samples), 12, or 24 
hours after loading completed. The free-swelling constructs were harvested at 0 hours, 
immediately after loading. Constructs were stored at -80 ºC until RNA isolation. 
6.3.11 RNA isolation 
Samples were thawed on ice, lysed, and homogenized. RNA was isolated using the Quiagen 
Total RNA Purification Plus Kit (Norgen Biotek, 48400) according to manufacturer instructions 
and immediately submitted for mRNA sequencing with the Genome Technology Access Center 
at Washington University in St. Louis (GTAC). 
6.3.12 Genome-wide mRNA sequencing 
Libraries were prepared according to manufacturer’s protocol. Samples were indexed, pooled, 
and sequenced at a depth of 30 million reads per sample on an Illumina NovaSeq 6000. Basecalls 
and demultiplexing were performed with Illumina’s bcl2fastq software and a custom python 
demultiplexing program with a maximum of one mismatch in the indexing read. RNA-seq reads 
were then aligned to the Ensembl release 76 primary assembly with STAR version 2.5.1a (22). 
Gene counts were derived from the number of uniquely aligned unambiguous reads by 
Subread:featureCount version 1.4.6-p5 (23). Isoform expression of known Ensembl transcripts 
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were estimated with Salmon version 0.8.2 (24). Sequencing performance was assessed for the 
total number of aligned reads, total number of uniquely aligned reads, and features detected. The 
ribosomal fraction, known junction saturation, and read distribution over known gene models 
were quantified with RSeQC version 2.6.2 (25). 
6.3.13 Transcriptomic analysis of sequencing datasets 
Working in RStudio, we used the DESeq package to read un-normalized gene counts and remove 
the genes if they had counts lower than 200 (26). Regularized-logarithm transformed data of the 
samples were visualized with the ggplot2 package (27) to create a principal component analysis 
(PCA). The two 3-hour replicates clustered together confirming reproducibility and were then 
averaged together. The up-regulated differentially expressed genes (DEGs) were determined at 
each time point compared to the free swelling control for each line and the total number were 
plotted using GraphPad Prism. Genes were considered differentially expressed if adjusted p 
value (padj) < 0.1 and log2(fold change) ≥ 1 or ≤ -1. The intersecting and unique DEGs between 
time points for each cell lines and between cell lines at each time point were determined and 
plotted with the intersect and setdiff, and venn.diagram functions (VennDiagram package (28)). 
The fold change of top 25 genes in the intersection of the two mutants, but not WT, for each time 
point were determined and the 0 and 3 hour gene lists and 12 and 24 hour gene lists were 
visualized with the Pheatmap package (29). The fold changes at each time point of cAMP/Ca2+ 
transcription factors and TRPV4-responsive genes (11) were plotted using GraphPad Prism and 
significance was indicated based on p values. The upregulated genes at 0, 3, 12, and 24 hours 
were ordered based on log2(fold change) and analyzed with g:Profiler (30) and Transcriptional 
Regulatory Relationships Unraveled by Sentence-based Text Mining (TRRUST) (31). gProfiler 
identified KEGG and reactome pathways associated with the ordered gene set. Then, we plotted 
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the negative log10 of the adjusted p value for each term using a function to scale circle diameter 
to the p value in Illustrator. TRRUST identified associated transcription factors with the gene set, 
and we plotted the log10(p value) of association for each transcription factor for either V620I or 
T89I vs. WT on a scatter plot using GraphPad Prism. The transcription factors with the strongest 
association to one line compared to the other on the graph were highlighted in that cell line’s 
color and labeled. If the transcription factor was strongly associated with both lines, it was 
labeled in grey. We also performed k-means clustering with 4 clusters and plotted the gene 
expression trends (scaled mean counts) for each gene within the cluster with the average 
expression trend overlaying for each cell line of the largest cluster using the tidyverse package 
(32). Cluster 1 represented increased expression at 12 and 24 hours, and cluster 2 and 3 
represented increased expression at 0 and 3 hours. The top 20 up-regulated genes from cluster 1 
or clusters 2 and 3 for each cell line were determined. The log2(fold change) of that gene for each 
group was plotted with pheatmap. 
6.3.14 Statistical analysis 
Replicates were graphed and analyzed using GraphPad Prism (Version 9.1.0). Outliers were 
removed from the data using the ROUT method (Q = 1%), and the data were tested for normality 
with the Shapiro-Wilk test (  = 0.05). A Kruskal-Wallis test was used if data was not normally 
distributed. For biochemical analysis and mechanical properties, data were analyzed using an 
ordinary two-way ANOVA, comparing each cell with all other cells, with Tukey’s post-hoc 
multiple comparison test. 
6.4 Results 
6.4.1 hiPSC-derived chondrocytes secrete a cartilaginous matrix in agarose 
hiPSC chondrogenesis occurs in a 3D, spherical pellet culture; however, compressive loading of 
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a sphere results in an uneven distribution of stress throughout the tissue. Therefore, we digested 
the day-28 chondrogenic pellets to obtain hiPSC-derived chondrocytes at a single-cell level that 
were then cast in 2% agarose, cylindrical constructs and cultured for 2 weeks. This culture 
system has been used extensively for mechanical loading studies with primary chondrocytes (4, 
11). Like primary chondrocytes, the hiPSC-derived chondrocytes secreted cartilaginous matrix 
(Figure 6.1A-C). Safranin-O staining of sGAGs showed the chondrocytes began secreting matrix 
directly around the cell, which was more distributed throughout the agarose in mutant lines 
(Figure 6.1A). All lines also showed COL2A1 labeling, which appeared more localized around 
the cell in WT (Figure 6.1B). The ratio of sGAG to dsDNA, as determined by biochemical 
analysis, was not significantly different between lines, but T89I trended higher (T89I: 45.4 µg/µg 
vs. WT: 22.2 µg/µg, p=0.4248 and V620I: 24.3 µg/µg, p=0.4720; Figure 6.1C). 
 
Figure 6.1 hiPSC-derived chondrocytes secrete cartilaginous matrix in agarose after 2 weeks of 
culture. (A-B) Day-28 hiPSC-derived chondrocytes seeded in agarose and cultured in 
chondrogenic medium for 14 days secrete matrix rich in sGAGs as shown by Safranin-O staining 
(A) and COL2A1 as labeled by IHC (B). Scale bar = 500 µm. (C) The three lines have similar 
sGAG/DNA ratios between 20-40 µg/µg. Mean ± SEM. n-4. No significance after ordinary one-
way ANOVA. 
Next, we investigated whether TRPV4 signaling was responsible for the matrix 
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production within the agarose since severe mutation T89I appeared to increase sGAG secretion. 
We continued to culture the agarose for an additional 2 weeks with and without TRPV4-specific 
antagonist GSK205. The differences between lines with localization of Safranin-O staining were 
no longer present at 4 weeks; however, WT had showed somewhat increased labeling for 
COL2A1 (Figure 6.2A-B). Treatment with GSK205 appeared to slightly decrease sGAG staining 
with no effect on COL2A1 labeling (Figure 6.2C-D). When quantified, TRPV4 inhibition 
trended toward decreasing sGAG/DNA in T89I (veh vs. GSK205 (µg/µg) – WT: 57.7 vs. 52.5; 
V620I: 52.3 vs. 59.9; T89I: 55.8 vs. 37.4; ns). The additional two weeks of culture did however 
increase the sGAG/DNA ratio for all lines from an average of 20 to 50 µg/µg. We also observed 
a trend of higher elastic moduli in mutants compared to WT, which was slightly attenuated by 
GSK205 in T89I (veh vs. GSK205 (kPa) – WT: 98.8 vs. 83.9; V620I: 134.1 vs. 116.6; T89I: 




Figure 6.2 TRPV4 inhibition during hiPSC-derived chondrocyte agarose culture. (A-B) WT, 
V620I, and T89I had similar matrix production after 4 weeks in culture as shown by Safranin-O 
staining of sGAG (A) and IHC labeling of COL2A1 (B). (C-D) TRPV4 inhibition with GSK205 
did not have a major effect on Safranin-O staining of sGAG (C) or IHC labeling of COL2A1 
(D). Scale bar = 500 µm. (E) Quantification of the matrix production showed all three lines, with 
and without GSK205, had an sGAG/DNA ratio of approximately 50 µg/µg. Mean ± SEM. n=3-
4. No significance with an ordinary two-way ANOVA. (F) V620I and T89I have slightly higher 
elastic moduli (approximately 150 kPa) compared to WT (approximately 100 kPa), which 
trended lower with GSK205 treatment. Mean ± SEM. n=3-4. No significance with an ordinary 
two-way ANOVA. 
6.4.2 Mutant chondrocytes are more responsive to loading 
WT, V620I, and T89I 2-week agarose constructs were loaded with 10% strain at 1 Hz for 3 
hours alongside a free swelling control (Figure 6.3A). The constructs were collected for mRNA 
sequencing 0, 3, 12, and 24 hours after loading completed (Figure 6.3A). Principal component 
analysis (PCA) shows that the 3 cell lines followed a similar trajectory over time post-loading; 
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however, WT samples were more similar to each other at each time point than mutants (Figure 
6.3B). This was further confirmed when comparing the number of upregulated DEGs at each 
time point; in fact, T89I has more than double the number of upregulated DEGs than WT (WT: 
887 vs. V620I: 1672 vs. T89I: 2379; Figure 6.3C). We then compared the DEGs at each time 
point within each line (Figure 6.3D). Interestingly, WT showed an increase in DEGs over time 
with the largest response at 24 hours (0hr: 92 vs. 3hr: 237 vs. 12hr: 233 vs. 24 hr: 325; Figure 
6.3D). However, V620I showed the largest response at 3 and 12 hours, with fewer DEGs than 
WT at 24 hours (0hr: 157 vs. 3hr: 549 vs. 12hr: 676 vs. 24 hr: 290; Figure 6.3D). T89I had a 
larger response at 0 hours than WT did at 24 hours, which continued to increase through 3, 12, 
and 24 hours (0hr: 464 vs. 3hr: 656 vs. 12hr: 567 vs. 24 hr: 692; Figure 6.3D). For all lines, 
many DEGs were unique to the time point, but the largest intersections were between 0 and 3 
hours or 12 and 24 hours (Figure 6.3D). V620I also showed significant overlap between 3 and 12 




Figure 6.3 Mechanical loading response of hiPSC-derived chondrocyte agarose. (A) The loading 
regimen and sample collection timeline. Agarose constructs were loaded with 10% compressive 
strain at 1 Hz for 3 hours alongside a free swelling control. Loaded constructs were harvested 0, 
3, 12, and 24 hours after loading. (B) PCA comparing the free swelling and 0, 3, 12, and 24 
hour-post-loading samples for WT, V620I, and T89I. Arrows indicate the trajectory over time for 
each cell line. Two samples at 3 hours to show reproducibility. (C) The number of up-regulated 
differentially expressed genes at each time point after loading compared to respective lines’ free 
swelling control. T89I had more than twice the number of up-regulated DEGs in WT. (D) Venn 
diagrams comparing the up-regulated DEGs at each time point for each cell line. Genes were 
typically unique to each time point; however, 0 and 3 hours and 12 and 24 hours showed the 
most similarity. 
We compared expression over time of each of the three lines for cyclic adenosine 
monophosphate (cAMP) and Ca2+ responsive transcription factors and other TRPV4-responsive 
target genes as previously identified in porcine chondrocytes (11) (Figure 6.4A-I). There was 
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immediate upregulation after loading, with higher expression in the severe T89I line, of 
transcription factors jun proto-oncogene, AP-1 transcription factor subunit (JUN: 0 hr, T89I vs. 
WT p<0.0001, T89I vs. V620I p<0.0001) and early growth response 1 and 2 (EGR1: 0 hr, T89I 
vs. WT p <0.0001, T89I vs. V620I p=0.0043; EGR2: 0 hr, T89I vs. WT p < 0.0001; Figure 6.4A-
C). Nuclear receptor subfamily 4 group A member 2 (NR4A2) showed upregulation at 0 hours in 
T89I (T89I vs. WT p<0.0001) but 3 hours in WT (WT vs. V620I p=0.0004, WT vs. T89I 
p=0.0003; Figure 6.4D). Bone morphogenic proteins 2 and 6 (BMP2 and BMP6) had peak 
expression at 3 hours post loading, with slightly higher expression in mutants (3 hr BMP2, T89I 
vs. WT p=0.0009; Figure 6.4E-F). However, WT had higher BMP2 expression at 24 hours (WT 
vs. V620I p<0.0001). Fos proto-oncogene, AP-1 transcription factor subunit (FOS) was 
upregulated immediately after loading but had much lower expression in T89I (3 hr, T89I vs. 
WT p=0.0019; Figure 6.4G). Nuclear receptor subfamily 4 group A member 3 (NR4A3; also 
known as NOR-1; 3 hr, WT vs. V620I p=0.0018, WT vs. T89I p<0.0001) and CAMP responsive 
element binding protein 1 (CREB1; ns) both had higher expression in WT compared to mutants 
and were upregulated short- and long-term, respectively (Figure 6.4H-I).  
 Given that the TRPV4 mutants and WT showed similar trends, with varying expression 
levels, we next investigated how similar the DEGs were between lines at each time point. The 
majority of WT’s DEGs were shared with at least one mutant at each time point other than 12 
hours with 74%, 81%, 36%, and 57% of the WT DEGs shared with both V620I and T89I at 0, 3, 
12, and 24 hours, respectively (Figure 6.4J). V620I also shared the majority of the DEGs with 
the other two lines and shared 43%, 41%, 44%, 24% of its total DEGs with T89I alone at 0, 3, 
12, and 24 hours, respectively (Figure 6.4J). However, T89I was the most unique of the 3 lines 
with 68%, 35%, 32%, and 54% of the total DEGs being unique to T89I at 0, 3, 12, and 24 hours, 
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respectively (Figure 6.4J). These data indicate that the TRPV4 mutations were more sensitive to 
loading with an increase in the number of upregulated genes as opposed to an altered response to 
loading by changing the upregulated genes.  
 To investigate the overall expression pattern of the loading response and the expression 
levels of the shared DEGS, we used hierarchical k means clustering. The loading response 
resulted in 4 clusters (Figure 6.4K-O). The largest cluster (i.e., cluster 1) represented a long-term 
response with genes that are upregulated at 12 and 24 hours post loading (Figure 6.4K-L). WT 
had the highest mean counts by 24 hours; however, it also had the highest counts in the free 
swelling control (Figure 6.4K-L). Cluster 2 and 3 represented the short-term response (Figure 
6.4K, M-N). Genes in cluster 2 had an increase in expression 3 hours after loading and had 
highest expression in T89I chondrocytes (Figure 6.4K, M). Genes in cluster 3 had increased 
expression at 0 and 3 hours in V602I and T89I and decreased expression at 12 and 24 hours in all 
lines (Figure 6.4K, N). Finally, cluster 4 represented genes downregulated by loading with the 






Figure 6.4 TRPV4 mutants had an altered and increased response to loading. (A-I) CAMP, Ca2+ 
responsive, and TRPV4 target genes JUN (A), EGR1 (B), EGR2 (C), NR4A2 (D), BMP2 (E), 
BMP6 (F), FOS (G), NR4A2/NOR-1 (H), CREB1 (I) show altered response profiles between 
WT, V620I, and T89I. *p<0.01 for T89I vs. WT; †p<0.01 for T89I vs. V620I; #p<0.01 for 
V620I vs. WT. (J) Venn diagrams comparing cell lines at each time point indicate TRPV4 
mutations upregulate many of the same as and additional genes compared to WT. (K) 
Hierarchical clustering of the DEGs into 4 clusters. (L-O) The scaled mean count profile of each 
line within the long-term upregulation cluster (L), 3-hour upregulation cluster (M), 0-hour 
upregulation cluster (N), and the downregulation cluster (O). 
6.4.3 Proliferative genes are upregulated long-term after loading 
We investigated cluster 1 to understand the long-term response to loading (i.e., 12 and 24 hours 
post-loading). Using the genes in cluster 1, we identified the top 20 upregulated genes for each 
line at 12- and 24-hours post-loading and plotted the LogFC in a heatmap (Figure 6.5A). Despite 
the mean count trends, mutants typically had higher LogFC of the top DEGs compared to WT, 
likely because WT had higher expression of these genes in the free swelling control. There were 
a few genes with the highest expression in V620I; these included cell adhesion genes integrin 
subunit alpha 5 (ITGA5) and CXADR like membrane protein (CLMP), cell proliferation 
regulator ALK and LTK ligand 2 (ALKAL2), and ECM remodeling protein matrix 
metallopeptidase 10 (MMP10). WT had high expression, despite little to no expression in 
mutants, of a few genes such as SRY-box transcription factor 12 (SOX12) and vascular 
endothelial growth factor B (VEGFB). However, most of the genes showed increasing expression 
from WT to the severe T89I mutant line. For example, many histone genes (e.g., H1-2 through 5, 
H2BC14, H4C1) had high expression at 24 hours for all lines but was highest for T89I. These 
genes also started increasing in expression at 12 hours in V620I and T89I but not in WT. Some 
helicase genes (e.g., MCM2, MCM5, MCM6, MCM10) had high expression at 12 hours, which 
slightly decreased at 24 hours, and was stronger in the mutants than WT.  
 Since many of the top up-regulated DEGs from cluster 1 were shared among the three 
cell lines, albeit higher expression in mutants, we next investigated genes that were uniquely 
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upregulated long-term in the mutants but not WT. We plotted the LogFC of top 25 upregulated 
DEGs unique to V620I and T89I at 12 and 24 hours in a heatmap (Figure 6.5B). Similar to the 
top genes in cluster 1, many of the long-term DEGs in mutants also showed increased expression 
in WT, although not significant. We observed that for many genes, there was increased 
expression at more time points in T89I compared to V620I and WT. An increase in expression 
and time of expression was associated with an increase in disease severity in many genes, 
including Ca2+ binding proteins S100A3 and S100A4, anti-synthetic insulin growth factor binding 
protein 3 (IGFBP3), metalloproteases tolloid like 1 (TLL1) and pappalysin 1 (PAPPA), and 
inflammatory interleukin 17 receptor C (IL17RC). Additionally, we observed that common 
biological processes and pathways associated with the mutant-specific DEGs were associated 
with cell cycle, mitosis, proliferation, and DNA elongation and replication, such as proliferative 
histone H1-2 and transcription factor E2F1 and mini-chromosome maintenance protein MCM3.  
 To determine the transcription factors that are driving the response to loading at 12 and 
24 hours, particularly those driving the differing responses between lines, we determined the 
transcription factors associated with the upregulated genes at each time point using TRRUST 
(Figure 6.5C-D). E2F1 and E2F4 were both strongly associated with V620I and T89I, but not 
WT, at 12 hours; however, at 24 hours, they became associated with all three lines (Figure 6.5C-
D). TP53 had a similar pattern but remained stronger in the mutants despite an increase in 
association in WT at 24 hours. All three are tumor suppressors and play a role in cell cycle 
control. Interestingly, the association of transcription factors between mutants and WT is more 
correlated at 24 hours (V620I vs. WT r2=0.8081, T89I vs. WT r2=0.8118) than 12 hours (V620I 
vs. WT r2=0.1822, T89I vs. WT r2=0.0999), indicating the differences in response due to mutant 
TRPV4 is occurring earlier.  
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 To better understand what pathways the upregulated genes were associated with, we used 
g:Profiler to identify top KEGG and REAC pathways. V620I and T89I had higher association 
with many DNA replication and stress and cell cycle processes compare to WT, both at 12 and 
24 hours (Figure 6.5E-F). The upregulation of many histone genes resulted in an association with 
DNA damage disorders such as systemic lupus erythematosus and alcoholism. Interestingly, 
lupus was only associated with T89I at 12 hours (Figure 6.5E); however, at 24 hours, it was more 






Figure 6.5 Long-term response to loading. (A) Top 20 up-regulated long-term genes from 
cluster 1. Most of the genes show higher, and earlier, expression in mutants than WT. (B) The 
top 25 genes upregulated in V620I and T89I, but not WT, at 12 and 24 hours. (C-D) Associated 
transcription factors with the upregulated DEGs at 12 hours (C) and 24 hours (D). Log10(p value 
of association) based on TRRUST data base plotted for V620I vs. WT and T89I vs. WT. Colored 
transcription factors indicate a stronger association with one line or the other. Linear fit indicates 
how correlated the mutant’s associated transcription factors are to WT’s. (E-F) The top 
associated KEGG and REAC pathways to the upregulated DEGs at 12 hours (E) and 24 hours 
(F) for each line. Circle color represents the cell line, and circle size represents the -log10(padj). 
6.4.4 Loading upregulates ECM-related proteins, particularly with mutant 
TRPV4 
Next, we investigated clusters 2 and 3 to understand the short-term response (i.e., 0 and 3 hours 
post loading). We plotted a heatmap with the LogFC of the top 20 upregulated genes in clusters 2 
and 3 for each line 0- and 3-hours post-loading (Figure 6.6A). Most genes showed increased 
expression at both 0 and 3 hours with higher expression at 3 hours. Interestingly, many of these 
genes also showed high expression at 12 hours but only in the V620I line. Interleukin 1 receptor 
like 1 (IL1RL1) was upregulated at 0, 3, and 12 hours for all lines but had the highest expression 
in V620I. In fact, most genes had higher expression in mutants than WT. Some of the top 
upregulated genes included actin filament protector xin actin binding repeat containing 1 
(XIRP1), integrin signaling and actin linker FERM domain containing kindlin 1 (FERMT1), 
tyrosine phosphorylation-dependent regulator CUB domain containing protein 1 (CDCP1), 
TGFβ family member inhibin subunit beta A (INHBA), mechanoresponsive FOS family member 
FosB proto-oncogene, AP-1 transcription factor subunit (FOSB), mechanoresponsive 
transcription factors early growth response 1 and 2 (EGR1 and EGR2), negative regulator of the 
MAPK family dual specificity phosphatase 2 (DUSP2), heparin binding epidermal growth factor 
like growth factor (HBEGF), and interleukin 6 family cytokine LIF. 
 Furthermore, we explored the DEGs unique to V620I and T89I at 0 and 3 hours. The top 
25 mutant-specific, short-term DEGs and their LogFC were plotted in a heatmap (Figure 6.6B). 
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As expected, there was a slight, non-significant upregulation of many genes in WT as well. 
There was also more sustained upregulation of a few genes in T89I compared to V620I. Short-
term genes were typically upregulated at either 0 and 3 hours or at 3 and 12 hours. However, 
interestingly, some genes showed upregulation and 0 and 3 for T89I but 3 and 12 for V620I, 
showing a faster response of the severely mutated TRPV4. Nuclear factor kappa B (NFκB) 
regulator long non-coding RNA MIR31HG, BMP/SMAD-regulated keratin 16 (KRT16), and 
mechanical signal transducer laminin subunit alpha 3 (LAMA3) were among the top mutant-
specific genes. Proliferation was a common theme for both short- and long-term with 
upregulation of cell cycle progression oncogene MYC and chondrocyte proliferation gene high 
mobility group AT-hook 2 (HMGA2) at 0 and 3 hours and 3 and 12 hours, respectively. The 
short-term, mutant-specific genes also showed association with IL4/IL13 signaling, cell 
migration and mobility, integrins, ligands, and ECM (e.g., upregulation of collagen chain 
assembly gene prolyl 3-hydroxylase 2 [P3H2] at 3 and 12 hours). Despite the dysregulated 
endochondral ossification associated with brachyolmia and metatropic dysplasia, many 
hypertrophy-associated genes were upregulated with loading in V620I and T89I, including 
RUNX Family Transcription Factor 3 (RUNX3), Indian hedgehog (IHH), and fibroblast growth 
factor 1 (FGF1), which is found in growth plate cartilage.  
We then looked at the transcription factors associated with upregulated genes at 0 and 3 
hours for each line using TRRUST. Both 0 and 3 hours showed less correlation between the 
mutants and WT than at 24 hours; however, the 3 lines were more similar at 3 hours (0 hr: V620I 
vs. WT r2=0.4638, T89I vs. WT r2=0.4948; 3 hr: V620I vs. WT r2=0.4908, T89I vs. WT 
r2=0.5639; Figure 6.5C, 6.6C-D). Pro-inflammatory nuclear factor kappa B subunit 1 (NFKB1) 
was strongly associated with the two mutant lines at 0 hours and became more associated with 
 258 
 
WT at 3 hours, especially compared to T89I. T89I was highly associated with transcription factor 
SP1 at both 0 and 3 hours while V620I was associated with SP1 at 3 hours. Enhancer of zeste 
homolog 2 (EZH2), an epigenetic regulator of development and differentiation, was associated 
with T89I and V620I, but not WT, at 0 and 3 hours, respectively. V620I and T89I also showed 
unique association compared to WT with TGFβ family signaling antagonist SMAD family 
member 7 (SMAD7) and NFκB inhibitor zinc finger protein 382 (ZNF382), respectively, at 3 
hours. WT, however, had a stronger association with cytokine and chemokine transcription 
factor ETS proto-oncogene 1 (ETS1) than both mutations at 0 hours. MEF2D was also unique to 
WT’s upregulated genes at 3 hours.  
 Again, we assessed the top associated KEGG and REAC pathways with the upregulated 
genes in each line at 0 and 3 hours (Figure 6.6E-F). The three lines shared a similar association 
with nerve growth factor (NGF)-stimulated transcription at 0 hours, which was slightly 
decreased at 3 hours in the mutant lines. At 0 hours, WT showed an association with 
inflammatory pathways such as interleukin 17 (IL-17) and tumor necrosis factor (TNF) signaling 
and cytokine-cytokine receptors unlike the mutations. In contrast, T89I uniquely had a strong 
association with ECM organization and receptors, collagen formation, and proteoglycan 






Figure 6.6 Short-term response to loading. (A) Top 20 up-regulated genes short-term from 
clusters 2 and 3. There is a similar expression profile between the three cell lines with slightly 
higher expression in mutants than WT. (B) The top 25 genes upregulated in V620I and T89I, but 
not WT, at 0 and 3 hours. (C-D) Associated transcription factors with the upregulated DEGs at 0 
hours (C) and 3 hours (D). Log10(p value of association) based on TRRUST data base plotted for 
V620I vs. WT and T89I vs. WT. Colored transcription factors indicate a stronger association 
with one line or the other. Linear fit indicates how correlated the mutant’s associated 
transcription factors are to WT’s. (E-F) The top associated KEGG and REAC pathways to the 
upregulated DEGs at 0 hours (E) and 3 hours (F) for each line. Circle color represents the cell 
line, and circle size represents the -log10(padj). 
6.5 Discussion 
To investigate how skeletal dysplasia-causing mutations alter TRPV4 mechanotransduction, we 
used CRISPR-Cas9-edited hiPSCs harboring the moderate V620I and severe, neonatally lethal 
T89I mutations. hiPSC-derived chondrocytes produced matrix rich in sGAGs and COL2A1 after 
2 weeks of culture in agarose, and the constructs were then mechanically loaded to 
physiologically mimic TRPV4 activation during development. V620I and T89I increased 
TRPV4 mechanosensitivity and resulted in increased upregulation both in fold change and 
number of differentially expressed genes (vs. free swelling controls) compared to WT. When we 
evaluated the associated transcription factors and pathways with the up-regulated genes, mutant-
specific genes were associated with ECM, inflammation, and cell mobility at 0 and 3 hours post-
loading and proliferation and cell cycle at 12 and 24 hours post-loading. The mutant associated 
transcription factors were the most different from WT 12 hours post loading; however, the three 
lines became more similar at 24 hours. Our results indicate that gain-of-function mutations 
V620I and T89I are hypersensitive to mechanical stimulus. The increased transcriptomic profiles 
and downstream signaling likely lead to dysfunctional skeletal development resulting in 
moderate brachyolmia and severe metatropic dysplasia.  
 To the best of our knowledge, this is the first study to mechanically load hiPSC-derived 
chondrocytes and investigate mechanotransduction of mutant TRPV4. After 4 weeks in culture, 
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WT hiPSC-derived chondrocyte-ridden agarose constructs achieved an elastic modulus of 100 
kPa. These values are lower than what has been reported for adult cartilage tissue and tissue-
engineered cartilage with fibrous scaffold systems (compressive Young’s modulus = 240-850 
kPa; aggregate modulus = 100-2000 kPa; Poisson’s ratio = 0.06-0.3) (33). However, the modulus 
is greater than free-swelling primary porcine chondrocytes in agarose for 6 weeks, which had a 
Young’s modulus of approximately 65 kPa (4), and hiPSC-derived chondrocytes in a collagen 
type I scaffold, which had an average aggregate modulus of 85 kPa (Young’s modulus = 62.4-
83.4 kPa, assuming Poisson’s ratio is consistent with reported values of primary cartilage (33)) 
(34). The increase in modulus from 100 kPa to 150 kPa with mutant hiPSC-derived 
chondrocytes, despite it not being significant, is indicative of increased TRPV4 activation. Not 
only did GSK205 inhibition of TRPV4 slightly decrease the mechanical properties, but TRPV4 
activation via mechanical, osmotic, and chemical stimuli has been shown to increase mechanical 
properties of cartilage (4, 35).  
The increased activation of mutant TRPV4 was further supported in this study with the 
increase in upregulated DEGs and fold change of DEGs in response to cyclical, compressive 
loading. Interestingly, there is conflicting evidence of the role of the gain-of-function V620I and 
T89I mutations on channel activity. Studies using Xenopus oocytes, porcine chondrocytes, and 
hiPSC-derived chondrocytes previously found both increases and decreases in basal, chemically 
activated, and osmotically activated V620I-TRPV4 and T89I-TRPV4 compared to WT (16-18). 
While it is well known that TRPV4 is activated by mechanical and osmotic loading and chemical 
agonists, among other stimuli, the mechanisms of action are not well understood. Therefore, 
TRPV4 may be activated and respond differently to various agonists. Additionally, the mutation 
may alter sensitivity to these agonists differently. In fact, the effects of mutations on TRPV4 
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mechanotransduction in chondrocytes has not been studied before despite studies in primary and 
derived (e.g., hiPSC, dental pulp mesenchymal cells) chondrogenic, osteogenic, and neurogenic 
cell types and model systems (e.g., oocytes) (16, 17, 36-40).  
Histology from patients with brachyolmia and metatropic dysplasia show fewer 
hypertrophic chondrocytes with cartilage islands within immature, woven bone, likely due to 
dysfunctional endochondral ossification (12, 15, 41). Additionally, our previous study showed 
that V620I and T89I inhibited BMP4-induced hypertrophy of hiPSC-derived chondrocytes (18). 
In contrast, osteoblasts derived from dental pulp mesenchymal stem cells harboring metatropic 
dysplasia-causing TRPV4 mutation L619F showed increased calcification and expression of 
osteogenic genes runt-related transcription factor 2 (RUNX2), osteocalcin (OCN), and nuclear 
factor of activated T cells 1 (NFATC1) (38). Therefore, it was hypothesized that ectopic 
ossification occurs after direct osteoblastic differentiation of mesenchymal cells (15, 38), 
indicative of dysfunction in the chondrocyte, hypertrophy, endochondral ossification pathway. 
This was again highlighted in our results with both pro- and anti-hypertrophic gene expression in 
response to loading in mutant chondrocytes compared to WT. For example, mutants had lower 
expression compared to WT of skeletal development regulator SOX12 (42) 12 and 24 hours post 
loading. In contrast, growth plate protein FGF1 (43) and endochondral ossification regulators 
IHH and RUNX3 (44) were upregulated at 0 and 3 hours post loading. Despite the conflicting 
expression of hypertrophy-associated genes, we observed an increase in expression of genes 
associated with inflammation, cell mobility, and proliferation in V620I and T89I chondrocytes, 
which may be responsible for the dysregulated skeletal development.  
Given that proliferation inhibits chondrocyte maturation (45), the increased expression 
and association with proliferative genes, such as E2F1, TP53, SP1, and MYC in mutants could be 
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preventing chondrocyte hypertrophy. There was a unique upregulation of E2F1 in mutants at 12 
and 24 hours, particularly in T89I. Additionally, association between the transcription factor and 
the upregulated genes occurred earlier (i.e., 12 hours vs. 24 hours) in mutants compared to WT. 
Beyond E2F1’s role in increasing proliferation, overexpression of the gene has been found to 
suppress endochondral ossification with reduced chondrocyte maturation, collagen type X 
expression and secretion, hypertrophic zones, and organization of the growth plate (46, 47). We 
also saw a similar association between upregulated genes and TP53 with the association 
occurring in mutants at 12 and 24 hours but only a small association with WT at 24 hours. 
Interestingly, unlike E2F1, TP53 was not a top upregulated gene; however, it is associated with 
many processes and genes involved in proliferation and endochondral ossification. TP53 is 
regulated by cell cycle checkpoint kinase ATM, which was uniquely associated with V620I 
DEGs compared to WT immediately after loading. Signaling from and overexpression of p53, 
the protein encoded by TP53, has been shown to inhibit chondrocyte and osteoblast 
differentiation (48-51). In fact, an increase in TP53 expression in MSCs promoted adipogenic 
but inhibited osteogenic differentiation (52). This anti-osteogenic effect was rescued by FGF2-
induced TWIST2 expression (52), which is also uniquely associated with WT at 24 hours.  
Furthermore, members of the p53 family have been found to promote SMAD7 expression 
(53). Upregulated genes in V620I at 3 hours showed high association with SMAD7, which 
inhibits TGFβ and activin signaling, and T89I had the highest expression of the transcription 
factor. While SMAD7 is required to mediate cell stress in the growth plate (54), overexpression 
inhibited chondrocyte hypertrophy (55). Interestingly, absence of SMAD7 increased HIF1α 
levels (54), and HIF1A was strongly and uniquely associated with WT DEGs at 24 hours, 
opposite of the association with SMAD7 at 3 hours. MYC, an oncogene, had increased expression 
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in and association with mutants compared to WT short- and long-term, respectively. MYC has 
been found to be present in proliferating, but not hypertrophic, chondrocytes (56, 57). SP1, a 
proliferative gene with decreased expression in hypertrophic chondrocytes (51, 58), also had 
increased association with mutants compared to WT at 0 and 3 hours. Despite SP1’s role in 
proliferation, a member of its family, KLF10, inhibited chondrocyte proliferation through 
downregulation of INHBB (59). We did observe increased, unique expression of INHBB in 
mutants. These results are indicative of a proliferative effect of the TRPV4 mutations, which 
ultimately prevents proper hypertrophy. 
We also observed increased association with and expression of NFKB1 in the mutant 
lines in response to loading. The increase in NFKB1 with GOF TRPV4 mutations is consistent 
with our previous study that used a NF-κB circuit stimulated by TRPV4 activation for drug 
delivery (11). Interestingly, the pro-inflammatory gene has been shown to promote both 
proliferation and apoptosis, including regulation of TP53 (60-62). Furthermore, RELA, which is 
bound with NFKB1 to form the most common NF-κB complex, prevents chondrocyte apoptosis, 
is active in early stage chondrogenesis, and increases degradative ADAMTS5 expression (63, 64). 
Additionally, a study found NF-κB to inhibit osteogenic gene transcription and transcription 
factor binding (65). Despite the increase in inflammatory NF-κB signaling cascades in TRPV4 
mutants in response to loading, other studies have found TRPV4 activation to have an anti-
inflammatory effect. In fact, TRPV4 activation attenuated loading-induced ADAMTS4 and IL-1R 
expression or IL-1β-induced degradation (66, 67). Therefore, TRPV4 activation, particularly in 
response to compressive loading, likely has both pro- and anti-inflammatory components due to 
differences in the activation of inflammatory signaling cascades.  
This study provides novel insights into hiPSC-derived chondrocyte mechanotransduction 
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on a transcriptomic level in addition to how this signaling is altered by dysplasia-causing TRPV4 
mutations V620I and T89I. However, it must be noted that this study has a few limitations. First, 
we had limited sample size due to the complexity of the experiment and the number of groups. 
The three-hour time point had two replicates that confirmed consistent results between samples. 
Also, the potential pathways responsible for the altered mechanotransduction that leads to the 
dysfunctional skeletal development have not been validated. In future experiments, we will 
repeat the loading. We will increase the sample size and inhibit TRPV4 and specific pathways 
(e.g., E2F1, p53, NF-κB/cMYC) to investigate gene expression. We will also analyze 
proliferation with an EdU assay as another output to validate the proposed pathways.  
6.6 Conclusion 
The results of the current and future experiments will offer better understandings of hiPSC-
derived tissue-engineered cartilage and the role of mechanical loading and TRPV4 
mechanotransduction on the tissue. Furthermore, this work will provide therapeutic targets for 
brachyolmia and metatropic dysplasia. 
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Conclusions and Future Directions 
Human induced pluripotent stems cells (hiPSCs) offer great potential in the field of cartilage 
tissue engineering. Beyond their extensive proliferation and differentiation capacity, hiPSCs are 
derived from adult somatic cells that can be harvested from a patient with minimal donor site 
morbidity. Here, we addressed the heterogeneity and off-target differentiation challenges 
associated with hiPSC chondrogenesis using a chemically defined, serum-free medium in 
Chapters 2-4. This improved, novel protocol creates possibilities for personalized medicine, 
disease modeling, and regenerative therapies.  
 In Chapters 5 and 6, we used the hiPSC chondrogenesis protocol for in vitro disease 
modeling. Using CRISPR-Cas9 gene editing technology, we created hiPSC lines harboring the 
V620I or T89I TRPV4 mutations, which cause mild brachyolmia and severe, neonatally lethal 
metatropic dysplasia. We differentiated the hiPSCs through chondrogenesis and into hypertrophy 
and tested TRPV4 activation in the hiPSC-derived chondrocytes to investigate how these 
mutations lead to skeletal dysplasias. We used mRNA sequencing and transcriptomic analysis to 
identify many key genes whose expression is altered by the mutations during chondrogenesis, 
hypertrophy, and loading. We found that the mutations suppressed hypertrophic differentiation, 
likely preventing proper endochondral ossification and long bone development. Furthermore, the 
mutations increased sensitivity of TRPV4 to loading with an increase in gene expression, 
especially of proliferative genes. 
 These key genes can be investigated in future studies as potential therapeutic strategies. 
For example, inhibition of genes upregulated in the mutants, such as HOX genes, could promote 
 271 
 
chondrocyte maturation. Additionally, the BMP/TGFβ signaling pathway could be modulated to 
allow for chondrocyte hypertrophy. Mutant hiPSC-derived chondrocytes appeared to be more 
prolific than wildtype; therefore, inhibition of these proliferation pathways may restore proper 
mechanotransduction. In fact, we are preparing an experiment to inhibit TRPV4 signaling and 
other pathways identified during loading. We will investigate if this inhibition decreases 
proliferation and increases similarity between mutants and WT. Furthermore, it would be 
interesting to continue the differentiation of TRPV4-mutant chondrocytes through osteogenesis 
to determine additional therapeutic targets. TRPV4 is a well-known signal regulator in both bone 
and cartilage. Apart from skeletal dysplasia therapeutic development, these findings may also be 
applicable for optimizing tissue engineering, particularly from hiPSCs. In fact, the proliferative 
and anti-hypertrophic properties of mutant hiPSC-derived chondrocytes are ideal for cartilage 
tissue engineering.  
 Other genetic mutations can also be studied using this protocol. For example, a mutation 
in collagen type VI alpha chain 3 (COL6A3) has been found to increase predisposition to 
osteoarthritis. Therefore, we created a mutant hiPSC line, and an isogenic control, to differentiate 
into chondrocytes and study how this mutation leads to disease. Since COL6A3 is a primary 
component of the pericellular matrix, a biochemical and biomechanical filter for chondrocytes, 
we hypothesize that the mutation alters PCM properties rendering the chondrocyte more 
susceptible to injurious loading and pro-inflammatory cytokines. Our lab and collaborators are 
currently using these hiPSC-derived chondrocytes in an inflammatory and loading model to 
investigate transcriptomic and epigenetic changes and differences in mutant chondrocytes.  
 The large volume of chondrocytes produced in a single round of differentiation is ideal 
for high throughput drug screening. hiPSCs can be made from a patient suffering from a cartilage 
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disease, such as degenerative arthritis. The resulting hiPSC-derived chondrocytes can then be 
used for drug screening to identify the therapeutic the patient will best respond to. Ideally, in the 
future, the hiPSC-derived cartilage will not only be applicable in vitro but also in vivo. For that 
to happen, there remains many obstacles. hiPSC-derived cartilage addresses the issue of immune 
rejection since it can be derived from the patient’s own cells. However, the mechanical 
properties are an order of magnitude lower than native cartilage. Moreover, due to their 
pluripotency, hiPSCs and hiPSC-derived cells are tumorigenic; therefore, this must be 
preventable prior to human implantation.  
 In summary, we believe the work in this thesis has made a significant contribution to the 
fields of tissue engineering and orthopedics. We have developed a novel hiPSC chondrogenesis 
protocol that addresses many current issues. We demonstrated one of the many uses for the 
protocol, disease modeling, to elucidate underlying mechanisms of skeletal dysplasias caused by 
mutations in ion channel TRPV4. We hope that the findings of these studies will be applied to 
the development of skeletal dysplasia therapeutics and continued in vitro disease modeling, drug 








Professional Profile   
• Biomedical Engineering PhD candidate at Washington University in St. Louis using human 
induced pluripotent stem cells, molecular and cellular biology techniques, including RNA 
sequencing, and mechanical bioreactors to study skeletal dysplasia-causing mutations in cartilage 
• Project manager for a student-run nonprofit consulting group in St. Louis 
• Editor-in-Chief of a trainee-run scientific communication network at Washington University 
• Incoming Strategy Insights and Planning Associate at ZS Associates 
 
Education   
 Washington University in Saint Louis St. Louis, MO 
 Biomedical Engineering, Doctor of Philosophy Candidate, NIH T32 Fellow Aug 2021 
  
 Indiana Institute of Technology (Indiana Tech) Fort Wayne, IN 
 Biomedical Engineering, Bachelor of Science, Summa Cum Laude May 2016 
  
 Johns Hopkins University  Coursera 
 Certificate, Clinical Trial Design 2020 
 
Scientific Research Experience 
Department of Orthopedic Surgery, Center of Regenerative Medicine, Musculoskeletal Research 
Center, and Shriners Hospital for Children  
Washington University School of Medicine, St Louis, MO Aug 2016 – present  
• Study skeletal dysplasia and osteoarthritis-causing mutations to understand cartilage 
development, homeostasis, and function in an effort to identify therapeutic targets 
• Lead a team, organize collaboration, schedule experiments, and mentor junior graduate students 
• Publish peer-reviewed articles in academic journals, most notably Nature Communications 
• Presented work at 6 international and institutional conferences and received a poster award 
• Skills: project management, experimental design, data analysis, cell culture, human iPSC 
differentiation, RNA sequencing, histology, immunohistochemistry, RT-qPCR, biochemical 
analysis, mechanical loading & testing, Microsoft Office Suite, RStudio, Adobe Illustrator, 
GraphPad Prism 
Department of Biomedical Engineering, Undergraduate Researcher 
Indiana Tech, Fort Wayne, IN   Aug 2014 – May 2016 
• Led a team in the R&D of a total revision knee arthroplasty system and individually developed a 
tracheostomy tube system making modifications and improvements compared to current systems 
on the market 
• Developed a design history file (DHF) and mock FDA 510(k) submission including all regulatory 
documentation 
• Presented work and won a presentation award at national honor society conference  
 274 
 
Life Science and Healthcare Professional Experience 
The BALSA Group, Project Manager, Consultant 
St. Louis, MO July 2019 – present  
• Manage projects and workstreams from client engagement kickoff to delivery by supervising 
and assigning weekly tasks for three junior team members to meet external stakeholder needs 
• Synthesize quantitative and qualitative results and assembles strategic recommendations via 
written communications and visual and verbal presentations at client meetings 
• Performed comprehensive primary and secondary market research and competitor analysis for 
emerging and mid-size pharmaceutical and medical device companies as a consultant 
• Promoted to project manager after three projects due to high performance consultant track 
record and strong understanding of client business needs – awarded Project Manager of the 
Year 2020 
InPrint – A Scientific Editing Network, Editor-in-Chief, Associate Editor-in-Chief, Secretary, 
Editor, Designer 
Washington University School of Medicine, St. Louis, MO Feb 2019 – present  
• Provide organizational, conceptual, structural, and grammatical advice, constructive criticism, 
and edits for abstracts, manuscripts, grants, and other types of scientific writing 
• Design vector graphic figures and supervise junior designers to visually communicate research 
studies for clients 
• Develop content for and present workshops and instruct scientists on effective science 
communication including data visualization 
• Lead a team of 50+ editors and designers, implement new external services and internal 
programming, initiate new collaborations and events, review applications, and conduct 
interviews as Editor-in-Chief 
• Launched the annual Scientific Communication Workshop Series with approximately 100 
attendees per workshop 
• Facilitated the commencement of the Presentation Consulting Service 
• Processed submissions, communicated with clients, reviewed applications, conducted 
interviews, and initiated collaborations and events with other departments and groups at the 
university as Associate Editor-in-Chief 
• Organized meetings, booked locations, scheduled events, and recorded meetings and 
membership as Secretary 
Engineering Product Development, Intern  
 K2M (Acquired by Stryker), Leesburg, VA May 2015 – Aug 2015 
• Collaborated with R&D engineers to 3D design a new implant system satisfying customer 
requirements 
• Restructured and revised FDA regulatory submission support material such as traceability 
matrices, risk forms, and clinical evaluation reports  
State Tested Nurses Aid, Masternick Memorial Health Care  
Windsor House, New Middletown, OH July 2013; May 2014 – Aug 2014; Dec 2014 – Jan 2015 
• Assisted residents in activities of daily living while monitoring and documenting vitals, inputs, 
and outputs 
• Collaborated with, mentored, and trained co-workers to provide optimal care 





Dicks AR, Maksaev GI, Harissa Z, Savadipour A, Tang R, Steward N, Liedtke W, Nichols CG, Wu 
CL*, Guilak F*. Skeletal dysplasia-causing TRPV4 mutations suppress the hypertrophic differentiation 
of human iPSC-derived chondrocytes. bioRxiv (2021). doi: 10.1101/2021.06.15.448562. eLife 
(submitted). 
Dicks AR, Steward N, Guilak F*, Wu CL.* Chondrogenic differentiation of human induced pluripotent 
stem cells. Methods in Molecular Biology: Cartilage Tissue Engineering (submitted). 
Dicks AR*, Harissa Z*, Kim Y, Steward N, Liedtke W, Wu CL, Guilak F. Skeletal dysplasa-causing 
TRPV4 mutations increase mechanosensitivity of human iPSC-derived chondrocytes. (in preparation). 
Dicks A*, Wu CL*, Steward N, Adkar SS, Gersbach CA, Guilak F. Prospective isolation of 
chondroprogenitors from human iPSCs based on cell surface markers identified using a CRISPR-Cas9-
generated reporter. Stem Cell Research & Therapy (2020).  
Wu CL*, Dicks A*, Steward N, Tang R, Katz DB, Choi YR, Guilak F. Single cell transcriptomic 
analysis of human pluripotent stem cell chondrogenesis. Nature Communications (2021).  
Dicks A, Bhatia H, Clemens A, Locke M, Mueller E, Murphy D, Pomper N, Robinson A, Schoch K. 
Improving scientific communication with service, education, and career development. Nature 
Biotechnology (submitted).  
Rodríguez Ruiz A, Dicks A, Tuerlings M, Schepers K, van Pel M, Nelissen RGHH, Freund C, 
Mummery C, Orlova V, Guilak F, Meulenbelt I, Ramos YFM. Cartilage from human induced 
pluripotent stem cells: comparison with neo-cartilage from chondrocytes and bone marrow 
mesenchymal stromal cells. Cell and Tissue Research (2021). 
Rai MF, Wu CL, Capellini TD, Guilak F, Dicks AR, Muthuirulan P, Grandi F, Bhutani N, Westendorf 
JJ. Single Cell Omics for musculoskeletal Research. Current Osteoporosis Reports (2021). 
Harasymowicz NS, Dicks A, Wu CL, Guilak F. Physiologic and pathologic effects of dietary free fatty 
acids on cells of the joint. Ann. N.Y. Acad. Sci Marrow (2019). 
Guilak F, Nims R, Dicks A, Wu CL, Meulenbelt I. Osteoarthritis as a disease of the cartilage 
pericellular matrix. Matrix Biology (2018). 
Adkar SS, Wu CL, Willard VP, Dicks A, Ettyreddy A, Steward N, Bhutani N, Gersbach CA, Guilak F. 
Highly efficient chondrogenic differentiation of human iPSCs and purification via a reporter allele 
generated by CRISPR-Cas9 genome editing. Stem Cells (2018). 
*authors contributed equally 
Posters and Presentations  
Dicks A, Wu CL, Harissa Z, Steward N, Guilak F. Differentiation and disease modeling using human 
iPSC-derived chondrocytes. Human Pluripotent Stem Cell Differentiation Work-in-Progress. 
Washington University School of Medicine, St. Louis, MO. March 2021. Virtual presentation. 
 276 
 
Dicks A, Wu CL, Harissa Z, Steward N, Liedtke W, Guilak F. Skeletal dysplasia-causing mutations in 
the ion channel TRPV4 alter human iPSC chondrogenic differentiation and calcium signaling. 
Orthopedic Research Society Annual Meeting, Virtual. February 2021. Podium presentation. 
Dicks A, Schoch K, Robinson A. Data Visualization: how to effectively communicate science through 
easily digestible data visuals. Presentation and interactive workshop. 
• Washington University School of Medicine Pediatric Fellowship. St. Louis, MO. January 2020.  
• Publication Writing Course, Engineering Communication Center. St. Louis, MO. February 2020, 
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